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Abstract
In the initial investigation of this thesis, Fick's second law of diffusion was modified to
describe both the transient, and the steady-state, transdermal transport of hydrophilic permeants
through unbranched, aqueous pore channels. This new transport model, combined with dual
radiolabeled diffusion experiments, was then used to separately evaluate how the porosity, the
tortuosity, and the hindrance factor of the aqueous pore channels that exist in the skin varied as
the extent of skin perturbation due to simultaneous treatment of the skin with low-frequency
ultrasound (US) and a chemical enhancer, the surfactant sodium lauryl sulfate (SLS), and as the
radius of the hydrophilic permeant delivered across the skin, were increased. This investigation
revealed that the values of the hindrance factor and of the tortuosity decreased as the radius of
the hydrophilic permeant increased, and that the value of the porosity of the aqueous pore
channels increased as the extent of skin perturbation due to the application of US increased. This
last result suggested that low-frequency US primarily enhances the transport of hydrophilic
permeants by increasing the fraction of the skin surface occupied by the aqueous pore channels.
This modeling approach was next applied to the passive delivery of hydrophobic
permeants through the branched pathways located in the intercellular lipid bilayer domain of
untreated stratum corneum (SC), the outermost layer of the skin. The existence of these
branched pathways led to the development of a new theoretical model, the Two-Tortuosity
Model, which requires two tortuosity factors to account for: 1) the effective diffusion path
length, and 2) the total volume of the branched, intercellular transport pathways, both of which
may be evaluated from known values of the SC structure. After validating the Two-Tortuosity
model with simulated SC diffusion experiments in FEMLAB (a finite element software
package), the vehicle-bilayer partition coefficient, Kb, and the lipid bilayer diffusion coefficient,
Db, in untreated human SC were evaluated using this new model for two hydrophobic permeants,
naphthol (Kb = 233 + 44, Db = 1.6*10-7 + 0.3*10 -7 cm 2/s) and testosterone (Kb = 100 + 14, Db =
1.8*10 -8 + 0.2*10 -8 cm 2/s). This investigation demonstrated that the new proposed method to
evaluate Kb and Db is more direct than previous methods, in which SC permeation experiments
were combined with octanol-water partition experiments, or with SC solute release experiments,
to evaluate Kb and Db.
Previous studies on ultrasound-mediated transdermal drug delivery had hypothesized that
the discrete regions which form on the surface of skin treated with low-frequency US in the
presence of a colored permeant are regions of high permeability. To test this hypothesis, full-
thickness pig skin was treated simultaneously with low-frequency US and SLS in the presence of
a hydrophilic fluorescent permeant, sulforhodamine B (SRB), which was used to observe the
location of the hypothesized localized transport regions (LTRs) and of the surrounding regions of
US-treated skin (the non-LTRs). After US-pretreatment, diffusion masking experiments, a novel
experimental method in which hydrophobic vacuum grease was selectively applied to the skin
surface, demonstrated that the permeability of calcein, another hydrophilic fluorescent permeant,
in the LTRs was -80-fold greater than in the non-LTRs. Furthermore, measurements of the skin
electrical resistivity in both the LTRs and the non-LTRs revealed significant decreases relative to
the skin electrical resistivity in untreated skin (-5000-fold and -170-fold, respectively),
suggesting that two levels of significant structural perturbation exist in skin treated
simultaneously with ultrasound and SLS. Finally, an analysis of the porosity-to-tortuosity ratio
values suggested that transcellular transdermal transport pathways exist within the LTRs.
To confirm the results of the previous investigation, the transdermal delivery of SRB and
of rhodamine B hexyl ester (RBHE), a fluorescent hydrophobic permeant, in skin treated with
low-frequency ultrasound (US) and/or a chemical enhancer (SLS) relative to untreated skin (the
control) was analyzed with dual-channel two-photon microscopy (TPM). An analysis of the
average fluorescence intensity profiles as a function of skin depth, obtained from the TPM
images, revealed that SRB and RBHE penetrated beyond the stratum corneum and into the viable
epidermis only in the LTRs of US-treated and of US/SLS-treated skin. Further analysis of the
average fluorescence intensity profiles and of the enhancements in the vehicle-skin partition
coefficient, the intensity gradient, and the effective diffusion path length confirmed that a
chemical enhancer was required in the coupling medium during US-treatment to obtain two
significant levels of increased penetration of SRB and RBHE into the skin. Finally, by
comparing the heights and the widths of the fluorescence intensity peaks obtained from the dual-
channel TPM images, the existence of transcellular pathways was confirmed in the LTRs of US-
treated and of US/SLS-treated skin for SRB and RBHE, as well as in SLS-treated skin for SRB.
In the final investigation of this thesis, the differences in the hindrance factor, the
porosity, and the tortuosity of the aqueous pore channels located in the LTRs and in the non-
LTRs were evaluated for the delivery of four hydrophilic permeants (urea, mannitol, raffinose,
and inulin) using the transport model developed in the initial investigation of this thesis
combined with dual radiolabeled diffusion masking experiments. In this analysis, three different
idealized cases were examined. In the first case, where the porosity and the tortuosity were
assumed to be independent of the permeant radius, the hindrance factor, and, therefore, the
average pore radius, was found to be statistically larger in the LTRs than in the non-LTRs. In the
second case, where a distribution of pore radii was assumed to exist in the skin, no meaningful
results could be obtained due to the large variation in the shape of the distribution of pore radii
used in the analysis. In the final case, where infinitely large aqueous pores were assumed to
exist in the skin, the value of the porosity of the LTRs was found to be 3- to 8-fold larger than
that of the non-LTRs, while there little difference was found in the values of the tortuosity of the
LTRs and of the non-LTRs.
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Chapter 1
Introduction
1.1 Overview of Transdermal Drug Delivery
1.1.1 Historical Development and Current Status of Transdermal
Drug Delivery (TDD) in Industry
Transdermal Drug Delivery (TDD) is the process in which drugs are administered to a
patient through the skin, either for topical or systemic application. In recent years, TDD
has become a viable alternative to traditional methods of drug administration, including
injections and oral delivery. Since the approval of the first transdermal patch in 1981 to
prevent the nausea and vomiting associated with motion sickness, the FDA has approved
more than 35 transdermal patch products for 13 drug molecules.' The US transdermal
market approached $1.2 billion in 2001 and was based on 11 drug molecules (see Table
1-1): fentanyl, nitroglycerin, estradiol, ethinyl estradiol, norethindrone acetate,
testosterone, clonidine, nicotine, lidocaine, prilocaine, and scopolamine.' Figure 1-1
gives a breakdown of the contribution of each drug to the global TDD market, which was
valued at $2.4 billion in sales in 2001. During the time that this thesis was completed,
two additional transdermal patch products containing norelgestromin and oxybutynin
have been made available by the FDA for clinical use.' Additionally, the global TDD
market has grown remarkably in the last few years. In 2005, the value of the market was
estimated at $12.4 billion, and it is projected to increase to $21.5 billion in 2010 and to
$31.5 billion in 2015.2 Approximately 90 companies are currently active in developing
transdermal technologies. 2
Table 1-1: Drugs Currently Delivered for Therapeutic Applications Using Transdermal
Methods. 3,4
Drug Name
Estradiol
Testosterone
Fentanyl
Lidocaine
Scopolamine
Nicotine
Nitroglycerin
Ethynil Estradiol
Clonidine
Prilocaine
Oxybutin
Molecular Weight
272.4
288.4
336.5
234.3
303.4
162.2
227.4
296.0
230.9
220.3
357.4
Log Ko/w
3.86
3.31
4.37
2.48
1.24
1.17
1.62
3.73
2.27
2.42
4.68
Uses
hormone replacement
hormone replacement
pain management
local anesthetic
motion sickness
smoking cessation
vasodilation
hormone replacement
antihypertensive
local anesthetic
bladder control
1.1.2 Advantages of TDD over Conventional Methods of Drug Delivery
Some of the advantages of TDD over traditional methods of drug delivery which account
for the growing interest of pharmaceutical companies and clinicians in TDD include: 1)
avoiding first-pass metabolism effects in the harsh environment of the gastrointestinal
(GI) tract, which pose a limitation for oral delivery, 2) offering a painless alternative to
injections, 3) enabling controlled release of the drug for both systemic and topical
delivery, and 4) increased patient compliance with drug dosing schedules - a patient can
apply a single drug-containing patch to the skin to have drug delivery occur over an
extended period of time (hours, days, weeks, etc.), thus eliminating the need to administer
repeated injections or take oral medications. However, despite these advantages, the use
of TDD as an alternative to traditional methods of drug delivery has been limited thus far
to low molecular weight (<400 Da) hydrophobic drugs (log Ko/, >1), as shown in Table
1-1, due to the barrier properties of the skin.
Tulobuterol, 4%
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Figure 1-1: Breakdown of Global TDD market circa 2001. The total market value is
estimated to be $2.4 billion. 1
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1.1.3 Impact of the Structure of the Skin on TDD
The barrier properties of the skin can be understood by examining the structure of the
skin. The skin is composed of three primary layers - the stratum corneum, the viable
epidermis, and the dermis (see Figure 1-2). The stratum corneum is the thinnest layer of
the skin having a thickness of 10-20 iim in humans, while the viable epidermis and the
dermis have thickness of 100-200 ýtm and 1-4 mm, respectively.5 Even though it is the
thinnest layer, the stratum corneum functions as the primary barrier to TDD. The stratum
corneum consists of corneocytes, which are thin, polyhedral-shaped, dead cells filled with
cross-linked keratin fibers, and a matrix of lipid lamellar bilayers, which together are
arranged in a brick-and-mortar structure (see Figure 1-3). This tightly packed brick-and-
mortar structure of comeocytes and highly-ordered lipid bilayers is the main source of the
resistance to transdermal diffusion in the stratum corneum. The corneocytes are
considered to be impermeable to drug transport due to the extensive amount of keratin
cross-linking within the corneocytes. 5 In addition, a thin (15 nm) comified cell envelope,
composed of a mixture of covalently bound cross-linked protein filaments and lipid
molecules, surrounds the corneocyte cells and provides further resistance to drug
diffusion into the corneocyte cells. 5 Therefore, the intercellular lipid lamellar bilayer
domain is widely believed to the primary transdermal permeation pathway under passive
transport conditions.6-8 The stratum corneum also presents an additional barrier function
for hydrophilic molecules due the hydrophobic nature of the intercellular lipid lamellar
bilayer domain. This characteristic property makes it difficult for hydrophilic molecules
to partition into the intercellular regions of the stratum corneum.
ratum
orneum
EPIDERMIS
DERMIS
SUBCUTA-
NEOUS
LAYER
Figure 1-2: Sketch of the cross-section of the skin.
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Figure 1-3: Schematic representation of the brick-and-mortar model of the Stratum
Corneum (SC). Corneocytes (depicted in gray) are shown with their characteristic
hexagonal shape and are contained within the lamellar lipid bilayers (depicted in white).
In humans, the thickness of the SC ranges from 10 - 20 ptm, and typically consists of 15
interlocking layers of corneocytes.
Beneath the stratum corneum lie the viable epidermis and the dermis layers of the
skin. Both the viable epidermis and the dermis are less densely organized skin layers,
compared to the stratum corneum.5 This structural feature of the viable epidermis and the
dermis allows nutrients and waste products to be easily transported via diffusion between
the capillaries in the dermal layer and the living cells of the viable epidermis. For the
purposes of TDD, this more open structure of the viable epidermis and the dermis allows
for easy diffusive transport of both hydrophilic and hydrophobic drugs. As such, the
viable epidermis and the dermis are not considered to be the rate-limiting layers in
passive transdermal drug diffusion, and therefore, do not provide any resistance to drug
transport. Additionally, the physicochemical properties of the viable epidermis and the
dermis differ from those of the stratum corneum. The viable epidermis and the dermis
have been shown to be more hydrophilic as compared to the stratum corneum. However,
the increased hydrophilicity of these two layers does not significantly hinder the transport
of hydrophobic drugs through these layers, due to the fact that the viable epidermis and
the dermis are more porous than the stratum corneum. For passive diffusion through the
skin, it is widely accepted, for both hydrophilic and hydrophobic drugs, that the primary
resistance to transdermal transport lies in the stratum corneum, 9 and, once this layer is
traversed, diffusion through the viable epidermis and the dermis to the capillaries is
comparatively easy. Therefore, to increase the permeability of the skin to allow delivery
of hydrophilic and hydrophobic drugs at therapeutic levels, it is necessary to either: 1)
find a drug transport route which bypasses the stratum corneum, or 2) perturb the
structure of the stratum corneum to reduce the resistance of the stratum comeum to
transdermal transport.
As Figure 1-2 shows, there are other structures in the skin - hair follicles, sweat
glands, and sebaceous glands - which may be used to bypass the stratum corneum and to
deliver drugs directly into the viable epidermis and dermis layers of the skin. Sebaceous
glands are found within hair follicles and have a skin surface density of 57-100 sites per
cm 2 of the skin.5 Their combined skin surface area fraction is approximately 1/ 1000 th of
the skin surface.5 Sweat glands are present in the skin in greater density, approximately
100-200 sites per cm 2 of the skin.5 However, sweat glands only take up 1/1 0 ,00 0 th of the
skin surface area.5 From the work of Johnson et al.,3 the permeable, intercellular regions
of the stratum corneum occupy approximately 1/500 th of the skin surface area, a similar
order-of-magnitude to the surface fraction of the skin occupied by hair follicles and
sebaceous glands.5 Therefore, the intercellular route and the follicular route may both be
significant for passive transdermal transport in native skin samples. Since only a small
fraction of the skin surface is taken up by each delivery route, an impractically large
amount of skin area would be required to deliver a therapeutic dose of a desired drug
using transdermal methods.
1.1.4 Current Methods for Reducing the Barrier Properties of the Skin to
Improve TDD
Since the two possible routes of transdermal delivery discussed in Section 1.1.3 occupy
such a small fraction of the skin surface area, transdermal delivery rates could be
increased several hundred fold if it were possible to perturb the stratum corneum to
utilize a larger fraction of the skin surface area for transdermal drug transport. Increasing
transdermal delivery rates is the motivation behind research in methods to enhance
transdermal drug delivery. Therefore, to deliver such compounds at therapeutic levels,
several methods have been developed to make the skin more permeable to drug transport
- (i) electroporation,' 0 15 (ii) iontophoresis, 16 22 (iii) chemical enhancers, 23 27 (iv)
sonophoresis, 27-33 (v) microneedles, 34 36 and (vi) laser-ablation.3 7
Each of the above methods attempts to either alter or bypass the highly-organized
structure of the stratum corneum, or to provide an additional driving force to increase
transdermal delivery rates. Electroporation increases drug transport across the skin
through the creation of temporary aqueous pores in the stratum corneum formed by the
application of pulsed electric voltages.'0-15 lontophoresis enhances drug transport by
means of electrophoresis, in which polar and charged molecules are pushed through the
skin by the applied electric field, or to produce enhanced diffusion.16-22 Chemical
enhancers utilize several mechanisms by which drug transport is enhanced. These
mechanisms include: (i) enhancing drug solubility in the donor solution,23 (ii) modifying
the partitioning of the drug between the donor solution and the SC,24 and (iii) disrupting
the lipid lamellar bilayers and connective proteins that make the SC a tight barrier to drug
transport. 25 Microneedles offer a painless alternative to traditional injections.34 36 In this
technique, very small, short needles are pressed into the skin surface. 34-36 The needles
are designed such that they only penetrate into the viable epidermis or the dermis,
effectively bypassing the stratum corneum, and resulting in no pain for the patient.
34 36
Delivery methods with this technique include: 1) the desired drug can be loaded into the
microneedle prior to insertion into the skin, 2) the drug can be coated on the microneedle
surface, and 3) the drug can be injected into the skin, through the microneedle, once it has
been inserted into the skin. In laser-ablation methods, the stratum corneum is physically
removed from the desired skin delivery site, thus enabling enhanced delivery methods. 37
Sonophoresis, the transdermal enhancement technique that is the focus of this thesis, uses
ultrasound to enhance transdermal drug transport. Ultrasound (US) corresponds to any
sound wave with a frequency higher than 20 kHz. The ultrasound wave can be
characterized by the frequency and the amplitude of the sound wave oscillations. Figure
1-4 presents a sketch of the typical experimental setup used for the application of
ultrasound on the skin. The ultrasound is generated by passing an electrical AC signal,
from a signal generator, through a piezo-electric crystal (e.g. the transducer) at the
desired frequency and amplitude. As shown in Figure 1-4, a coupling medium in the
donor chamber is required to transmit the ultrasound wave from the transducer to the
skin. Without an appropriate coupling medium (i.e. a material with an acoustic
impedance similar to that of the skin), the ultrasound wave will be reflected off the skin
surface rather than being able to penetrate into the skin, thus minimizing the effectiveness
of the ultrasound on the skin. Previous studies (see Section 1.2) have demonstrated that
sonophoresis enhances drug transport primarily by inducing acoustic cavitation bubble
formation, both in the skin and in the coupling medium. 32  Implosion of the acoustic
cavitation bubbles in, and near, the skin surface leads to the onset of violent shockwaves
that can disrupt the tight structure of the SC. When these implosions occur near the skin
surface, microjets are formed and are directed toward the skin surface, which drives the
drug solution into the disrupted SC.32 Additionally, operation of ultrasound in the
coupling medium can create acoustic streaming of the coupling medium fluid.3 2 If a
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Figure 1-4: Schematic representation of the typical experimental setup used in
sonophoresis. The signal generator is programmable, allowing different duty cycles and
intensities to be selected. The signal from the generator is amplified before it is
transferred to the transducer through the US horn. The transducer in this setup is screwed
into the tip of the horn, and can be replaced as needed to ensure proper function.
drug is included in the coupling medium during sonophoresis, the acoustic streaming can
also contribute to enhanced delivery of the drug into the skin.32
Currently, the preferred method of sonophoresis in transdermal drug delivery
involves pre-treating the skin with ultrasound to perturb the structure of the stratum
corneum followed by passive delivery of the desired drug from a patch through the
ultrasound pre-treated skin site. In all the above enhancement techniques, the skin is not
exposed to the external environment, both during application of the enhancing technique
and during delivery of the desired drug, to prevent the possibility of infectious agents
entering into the skin through the weakened skin sites. Each of these enhancement
techniques has yielded successful results in increasing the skin permeability in order to
facilitate drug transport. Additionally, combinations of these enhancement methods
have been attempted with some synergistic effects observed, resulting in even greater
enhancements of TDD.24, 28, 38-40
1.2 Literature Review
In this section, I review the previous work conducted on the ultrasound TDD project by
two former students in our group - Samir Mitragotri and Hua Tang. Additionally, I will
also include a brief review of published work that is relevant to the experimental and the
theoretical work that I undertook for my thesis. In my discussions of the previous work,
both done by our group and discussed in the literature, I will highlight the issues that
remain unresolved which impact our understanding of ultrasound-mediated transdermal
drug delivery.
1.2.1 Ph.D. Thesis of Samir Mitragotri
Mitragotri began his thesis studies by conducting a mechanistic investigation of
sonophoresis to determine which of several ultrasound-related phenomena (cavitation,
thermal effects, convective velocities, and mechanical effects) were responsible for the
observed transport enhancements of drugs delivered across ultrasound-exposed skin.4 1
These studies were carried out in the high frequency (1-3 MHz) ultrasound region, also
referred to as the therapeutic region, which is typically used for ultrasound imaging and
dental care, as well as over a range of intensities from 0-2 W/cm 2. 4 1 The findings from
his experimental analysis indicated that cavitation taking place in the SC appears to be
the dominant phenomenon contributing to ultrasound enhancement of TDD, through the
action of cavitation bubbles disordering the lipid bilayers in the stratum corneum.41
Additional theoretical studies further indicated that the observed enhancement factor
depended mostly on the passive permeant diffusion coefficient. 41
Having concluded that cavitation events within the keratinocytes of the stratum
corneum were the primary enhancement mechanism, Mitragotri examined low-frequency
sonophoresis studies in an effort to increase the enhancement factors that exposure of the
skin to ultrasound could provide.4' The rationale for conducting studies in the low-
frequency range (20 kHz) was that cavitation events vary inversely with acoustic
frequency.41 Accordingly, cavitation events are more likely to occur at lower ultrasonic
frequencies, resulting in increased cavitation and greater enhancements in transdermal
drug permeabilities.4 ' In vitro studies using a variety of permeants showed enhancements
in the range of 3-fold to 5000-fold in the permeability of a drug when compared to its
passive permeability. 41 In vivo studies showed enhancements in drug permeability of
near 300-fold for salicylic acid in hairless rats.4 1 Since the increase in cavitation events
that lead to an increase in transdermal drug permeability also lead to an increase in
disordering of the stratum corneum, histological and safety tests were conducted to
determine if low-frequency ultrasound exposure was safe for the skin.4  These tests
showed that no long-term damage was produced in the stratum corneum or in the
underlying tissue at the conditions used for the low-frequency ultrasound experiments (20
kHz, 125 mW/cm 2, 100 msec pulses applied every second). 41
Following the results of the high-frequency studies, Mitragotri proposed that, at
low frequency, enhancement occurs as a result of cavitation disrupting the lipid bilayers
of the stratum corneum.41 Additionally, he proposed that aqueous channels, which can
further facilitate the transport of hydrophilic permeants across the hydrophobic stratum
corneum, may form within the lipid bilayers from water supplied by the keratinocytes.4 1
Finally, Mitragotri illustrated the potential utility of sonophoresis in TDD by conducting
experiments for the transdermal delivery of proteins and other high molecular weight
permeants.4 1 These experiments showed that low-frequency sonophoresis was able to
enhance the transport of these large, hydrophilic permeants by several orders of
magnitude.4 1
1.2.2 Ph.D. Thesis of Hua Tang
Tang continued the work on the ultrasound TDD project identifying four major areas of
the project that required further study after the completion of Mitragotri's work: (1)
justifying the selection of various in vitro skin membrane models for low-frequency
sonophoresis studies, (2) determining the primary mechanisms of ultrasound
enhancement at low-frequency conditions, specifically focusing on characterizing the role
of cavitation, (3) developing a model to predict sonophoresis effects for hydrophilic
permeants from knowledge of the ultrasound parameters and the physicochemical
properties of the permeants, and (4) studying the effects of LFS on living skin samples. 42
In her studies of the correlation between in vivo and various in vitro skin models,
Tang discovered that in vivo and in vitro skin models react to low-frequency
sonophoresis at different rates.42 Because of this important finding, no correlation was
observed between the in vivo and the in vitro (full-thickness skin, split-thickness skin,
and heat-stripped skin) skin models at equivalent ultrasound energy doses.42 However,
when skin electrical resistance was used instead of the ultrasound energy dose as the
comparative factor, a correlation was observed between the permeability values obtained
from the in vivo and the different in vitro skin models having the same electrical
resistances.42 This correlation makes it possible to use data from in vitro skin models to
predict what would occur in vivo.4 2
To characterize the role of cavitation in low-frequency sonophoresis, Tang
conducted two different sets of permeability experiments. 4 2 First, using a custom-made
high pressure cell, she investigated how the transdermal drug permeability changed as
pressure was increased.42 It is known that increases in pressure reduce cavitation events,
and therefore, Tang hypothesized (and observed) that increases in pressure would reduce
the transdermal drug permeability due to decreased cavitation in the high-pressure cell.42
Once cavitation was found to be a key mechanism in low-frequency sonophoresis, the
exact location of the cavitation events - inside or outside the skin membrane - needed to
be determined. 42 By using a highly viscous coupling medium (castor oil) to suppress
cavitation events outside the skin, Tang demonstrated that, for low-frequency
sonophoresis, cavitation events occur outside the skin layer.42 This is fundamentally
different from the previous findings of Mitragotri et al. using high-frequency
sonophoresis, 43 where it was concluded that cavitation takes place inside the skin.42
Additionally, Tang determined that high-velocity microjets, resulting from the collapse of
transient cavitation bubbles in the vicinity of the skin surface, are most responsible for
permeabilizing the skin.42 This key finding is not only fundamentally important, but will
also drive future practical research in low-frequency sonophoresis to identify ways to
maximize cavitation activity outside the skin in the vicinity of the skin surface in order to
maximize transdermal drug permeabilities.
Two theoretical models were developed by Tang in the course of her thesis work
- one for predicting the steady-state transdermal drug permeability from measurements
taken during the transient diffusion phase, and the second to characterize the skin porous
pathway of hydrophilic permeants, including accounting for the role of convection,
during low-frequency sonophoresis. A two-parameter Fickian diffusion model (with
constant parameter values) was developed to predict the steady-state transdermal drug
permeability from transient diffusion data, and was found to be applicable in the case of
hydrophobic permeants. 44 In the case of hydrophilic permeants, although the model did
not work quantitatively, it allowed Tang to develop an understanding of hydration effects
on the polar pathway that affects the transdermal permeability of hydrophilic compounds.
The aqueous pore pathway model was found to be able to predict the rate of drug
penetration across the skin, in addition to characterizing the effect of ultrasound on the
skin microscopic transport properties (specifically, the effective pore radius in the skin
and the ratio of skin porosity to tortuosity).4 5
Finally, Tang conducted in vivo experiments using the low-frequency ultrasound
protocols and showed, through histological studies, that low-frequency sonophoresis is
indeed safe for living tissue.31
More recently, Tang uncovered the existence of discrete "red spot" regions in skin
treated with low-frequency ultrasound (20 kHz) in the presence of sulforhodamine B
(SRB), a red fluorescent dye, as the model permeant while studying the permeation
pathways of this model compound using two-photon microscopy.42  Based on visual
observations of skin samples treated with low-frequency ultrasound in the presence of
SRB, it was hypothesized that the observed "red spots" were regions of high transdermal
permeability. 42 As a result of this hypothesis, the "red spots" are referred to as localized
transport regions (LTRs).42 In order to test this hypothesis, I compared the permeability
and skin electrical resistance measurements of the LTRs formed during pre-treatment of
the skin with low-frequency sonophoresis with the surrounding regions of ultrasound-
treated skin. If these LTRs are indeed regions of high permeability, then it would be
possible to further increase transdermal permeation rates if the red spots could be formed
uniformly over the entire surface of the ultrasound-treated skin sample.
1.2.3 Effects of Ultrasound and Surfactants on TDD
Mitragotri et al. conducted a study of the synergistic effect of low-frequency ultrasound
and the surfactant, sodium lauryl sulfate (SLS), on transdermal drug transport.38 Their
findings indicate that addition of SLS into the coupling medium during ultrasound
exposure greatly increases the enhancement of transdermal drug delivery when compared
to permeability studies without SLS in the coupling medium by two mechanisms: (1)
ultrasound drives more SLS into the skin, and (2) ultrasound enhances dispersion of SLS
within the skin.38 While the presence of SLS during ultrasound treatment of the skin
increases the perturbation of the skin, it has also been demonstrated by sonochemical
oxidation KI to 12 that the rate of cavitation may be reduced by half when SLS is included
in the coupling medium.46 This observed reduction in cavitation rate in the presence of
SLS is countered by an increase in the velocity of the microjet formed after implosion of
a transient cavitation event when a surfactant is present in the coupling medium. For
example, it has been found that a four-fold decrease in the surface tension of the coupling
medium can result in a 50-fold increase in the velocity of the microjets produced after the
transient cavitation bubbles collapse.47 As stated in the work by Tang, microjet
formation seems to be the primary effect of cavitation that leads to increased permeability
of the skin.32 Therefore, even though SLS seems to reduce the rate of cavitation in the
coupling medium during ultrasound treatment of the skin, the greater increase in microjet
velocity from the collapse of transient cavitation events translates into increased
perturbation of skin treated with ultrasound in the presence of a surfactant. In the context
of the experimental work conducted in this thesis, the advantage of using SLS in my
experiments lies in being able to permeabilize the skin faster, which will allow a larger
number of experiments to be conducted in a shorter period of time.
Tezel et al. have recently conducted two interesting studies. 29 ,40 The first study
examines the effects of ultrasound frequency on sonophoresis. In this work, some initial
observations on how the appearance of localized transport regions (LTRs) varies with
frequency were made - a single LTR was observed at 20 kHz while multiple LTRs were
observed at -40 and -60 kHz, and no LTRs were observed above 60 kHz.29
Additionally, it was suggested that the optimal frequency for drug delivery is 58.9 kHz. 29
However, this conclusion was based solely on skin electrical resistance measurements
and not on actual drug permeability measurements. In addition, given the widely-
accepted belief that cavitation is the primary mechanism of transdermal enhancement,
this proposed optimum value of -60 kHz appears to contradict cavitation as the sole
enhancing mechanism, since cavitation is inversely proportional to ultrasound frequency,
and it would be expected therefore that the optimal frequency would occur at -20 kHz.
Therefore, there is a need for further investigation into the mechanisms responsible for
ultrasound enhancement of transdermal drug delivery.
The second study involves a fundamental analysis of the synergistic effect of
ultrasound and surfactants on transdermal drug delivery. In this study, it was discovered
that 12-carbon tail surfactants are most disruptive to the skin passively, while 14-carbon
tail surfactants are most disruptive to the skin in the presence of ultrasound.40
Furthermore, charged surfactants appear to have a greater enhancing effect than neutral
surfactants. 40 Additional studies were also conducted using surfactant mixtures which
resulted in varied results.40 Mixtures of surfactants provide a possible means to increase
transdermal drug permeability enhancements, as it has been shown that surfactant
mixtures can interact synergistically to reduce the surface tension of the mixed surfactant
solution to values which are lower than those of the pure surfactant solutions at
equivalent surfactant concentrations. 48 The surface tension lowering using surfactant
mixtures would increase microjet velocity, and thereby potentially increase the drug
permeability enhancements, while reducing the exposure of the skin to irritating
surfactants. Additionally, lowering the surface tension should also reduce the cavitation
threshold, making it easier for cavitation events to occur. 38
1.2.4 Safety of Sonophoresis
In determining the safety of low-frequency sonophoresis, Boucaud et al. have conducted
some interesting work exploring the safety threshold in freshly excised human skin
samples. Their findings, applicable to ultrasound at 20 kHz only, indicate the existence
of an intensity maximum of 2.5 W/cm 2 under pulsed or continuous ultrasound operation,
before skin damage occurs. 49 Other safety analyses50 '51 have shown that damage occurs
in in vivo hairless rat and mice skin at lower ultrasound intensities (1.0 W/cm2),
indicating that these would not be good models for human skin. This further justifies the
selection of pig and human skin as acceptable models for use in the experiments
conducted in this thesis.
1.2.5 Visualization of Transdermal Permeation Pathways
Several researchers have conducted studies to determine the pathways followed by
permeants to traverse the SC and other skin layers, for both passive and ultrasound-
enhanced drug delivery. Based on work conducted on passive permeation, it was
concluded that permeation of polar molecules through the skin occurs via the intercellular
route, specifically through pathways lined with lipid molecules containing polar head
groups.6-8 The pore radius of these pathways has been estimated to be on the order of 1
nm.8,52 In addition to elucidating the likely pathway for polar permeant transport under
passive conditions, the work of these groups has also clarified the structure of the lipid
bilayers of the stratum corneum and outlined several useful techniques, including
chemical staining and a host of electron microscopy methods, for visualizing the
permeation pathways within the skin.6 8 There is also evidence that the intercellular
permeation pathway exists when ultrasound is applied to the skin.53-55 Menon and Elias
found that, at high frequency, ultrasound acts to connect segregated lacunar domains
within the skin, creating a temporary network of channels which both polar and nonpolar
permeants may use to traverse the skin barrier. 54 However, all the ultrasound permeation
pathway visualization studies in the literature have been conducted at high frequency
(MHz range). Since the focus of this thesis is on the low-frequency range of ultrasound,
it will be necessary to evaluate the types of transdermal pathways present in skin treated
with low-frequency ultrasound.
A relatively new technique, two-photon microscopy, shows excellent promise as a
new method not only for determining permeation pathways, but also for determining
enhancement factors. Recent work by Yu et al. has demonstrated the value of this
technique in investigating the in vitro permeation of both hydrophobic and hydrophilic
permeants in the presence of a chemical enhancer (oleic acid). 56 Using two-photon
microscopy, it is possible to visualize the concentration of the permeant throughout the
skin sample in 3 dimensions. This makes it possible to determine the exact location of
the permeants throughout the skin sample. This technique, which has yet to be
extensively applied to low-frequency sonophoresis, would allow visualization of the
differences in the permeation pathways of the LTRs and the unenhanced regions of an
ultrasound-treated skin sample (the non-LTRs). Additionally, valuable quantitative
information on the enhancements of the probe diffusion path length through the skin, the
probe diffusion coefficient, and the probe vehicle-to-skin partition coefficient can be
obtained from an analysis of the TPM data. The permeation pathway and enhancement
information obtained fiom TPM imaging of the LTRs and the non-LTRs would be useful
in furthering our understanding of the mechanisms of formation of these regions in
ultrasound-treated skin.
1.2.6 Fundamental Modeling of Transdermal Transport
Most of the modeling work conducted on predicting transdermal drug permeability of
hydrophobic and hydrophilic permeants is applicable only to passive delivery conditions.
For hydrophobic permeants, several empirical models, 57 61 whose important parameters
are the molecular weight and the octanol-water partition coefficient of the permeant, were
tested for accuracy by Wilschut et al. in 1995, and it was found that the revised Robinson
model was most accurate for in vitro permeation experiments with human skin samples. 62
Recently, Mitragotri has developed a predictive model for determining the permeability
of small hydrophobic solutes (MW<500) across the stratum corneum using Scaled-
Particle Theory, 63 which relates the work required to create cavities in the lipid bilayers
to the lipid density, the lipid order parameters, and the solute radius. 64 Other researchers
have attempted to use the structural parameters of the stratum corneum to model
transdermal delivery through the hydrophobic intercellular regions of the SC.3, 65-69
However, there has been some difficulty in developing a first-principles model of
hydrophobic (intercellular) transport through the stratum corneum. The primary
difficulty has been in obtaining agreement in the values of the steady-state permeability
and the diffusion lag time to steady-state. 3 In order to improve our understanding of
intercellular transport in the stratum corneum, it will be necessary to develop an
improved model for transdermal transport in the intercellular regions of the stratum
corneum which will successfully predict both steady-state permeability values and the
diffusion lag time to steady-state. By applying this improved model of intercellular
transport in the stratum corneum to ultrasound-treated skin samples, it will be possible to
better understand the role of intercellular diffusion in ultrasound-treated skin samples.
For hydrophilic permeants, the aqueous pore pathway model is the primary
theoretical model used to describe hydrophilic transdermal transport. This model has
been used to describe hydrophilic transdermal transport in untreated skin samples, as well
as in skin samples perturbed by ultrasound,46.70 chemical enhancers, 7 1' 72 and
iontophoresis.73 A key feature of the model is the inclusion of the aqueous pore radius in
the model equations. With this feature, hydrophilic permeability data can be analyzed to
determine the size of the aqueous pores in the skin, thereby allowing comparisons
between untreated skin and enhanced (by sonophoresis or other methods) skin. Such
comparisons can shed light on the mechanisms of transdermal enhancement of
hydrophilic permeant delivery. Specifically, it is possible to determine whether the
aqueous pores in the skin increase in size as the skin is enhanced, or if more aqueous
pores of the same size are generated by the enhancing method used on the skin. For the
case of LTR formation in ultrasound-treated skin, interpreting permeability data from the
LTRs and the non-LTRs with the porous pathway would make it possible to determine the
mechanism of how the skin is enhanced by ultrasound in these regions of ultrasound-
treated skin.
However, there is currently some debate in the literature on the proper application
of the aqueous pore pathway, specifically on how to characterize the aqueous pore sizes
in the skin. There are currently two methods for characterizing the aqueous pores in the
skin. The first, used by Peck et al.72 and Tang et al.,45 assumes that the aqueous pores in
the skin can be described sufficiently by a single, average aqueous pore radius. The
value of the average aqueous pore radius is a structural property of the skin and is
independent of the size of the permeant delivered through the skin. The second, used by
Tezel et al.,70 assumes that there is a distribution of aqueous pore sizes in the skin. In this
case, the average aqueous pore radius increases as the size of the permeant increases (and
vice versa), since smaller permeants can access a larger fraction of the total aqueous pore
distribution relative to larger permeants. While there is experimental data to suggest that
a distribution of aqueous pores may be a more accurate representation of the aqueous
pore pathways in the skin, some other assumptions in the model of Tezel et al. on the
behavior of the porosity and the tortuosity of the aqueous pore pathways as the skin is
treated with ultrasound need to be verified. Therefore, before applying the aqueous pore
pathway to the LTRs and the non-LTRs of ultrasound-treated skin, it is first necessary to
re-examine the assumptions and analysis techniques of the aqueous pore pathway
hypothesis to determine how best to characterize the porosity, the tortuosity, and the size
distribution of the aqueous pores in both untreated and ultrasound-treated skin.
1.3 Thesis Objectives
This thesis will address three major issues that remain unresolved, based on the review of
the available TDD literature presented in Section 1.2, that are relevant to furthering our
mechanistic understanding of ultrasound-mediated TDD.
The first issue investigates in further detail the use of the porous pathway
hypothesis to understand the mechanisms by which ultrasound enhances the transdermal
transport of hydrophilic drugs. Specifically, the goals of these studies are: 1) to
determine if the porous pathway hypothesis is a valid model for interpreting experimental
data for the transdermal delivery of hydrophilic drugs over a wide range of drug
molecular weights, and 2) to use the porous pathway hypothesis, if it is indeed valid, to
examine how ultrasound alters the skin structure, resulting in the well-documented
enhancement of hydrophilic drug transdermal transport in ultrasound-treated skin
samples.
The second issue focuses on the fundamental modeling of drug transport through
the intercellular regions of the stratum corneum. Since the intercellular regions of the
stratum corneum are hydrophobic in nature due to the presence of the lipid lamellar
bilayers, this particular transdermal modeling investigation is primarily applicable to
hydrophobic drugs. However, it has been demonstrated that the corneocyte cells of
untreated stratum corneum are essentially impermeable to both hydrophobic and
hydrophilic drugs due the presence of the cornified envelope which surrounds the
corneocyte cells. 5 Therefore, it has been hypothesized, and subsequently demonstrated,
that hydrophilic molecules also utilize the intercellular transport pathway in untreated
stratum corneum. 6 8 For hydrophilic permeants delivered in ultrasound-treated skin, it
has been hypothesized that transcellular pathways may be present in the stratum corneum
as a result of treatment of the skin with ultrasound (both in the presence and in the
absence of surfactant). The goal of this investigation is to develop a fundamental model
of drug transport through the intercellular regions of the stratum corneum based on the
structure of the stratum corneum. By using the results of this model to determine a
maximum intercellular stratum corneum permeation rate for hydrophilic permeant
delivery, it will be possible to determine indirectly whether intercellular or transcellular
permeation pathways are present in skin samples which have been treated with low-
frequency ultrasound.
The third issue examines how the formation of hypothesized LTRs in ultrasound-
treated skin samples impacts our understanding of the transport mechanisms underlying
ultrasound-mediated transdermal drug delivery. The goals of this study include: 1)
verifying that the hypothesized LTRs are, in fact, localized regions of high permeability
in ultrasound-treated skin samples compared to the surrounding regions of less permeable
ultrasound-treated skin (the non-LTRs), 2) using Two-Photon Microscopy to visualize
the location of a model hydrophilic and a model hydrophobic drug to examine the types
of transdermal pathways present in the LTRs and in the non-LTRs of ultrasound-treated
skin samples, and 3) using the porous pathway hypothesis to interpret transport data
through the LTRs and the non-LTRs in ultrasound-treated skin samples to gain
mechanistic insights into how a single ultrasound dose is able to perturb the structure of
the skin to two significantly different levels.
Addressing these three issues, which were discussed in the literature review
presented in Section 1.2, will further our understanding of the fundamental transport
processes relevant to ultrasound-mediated TDD. Additionally, deeper investigations into
the porous pathway model and into intercellular stratum corneum transport models will
further our understanding of the basic fundamental principles that are relevant in
transdermal drug delivery.
1.4 Thesis Overview
The remaining chapters of this thesis cover, in detail, investigations into the three issues
concerning ultrasound-mediated transdermal drug delivery discussed in Section 1.3.
Chapter 2 presents a theoretical and experimental investigation into the use of the
porous pathway hypothesis to describe the transdermal transport of hydrophilic drugs. In
previous studies of ultrasound-mediated hydrophilic drug transport, the transdermal
transport of a single hydrophilic drug and skin electrical resistivity measurements were
analyzed in the context of the porous pathway hypothesis to characterize the nature of the
hypothesized aqueous pore pathways in both ultrasound-treated and untreated skin
samples. In Chapter 2, two hydrophilic drugs of differing molecular weight were
delivered simultaneously through untreated human full-thickness skin, heat-stripped
human dermis, and ultrasound-treated human full-thickness skin, in conjunction with skin
electrical resistivity measurements. This experimental data was analyzed using the model
of porous pathway transport as it applies to the time-dependent solution to Fick's Second
Law of diffusion. By simultaneously delivering two hydrophilic drugs across the same
skin sample, it was possible to use the Fickian form of the porous pathway hypothesis to
evaluate the following critical drug transport properties - the porosity, the tortuosity, and
the diffusive hindrance factor - for each hydrophilic drug in each type of skin sample
examined. Finally, using the skin electrical resistivity as a quantitative measure of the
structural perturbation in the skin due to ultrasound exposure, it was possible to evaluate
how these important transport properties changed as a function of ultrasound exposure.
Chapter 3 presents an analysis of drug transport in the intercellular regions of the
stratum corneum. Building on previous structure-based models for the transport of drugs
through the intercellular regions of the stratum corneum, a new model was developed for
drug transport in the intercellular regions of the stratum corneum which accounts for the
existence of parallel diffusion pathways in the stratum corneum. The results of the model
derivation indicated that two tortuosity factors, one accounting for the total amount of
intercellular space and the second accounting for the impact of parallel diffusion
pathways on the diffusive flux, are required in the time-dependent solution to Fick's
Second Law for diffusion through the intercellular regions of the stratum corneum. This
new model was then validated against data from simulated stratum corneum diffusion
experiments conducted with the finite element software package, FEMLAB. The new
model for transport through the intercellular regions of the stratum corneum was also
useful for evaluating the vehicle-to-lipid partition coefficient, Kb, and the diffusion
coefficient, Db, for hydrophobic drugs from a single permeation experiment, which
represents an improvement over previous experimental methods used to obtain values of
Kb and Db.
Chapter 4 presents an experimental verification that the hypothesized localized
transport regions formed in skin samples treated with low-frequency ultrasound are
indeed localized regions of high transdermal transport. Analysis of the passive transport
of calcein, a hydrophilic permeant, through the LTRs and non-LTRs of ultrasound pre-
treated pig full-thickness skin samples was achieved with a novel experimental
technique: diffusion masking experiments. A colored hydrophilic permeant penetrating
into the skin was used as a marker to indicate the locations of the LTRs and the non-
LTRs on the skin. Separate skin electrical resistivity measurements of the LTRs and the
non-LTRs were used to verify the results obtained from the calcein transport
experiments. Values of the porosity/tortuosity ratio for the LTRs and the non-LTRs were
obtained from the electrical resistivity measurements and compared to the
porosity/tortuosity ratio for the intercellular regions of the skin, obtained in Chapter 3, to
determine whether intercellular or transcellular pathways were present in the LTRs and
the non-LTRs of ultrasound-treated skin.
Chapter 5 presents further analysis on the LTRs and the non-LTRs generated with
low-frequency sonophoresis. In Chapter 5, two-photon microscopy was used to visualize
the transdermal pathways within the LTRs and the non-LTRs in human full-thickness
skin. The primary goal of this study was to observe the location in the skin of a
fluorescent hydrophilic permeant, SRB, with TPM imaging to determine whether
intercellular or transcellular pathways are the primary route of delivery within the LTRs
and the non-LTRs. These images were used to confirm results obtained from an analysis
of the experimental data in Chapter 4. In this study, four cases were examined: 1)
untreated skin, 2) surfactant-treated skin, 3) ultrasound-treated skin, and 4) ultrasound
and surfactant treated skin. In addition to evaluating the types of pathways traversed by
the model hydrophilic permeant, it was also possible to generate profiles of intensity as a
function of skin depth. These profiles allowed determination of enhancements in the
surface partitioning and in the concentration gradient in the skin relative to the untreated
skin case, which can provide useful clues to the mechanism of enhancement of the skin
induced by the surfactant and/or ultrasound. While Chapter 4 examined the creation of
the LTRs and the non-LTRs in the presence of the hydrophilic probe, SRB, in Chapter 5,
the delivery of a model hydrophobic probe, RBHE, was also examined for each of the
fours cases listed above. This additional investigation was conducted to compare the
transdermal transport pathways traversed by hydrophilic and by hydrophobic drugs in the
presence of ultrasound treatment, as well as to examine any differences in the
enhancements of the transdermal transport properties resulting from the three skin
enhancing methods.
Chapter 6 presents an application of the porous pathway model to the LTRs and
the non-LTRs of ultrasound-treated skin. In this study, the methods and results of
Chapter 2 were applied to permeability data obtained from the LTRs and the non-LTRs in
full-thickness human skin generated by ultrasound in the presence of the hydrophilic
probe, SRB. The goal of this study was to examine the differences between the transport
properties associated with the aqueous pores formed by ultrasound in the LTRs and the
non-LTRs. By evaluating the porosity, the tortuosity, and the diffusive hindrance factor
for the LTRs and the non-LTRs in the context of the porous pathway model, it was
possible to examine the differences in these transport properties of the two different
regions of ultrasound-treated skin. As with the TPM imaging studies presented in
Chapter 5, this analysis provided useful clues as to how the skin was perturbed in a
heterogeneous manner from a single ultrasound treatment.
Chapter 7 completes the presentation of this thesis with a summary of the thesis
work done and a brief exploration of some potential areas for continuing future research
in the field of ultrasound-enhanced transdermal drug delivery.
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Chapter 2
Evaluation of the Porosity, the Tortuosity, and the
Hindrance Factor for the Transdermal Delivery of
Hydrophilic Permeants in the Context of the Aqueous
Pore Pathway Hypothesis using Dual Radiolabeled
Permeability Experiments
2.1 Introduction
Modeling the transport of hydrophilic permeants across the skin membrane is essential to
understanding transdermal drug delivery (TDD). A particular challenge in this area of
TDD involves understanding the mechanism of hydrophilic permeant delivery across the
stratum comeum (SC). As discussed in Chapter 1, the SC is the outermost layer of the
skin, typically having a thickness of 10-20 Iim, and consists of a brick-and-mortar
structure of impermeable corneocyte cells (the bricks) and intercellular lamellar lipid
bilayer domains (the mortar) (see Figure 1-3).' Primarily because of its lipophilic nature
due to the presence of the lipid bilayers in the intercellular regions,' the SC exhibits
increased resistance to the permeation of hydrophilic compounds as compared to the
permeation of hydrophobic compounds. Because of this observed difference in the SC
permeation rates of hydrophobic and hydrophilic compounds, it has been proposed that
hydrophobic and hydrophilic permeants traverse the SC along different permeation
pathways. Hydrophobic permeants traverse the SC primarily along the intercellular lipid
lamellar domains (see Chapter 3 for details), 2-6 while hydrophilic permeants are believed
to traverse the SC, as well as the viable epidermis and the dermis, along aqueous pore
pathways.7-1
The aqueous pore pathway hypothesis has been developed as a model to describe
the transport of hydrophilic solutes through the aqueous pore pathways of the skin. The
basic assumption of this model is that the transport of hydrophilic permeants across the
skin occurs through cylindrical aqueous channels, or pores, that traverse the skin barrier
(see Figure 2-1).9-11 Because the radii of the hypothesized aqueous pores may be similar
to the radii of the aqueous permeants which are delivered across the skin, equations from
hindered transportl 2 have previously been incorporated into the model equations
characterizing the aqueous pore pathway hypothesis.9-11 While there has been no direct
evidence for the physical existence of aqueous pore channels in the SC to date, some
researchers have claimed that the presence of an aqueous pore pathway can be inferred
from evidence of connected lacunar domains within the lipid lamellar bilayers, 7'8' 13 ,14 or
from the presence of defects in the lipid lamellar bilayers of the intercellular regions of
the SC.'0o 5 Despite the lack of direct physical evidence for the existence of the aqueous
pore pathways in the SC, the porous pathway hypothesis has been used extensively to
study the permeation of hydrophilic permeants across the SC.
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Figure 2-1: Sketch of the hypothesized cylindrical aqueous pore channels (shown in
white) which traverse the skin barrier (shown in grey).
One of the main reasons that transdermal transport models for hydrophilic
permeants, which are based on the aqueous pore pathway hypothesis, continue to be
useful in the field of hydrophilic transdermal transport is their ability to evaluate several
key transport parameters characterizing the structural features of the hypothesized
aqueous pores. These include: 1) the fraction of the skin surface occupied by the aqueous
pore channels, E, (i.e. the porosity), 2) the tortuosity, T, of the aqueous pore channels
present in the skin, and 3) the average aqueous pore radii, or the distribution of aqueous
pore radii, of the hypothesized aqueous pore channels, which determines the amount of
hindrance experienced by a hydrophilic permeant diffusing through an aqueous pore
channel in the skin. Previously, Peck et al. used the aqueous pore pathway hypothesis to
determine the average aqueous pore radius in untreated and in ethanol-treated human
epidermal membrane from permeability experiments using four small hydrophilic
permeants - urea (MW = 60.1 Da, log Ko/w = -2.75), mannitol (MW = 182.2 Da, log
Ko/w = -3.10), sucrose MW = 342.3 Da, log Ko/w = -3.67), and raffinose (MW = 504.4
Da, log Ko/w = -3.67) (see Section 2.2.1 for model details).9 Tang et al. used the aqueous
pore pathway hypothesis in conjunction with principles of electrochemistry to
demonstrate that the permeability of small hydrophilic permeants (mannitol and sucrose)
can be predicted from measurements of the skin electrical resistance.' 0 These studies
allowed for the determination of the average aqueous pore radius and the porosity-to-
tortuosity ratio, (s/I), in untreated and in ultrasound-treated full-thickness pig skin and
human epidermal membrane (see Section 2.2.2 for model details).' 0 Tezel et al. extended
the work of Tang et al. by modifying the aqueous pore pathway hypothesis to account for
the possible existence of a distribution of aqueous pore radii in the skin. This
modification was required to account for deviations from the model equations in the
aqueous pore pathway hypothesis proposed by Tang et al. observed in permeability
experiments in the case of larger hydrophilic permeants (i.e. inulin (MW = 5000 Da, log
Ko/w = -2.75) and dextran (MW = 70,000 Da, log Ko/w = -2.75))." This modification
also allowed prediction of the permeability of larger hydrophilic permeants in untreated
and in ultrasound-treated skin using skin electrical resistance measurements. Moreover,
this modification to the aqueous pore pathway hypothesis made by Tezel et al. allowed
for the separate evaluation of the porosity, E, and the tortuosity, T, rather than of the ratio,
(s/T) (see Section 2.2.3 for model details)." In addition, the studies with ultrasound-
enhanced skin conducted by Tang et al. and by Tezel et al. suggested that permeability
enhancement of the skin structure is due to the creation of more pores having the same
pore size distribution as that in untreated skin samples, and not due to the creation of
larger or smaller pores than those observed in untreated skin samples. 1011
However, there are some model assumptions made by Tang et al. and by Tezel et
al. that need to be re-examined. Regarding the work of Tezel et al., the assumptions that
will be examined in more detail include assuming that: 1) the porosity is an intrinsic
property of the skin membrane, 2) there is an increase in the skin tortuosity with a
corresponding increase in skin perturbation due to the application of ultrasound, and 3)
the tortuosity of the aqueous pore pathways depends on the size of the hydrophilic
permeant. This examination of previous model assumptions (see Section 2.2.4 for
details) provides the motivation for revising the techniques used to analyze experimental
permeation data of hydrophobic compounds in the context of the aqueous pore pathway
hypothesis.
With all of the above in mind, in this chapter, I present a novel technique to
analyze the experimental permeation data of hydrophilic compounds in the context of the
aqueous pore pathway hypothesis. This technique allows one to evaluate the porosity,
the tortuosity, and the radii of the aqueous pore channels, while circumventing the need
to make potentially problematic assumptions about the structure of the hypothesized
aqueous pores in the skin. Specifically, in Section 2.3, I propose a novel method to
analyze skin permeation data of hydrophilic compounds in the context of the aqueous
pore pathway hypothesis, which requires the application of this hypothesis to both the
transient and the steady-state diffusion domains of permeation experiments involving
dual radiolabeled hydrophilic compounds. In Section 2.4, the methods and materials
required to perform permeation experiments involving dual radiolabeled hydrophilic
compounds in untreated and in ultrasound-treated human full-thickness skin samples are
described. Finally, in Section 2.5, the data from the diffusion experiments are presented
and analyzed using both previously-used steady-state methods and the novel method
developed in Section 2.3, which allows the determination of the porosity, the tortuosity,
and the radii of the aqueous pore channels, which are hypothesized to exist in the skin.
2.2 Review of Previous Models for the Transdermal Transport of
Hydrophilic Permeants Based on the Aqueous Pore Pathway
Hypothesis
In this section, three transdermal transport models for hydrophilic permeants, which are
based on the aqueous pore pathway hypothesis, are reviewed, followed by motivating the
need to further improve these models.
2.2.1 Evaluation of the Aqueous Pore Radius in the Skin using Dual
Radiolabeled Transdermal Permeation Experiments
The steady-state permeability, P, of hydrophilic permeants through the aqueous pore
pathways in the skin can be described by the following equation: 9
c Dc'H( )
P= P (A) (2.1)
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where Ep is the total area fraction of the skin available for transport (i.e. the porosity), D'
is the diffusion coefficient of the permeant (p) in the bulk solution at infinite dilution, L is
the thickness of the skin membrane, tp is the tortuosity factor, and H(hp) is the hindrance
factor. For k, < 0.4, H(kp) is defined by the following equation:12
H(J,)= (1-,,)2[1 - 2.104,,, + 2.091Z,, - 0.951/,, 5  (2.2)
where X, is defined as follows:12
A p = rp (2.3)
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where rp is the radius of the permeant and rpore is the radius of the aqueous pore channels,
which are assumed to have a single average radius. Equation (2.1) was used by Peck et
al. to determine the average radius of the aqueous pore pathways in both untreated and in
ethanol-treated human epidermal membranes. 9 Since sp, Tp, and rpore are unknowns,
experiments were designed to eliminate ,p and t, in order to evaluate rpore. This was
accomplished by delivering two permeants simultaneously through the same skin sample.
For this case, the ratio of the expressions for the permeabilities of permeants 1 and 2 can
be expressed as follows:
P, ( /r), D- H(/ý )
= (E / 02 D2  2)
It is useful to express Eq. (2.4a) in logarithmic form as follows:
D___ H(A,) e z"
logP, =log + log + log + log-- + log P2 (2.4b)
If one assumes that the porosity and the tortuosity are not dependent on the size of the
permeant, such that the values are identical for the two permeants, then, E and T (as well
as L) may be eliminated from Eqs. (2.4a) or (2.4b). 9 This assumption also implies that
the two permeants traverse the skin using the same aqueous pore pathways. Once the
permeability of each of the permeants is measured experimentally, Eqs. (2.4a) or (2.4b),
in conjunction with Eqs. (2.2 and (2.3), can be used to determine the value of rpore, the
remaining unknown.
2.2.2 Evaluation of the Aqueous Pore Radius in the Skin using Electrical
Resistance Measurements and Transdermal Permeation Experiments
Tang et al. examined a specific application of the aqueous pore pathway hypothesis
where the second hydrophilic permeant is a current-carrying ion.10 The assumption of
this specific application was similar to the assumption of Peck et al., i.e. current-carrying
ions accessed the same aqueous pore channels as the model hydrophilic permeant. From
this assumption, it follows that the values of E and r are independent of the size of the
permeant and the current-carrying ion. For this case (where sion = s, and Tion = rp), Eq.
(2.4b) can be rewritten as follows: 0
Do H(A,)logP, =log " +og Pf,,, (2.5)
D,,on H(k,, )
where Pion is the permeability of the current-carrying ions, D',,2 is the diffusion
coefficient of the ion in the bulk solution at infinite dilution, and H(Xion) is the hindrance
factor of the ion (see Eqs (2.2) and (2.3) with "p" replaced by "ion"). Using principles
from electrochemistry, Tang et al. were able to derive the following equation relating the
permeability of the ions through a membrane to the electrical resistance measured across
the same membrane:' l
kT 1
S kT 1 (2.6)2z 2Fc o , eo RA
where k is the Boltzmann constant, T is the temperature (in degrees Kelvin), z is the
electrolyte valence, F is the Faraday constant, R is the resistance measured across the
skin, A is the area of the skin available for transport, and cion is the electrolyte molar
concentration in the skin membrane (assumed to be the bulk ion concentration).
Substituting Eq. (2.6) in Eq. (2.5) yields: 0
kT DP H (A,)log P, = log + log +log -log RA (2.7)22 Fc,,,eo D,,,, H ,,,, )
Equation (2.7), then, relates the permeability of a model hydrophilic permeant to the
electrical resistance of the skin through which the model hydrophilic permeant is being
delivered. Equation (2.7), in conjunction with Eqs. (2.2) and (2.3), can then be used to
estimate the permeability of a desired hydrophilic permeant through a membrane using
electrical resistance measurements, if the aqueous pore radius, rpore, as well as the radii of
the permeant, rp, and of the current-carrying ions, rion, are known.
Interestingly, even if the aqueous pore radius is unknown, as in human skin
samples, Eq. (2.7) can nevertheless be used to determine the aqueous pore radius using
both skin electrical resistance measurements and hydrophilic permeability measurements.
On a log P vs. log RA plot, Eq. (2.7) predicts that a slope of -1 passes through the
experimental data. The first three terms on the RHS of Eq. (2.7) contribute to the value
of the y-intercept in the log P vs. log RA plot. From the experimental value of the y-
intercept, the radius of the aqueous pores in the membrane (found in H(Xp) and H(,ion))
can then be determined. Tang et al. used this technique, with mannitol and sucrose as the
model hydrophilic permeants, to determine the average available pore radius in both
untreated and in ultrasound-treated skin samples.' 0 Their results indicated that the
average available pore radius in the skin was similar for both model permeants, and was
also similar for the untreated and the ultrasound-treated full-thickness pig skin samples.' l
These results led Tang et al. to the conclusion that ultrasound enhancement of the skin
results in the creation of additional aqueous pores which have radii that are similar to
those of the aqueous pores present in the untreated skin samples.' 0
2.2.3 Modification of the Aqueous Pore Pathway Hypothesis to Account for
the Presence of a Distribution of Aqueous Pore Radii in the Skin
The next advance in the development of the porous pathway model came as a result of an
experimental analysis conducted by Tezel et al." In their experiments, Tezel et al.
repeated the experiments of Tang et al. using a broader range of permeant radii. The
previous work done by both Peck et al. and by Tang et al. used similarly sized permeants,
ranging from 2.2 A to 6.6 A in radius. The work of Tezel et al. compared the transdermal
permeability of four permeants (mannitol - rp = 4.4 A, luteinizing hormone relasing
hormone (LHRH) - r, = 8 A, inulin - rp = 12 A, and dextran - rp - 26 A) to skin electrical
resistance measurements for both untreated and ultrasound-treated skin samples. " Tezel
et al. observed that the slope of the experimental data for these four permeants
significantly deviated from the slope of -1 predicted by the model of Tang et al.,10 and
that the experimental data could be fit to the following empirical expression:"
log P = log C - (i - a)log RA (2.8)
where log C is the y-intercept value from the log P vs. log RA plot, and a is an empirical
modifier to the -1 slope. Furthermore, the value of a was found to increase as the radius
of the permeant increased.
The experimental observation made by Tezel et al." required a revision of three
key assumptions in the aqueous pore pathway model proposed by Tang et al. 1'0 to account
for the fact that the slope in the log P vs. log RA plot was observed to be greater than -1,
as well as to increase with the permeant radius. First, Tezel et al. revised the calculation
of the hindrance parameter by proposing a distribution of pore radii, y(rpore), and, then,
integrating the product of y(rpore)*H(X) over all values of rpore larger than the radius of the
permeant, rp, as shown in the following expression:''
H(;,,) = y(r,,,o)H(L)drr,,, (2.9)
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Second, they proposed that the smaller permeants would access more tortuous aqueous
pore channels within the skin than the larger permeants, resulting in the smaller
permeants having a larger t value than the larger permeants." Finally, they also
proposed that the tortuosity in the dermis would be larger than in untreated skin due to
the increased amount of aqueous pore connectivity in the dermis. 11 If ultrasound
enhances the connectivity of the aqueous pores, as proposed by Tezel et al., " then, it also
follows that the tortuosity of the skin should increase as the skin is treated with
ultrasound until it reaches the tortuosity value of the dermis. To account for the third
model proposition, the following empirical power law relations were proposed for the
hydrophilic permeant and the current-carrying ions:'
=p RAder.
"i (2.10a)
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Combining Eq. (2.4b) (with 1 = p and 2 = ion) with Eq. (2.6), the following general
expression can be written which relates the permeability of a model hydrophilic permeant
(p) to the skin electrical resistance:' I
kT D; H(Ap, ) llog P, = log + log + log- +log " +log !o " -logRA (2.11)
2z2Fc,,,,eo  Dio H ,,,,, ) E,,, T
For the case where E is assumed to be an intrinsic property of the skin and independent of
the radii of the permeant and of the current-carrying ion, such that Sp = Sion, substituting
Eqs. (2.9), (2.10a) and (2.10b) in Eq. (2.11) yields:1'
kT DO
log P= log F + log P2z-Fc,,,,eo D, ,,
JY(rpre )H(A)drPore (2.12)
+ log - a log RA,,,dr,, - (1 - a)log RA
fy(rpore )H(1I)drpore
where it was assumed that, in the dermis, Tion = Tp, and that a = m - n. The proposed
modifications to the aqueous pore pathway model, embodied in Eq. (2.12), allows the
slope of the data in the log P vs. log RA plot to deviate from the slope of -1 predicted by
Tang et al.'o Equation (2.12) then fits the form of the empirical relationship presented in
Eq. (2.8) which describes the experimental data obtained by Tezel et al." Using Eq.
(2.12) to interpret their experimental data, Tezel et al. observed that the distribution of
pore radii does not change as the skin is treated with ultrasound." Accordingly,
ultrasound creates more pores having a distribution of pore radii which is similar to that
found in untreated skin. This proposed mechanism of ultrasound enhancement is similar
to that proposed by Tang et al. (i.e. ultrasound enhancement serves only to augment the
number of aqueous pores found in untreated skin),' 0 with the key difference that it
replaces the single average pore radius used by Tang et al. with an entire distribution of
pore radii.
In addition, Tezel et al. were able to estimate the porosity and the tortuosity of the
aqueous pore pathways separately using other equations based on their additional model
assumptions. First, Tezel et al. proposed the following empirical power law expression
for the porosity by assuming that the skin membrane thickness and the ion tortuosity are
both functions of the skin resistivity:
E - (2.13)
RA'
where T and K are empirical constants. The ratio, (c/,p), can then be expressed using
Eqs. (2.10a) and (2.13) as follows:"
log = log RA + (n+•a -c)logRA (2.14)dermfis +a
p) P dermis
The values of n, T, and K are permeant independent, while those of c and pdermis are
permeant dependent." By plotting (e/t,) as a function of the skin resistivity, RA, for
several permeants, it is possible to determine the values of n, T, K, and Tpdermis for each
permeant. Once these values have been determined, the skin porosity and the skin
tortuosity can be determined for each permeant. Using this method, Tezel et al.
demonstrated that the skin porosity increased with decreasing skin electrical resistivity,
while the skin tortuosity increased with decreasing skin electrical resistivity and
decreased with increasing permeant radius."
2.2.4 Reexamination of Previous Aqueous Pore Pathway Model
Assumptions
In this section, I reexamine four key model assumptions made by the previous
researchers. 9 "- These assumptions include: 1) the two hydrophilic permeants traverse
the skin through the same aqueous pore channels, 2) the porosity of the skin is an
intrinsic skin property, and therefore, is independent of the permeant radius, 3) the
tortuosity decreases as the radius of the permeant increases, and 4) the tortuosity
increases as the skin is perturbed with low-frequency ultrasound.
An examination of assumption (1) - that the two permeants being delivered across
the skin traverse the exact same aqueous pore pathways, has already been carried out by
Tezel et al.," and led to their hypothesis that a distribution of aqueous pore radii may
exist in the skin. Note that this hypothesis is not at odds with the assumption made by
previous researchers9" 0 that the two hydrophilic permeants traverse the skin through the
same aqueous pores, in cases where the two permeants delivered transdermally have
similar radii. In the works of Peck et al. and Tang et al., the radii of the permeants that
they utilized ranged from 2.2 A to 6.6 A.9,10 These radii were small compared to the
average aqueous pore radii, - 20-25 A,9,'0 thus satisfying this requirement.
However, when the radii of the two permeants delivered transdermally are very
different, such that the smaller permeant can access a larger fraction of the aqueous pore
pathways than can the larger permeant, additional considerations are needed. First, since
the smaller permeant accesses a larger fraction of the aqueous pore pathways than does
the larger permeant, it would also appear that the value of the porosity, which is the
fraction of the skin surface occupied by the available aqueous pore channels,
corresponding to the smaller permeant would be larger than the porosity corresponding to
the larger permeant. This observation differs from the assumption made by Tezel et al.
that the porosity is an intrinsic property of the skin and is independent of the radius of the
permeant. I" By evaluating the porosity of the skin as a function of the radius of the
permeant delivered transdermally, it should be possible to determine if there is a
dependence of the skin porosity on the radius of the permeant.
Tezel et al. also assumed that the tortuosity of the aqueous channels decreases as
the radius of the permeant increases. In making this assumption, in effect, Tezel et al.
claim that the transport process in the skin is similar to the transport process in size-
exclusion chromatography.'l In size-exclusion chromatography, molecules are separated
based on molecular radii, where the smaller molecules are able to access the more
tortuous channels within the chromatography column when compared to the larger
molecules.2 While Tezel et al. do provide some data which is consistent with this
assumption, the data does depend on their proposed model equations, which account for
their assumption that the tortuosity of the aqueous channels decreases as the radius of the
permeant increases. It would be preferable if the tortuosity of the aqueous pore channels
in the skin could be evaluated as a function of the radius of the permeant delivered
transdermally using model equations that are not based on any prior assumptions about
the dependence of the tortuosity of the aqueous pore channels on the radius of the
permeant.
Finally, Tezel et al. also assumed that the tortuosity of the skin increases as the
skin is perturbed with ultrasound. This assumption is problematic, if the equation for the
lag time to reach steady-state, given by: 17
t = (2.15)S6D H((A)
is considered carefully. As part of their analysis, Tezel et al. concluded that the
distribution of aqueous pore radii in the skin does not change with ultrasound treatment
(implying that H(Xp) should be constant)." Therefore, under the assumption that the
tortuosity of the skin, r,, increases as the skin is treated with ultrasound, the lag time to
reach steady-state should also increase (see Eq. (2.15)). As an example, using the values
reported by Tezel et al. for the tortuosity of dextran in untreated skin (RA - 100 kQ**cm 2,
P, - 1) and in ultrasound-treated skin (RA- 1 kQ*cm2, p~ 11), and assuming that L,
H(Qp), and D' are independent of the extent of skin perturbation induced by ultrasound,
Eq. (2.15) can be used to show that there is a 121-fold increase in the lag time to reach
steady-state in ultrasound-treated skin samples as compared to untreated skin samples for
similarly large molecules. Clearly, treating the skin with low-frequency ultrasound
would not be an efficacious enhanced transdermal drug delivery method if more time was
required for the drug to reach steady-state in ultrasound-treated skin than in untreated
skin. By evaluating the tortuosity of the aqueous pore channels in the skin as a function
of the extent to which the skin is perturbed due to ultrasound exposure,2 2 which can be
evaluated quantitatively using skin electrical resistance measurements, it should be
possible to determine if there is a dependence of the tortuosity of the aqueous pore
channels in the skin on the amount of ultrasound treatment to which the skin was
subjected.
In order to evaluate the porosity, the tortuosity, and the radii of the aqueous pore
channels in the skin, an improved theoretical analysis method needs to be developed that
does not require a priori assumptions about the behavior of the porosity, the tortuosity,
and the radii of the aqueous pore channels in the skin as function of the permeant radii or
of the extent of skin perturbation, as was done in previous investigations. 9 11 Previous
theoretical analysis methods have also relied solely on steady-state permeability
measurements, which limits the number of unknowns that can be determined (see Section
2.4.6). In the following section, I extend the aqueous pore pathway model to include the
transient domain of the transdermal transport of hydrophilic permeants. Combining the
resulting new theoretical equations with the dual radiolabeled experimental technique, I
will show that it is possible to evaluate the porosity, the tortuosity, and the radii of the
aqueous pore channels in the skin as a function of both the hydrophilic permeant radii
and the extent of skin perturbation induced by the ultrasound treatment.
2.3 Theory
2.3.1 Development of Fick's Second Law of Diffusion in the Context of the
Aqueous Pore Pathway Hypothesis
Figure 2-2 shows a thin slice of the skin containing the hypothesized aqueous pore
channels, which are assumed to have: 1) a uniform pore radius over the length of the
aqueous pore channel, 2) a tortuous shape, and 3) no branching of the pore channels in
the skin such that there are no parallel diffusion pathways present. Assuming that drug
transport is restricted to these hypothesized aqueous pores in the skin slice, the following
mass balance can be written on the thin slice of skin shown in Figure 2-2:
A__-
Figure 2-2: Sketch of a thin slice of the skin having cross-sectional area, A, and
thickness, Az, containing the hypothesized aqueous pore channels.
8m
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where ri in and rh out are the drug mass flow rates into, and out of, the hypothesized
aqueous pore channels in the skin. The mass, m, which accumulates in the thin slice of
the skin can be defined as the product of the volume of the hypothesized aqueous pore
channels in the thin slice of skin, Vpores, and the drug concentration, C(z,t), where z
denotes the direction perpendicular to the thin slice of skin (see Figure 2-2), and t denotes
time. Note that, since the length of the hypothesized aqueous pores is much larger than
the radius of the hypothesized aqueous pores, diffusion in the pores may be assumed to
be 1-D, along the z-direction. Assuming that Vpores is independent of time, an assumption
which is valid when the skin is not perturbed during diffusive transport, Eq. (2.16) can be
rewritten as follows:
aC(z,t)
min - mout - Vpores (2.17)
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Based on the geometry of the thin slice of skin shown in Figure 2-2, Vpores can be defined
as follows:
Vpore s. = (e,,pAXi Az) (2.18)
where ,PAz is the length of the tortuous aqueous pore channels in the thin slice of skin
shown in Figure 2-2, and FpA is the area of the skin cross-section, perpendicular to the z-
direction, occupied by the hypothesized aqueous pore channels. It should be noted that F,
can be defined, for the case of a single average aqueous pore radius, rpore, in the skin, as
follows:
N 2E A = Anr 2 (2.19a)
or, for the case of a distribution of aqueous pore radii, y(rpore), in the skin, as follows: 15
.6 = rA r,Ore ),4Z, dr (2.19b) A prorL rtr por e (2.19b)
where N is the number of hypothesized aqueous pore channels present in a skin sample of
area A. Substituting Eq. (2.18) in Eq. (2.17) yields:
thin -tho,,, = E,,, AAz rB t) (2.20)
Dividing Eq. (2.20) by the cross-sectional area of the skin slice, A, and noting that mass
per unit area and per unit time is the flux, F, Eq. (2.20) can be rearranged as follows:
1 F(z + Az,t)- F(z,t) = C(z,t)(2.21)
In the limit when Az approaches 0, Eq. (2.21) reduces to:t
In the limit when Az approaches 0, Eq. (2.21) reduces to:
= at (2.22)r az P at
It now remains to evaluate F(z,t) in terms of C(z,t) to obtain a model equation for
the partial differential form of Fick's Second Law of diffusion. The mass flow rate of
drug delivered through the hypothesized aqueous pores of the thin slice of the skin (see
Figure 2-2) can be modeled as follows: 23
=t()A)D- •H( C( z + Az, t) - C(z, t) (2.23)
where cpA is the cross-sectional area of the hypothesized aqueous pore channels available
to the drug at the inlet and at the outlet of the skin slice, -cpAz is the effective diffusion
path length through the hypothesized aqueous pore channels in the thin slice of skin, and
H(,p) is the hindrance factor, which is defined using Eqs. (2.2) and (2.3). Dividing Eq.
(2.23), by the cross-sectional area of the thin slice of skin, A, to obtain the flux yields:
F r  -P D[H(f C(z + Azt)-C(z,t) (2.24)
A Az
As Az approaches 0, Eq. (2.24) can be further simplified to yield Fick's First Law of
diffusion for the hypothesized aqueous pore channels present in the thin slice of skin:
F = L D H(AnP)ac(z, t) (2.25)
Substituting Eq. (2.25) in Eq. (2.22) yields the form of Fick's Second Law of diffusion
through the hypothesized aqueous pores in the skin:
ac D H(A , ) a2C
S P 2  aZ2  (2.26)
at T P z
2.3.2 Obtaining Expressions for the Transient Solution to Fick's Second
Law of Diffusion in the Context of the Hypothesized Aqueous Pores
in the Skin
Equation (2.26) can be solved for the general case with the following boundary and initial
conditions: 23
C(z = L,t) = C, (2.27a)
C(z = 0, t)= C,. (2.27b)
C(z,t = 0) = Co  (2.27c)
where Cd is the bulk concentration of the hydrophilic permeant on the donor side of the
skin, Cr is the bulk concentration of the hydrophilic permeant on the receiver side of the
skin, and Co is the initial concentration of the hydrophilic permeant within the
hypothesized aqueous pore channels in the skin. Note that in the z-direction, z = 0
corresponds to the outlet of the skin, rather than to the inlet of the skin, in order to
simplify the solution of Eq. (2.26). Following the solution procedure of Fick's Second
Law of diffusion through a homogeneous membrane, 23 the solution of Eq. (2.26) with the
subject to the initial and boundary conditions given in Eqs. (2.27a) - (2.27c), is given by:
C(z, t) = Cr + (C,, - C,. )
+ -2 •C•, cos n;T- Cr sin D ) exp- ) n 2 T+I - ' sm - ex -, (2.28)
, n -L T ?
+-- - s m exp -r 2
r ,,,1=0 2m + 1 L r, L
The total amount of mass of hydrophilic permeant per unit area delivered across the skin,
Q(t), is given by a time integral over the flux, that is, by:23
Q(t) F(z = 0,t)dt = J" D7H(APaC(zt>) dt (2.29)
0 0 p z =0
where Eq. (2.25) has been used for the definition of the flux of the hydrophilic permeant
in the skin. Substituting Eq. (2.28) in Eq. (2.29) and carrying out the integration over
time yields:23
is DH(A, )tQ(t) = (CL d r))Tr,L
+ P r 1- exp - , n 2;2t (2.30)
S ,,= n (r-L)
4&,COr-,L Cd cosnr - Cr D )H 12) 2+ ), P 11 + 1ex - exp P '), P (2m + 1); t
7r ,,,=0 (2m + 1) exp L)
For the special case when Cr = Co = 0, which is applicable for most permeation
experiments, Eq. (2.30) can be further simplified by noting that cos(nrt) = (-1)n and that
(-1) 23 This yields:
,,= n 12
D H) =V 1 2 (-1) - D H( P 2tQ (t) = 6 1Cd 22 L, 2 --- exp (2.31)(rPL)- 6 2 ( , 1, n- (rL)3
Equation (2.31) describes the cumulative amount of mass of hydrophilic permeant
delivered through the hypothesized aqueous pore channels in the skin, per unit area, at
time, t. At steady-state (for large t), Eq. (2.31) simplifies as follows:
Q(t) PC,, rPL, H(P t -- (2.32)) ('r,, L )2 6
From Eq. (2.32)., the lag time to reach steady-state for diffusion of the hydrophilic
permeant through the hypothesized aqueous pores in the skin can be evaluated by setting
Q(t) equal to zero and solving for tlag. 23 This yields:
t /ia = (2.33)
6D H(A,,)
Finally, the steady-state permeability, P, for the transport of hydrophilic permeants
through the hypothesized aqueous pore channels in the skin can be evaluated by dividing
Eq. (2.32) by Cd and evaluating the time derivative to obtain:23
1 Q(t) cpD H(2,,)P = (2.34)
C, at r,, L
which is the expression for the permeability given in Eq. (2.1). Note that for the case of a
homogeneous membrane where ,p and p, are equal to 1, Eqs. (2.28) - (2.34) reduce to the
equations describing transport through a homogeneous membrane.23
2.4 Materials and Methods
2.4.1 Chemicals
Four hydrophilic permeants, 14C-Urea, 3H-Mannitol, 3H-Raffinose, and 3H-Inulin, were
obtained from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Phosphate
Buffer Saline and Sodium Lauryl Sulfate (SLS) were obtained from Sigma-Aldrich (St.
Louis, MO). All these chemicals were used as received.
2.4.2 Skin Preparation
Full-thickness human cadaver skin was obtained from the National Disease Research
Institute (Philadelphia, PA) and stored at -800C until use. Prior to use in the diffusion
experiments, the skin was thawed and the subcutaneous fat was removed from the skin
using a razor blade. For the experiments with untreated and with ultrasound-treated skin,
the skin was sectioned and mounted in vertical Franz diffusion cells (15-mm inner
diameter) obtained from Permegear (Bethlehem, PA). For the experiments with human
dermis, the skin was heat-stripped to remove the epidermis by submersing the full-
thickness skin in 60 TC water for 2 minutes. The epidermis was subsequently removed
from the dermis by pulling off the epidermal layer with tweezers.
2.4.3 Skin Electrical Resistance Measurements
Prior to ultrasound pre-treatment, the electrical resistance of the skin mounted on the
diffusion cells was measured according to previously published methods, 22 which are
summarized next. A 100 mV AC voltage source at 10 Hz was generated using a signal
generator (Hewlett-Packard, model HP 33120A) and applied across the skin membrane
using two Ag/AgCl electrodes (In Vivo Metrics, Healdsburg, CA) for 5-10 seconds. The
skin electrical current was measured using a Fluke Multimeter (Model 139, Fluke
Corporation). The skin electrical resistance was obtained from the skin electrical current
using Ohm's Law. Since this measurement also includes the resistance of the donor and
the receiver cell solutions, a background electrical resistance measurement of just the
PBS solution was made separately, and was then subtracted from the electrical resistance
of the skin in the diffusion cell to determine the actual skin electrical resistance. The
electrical resistance, R, of all the skin samples was measured and multiplied by the skin
area available to ultrasound exposure in the diffusion cell (A = 1.77 cm 2 ). Any skin
sample with an initial RA value of <50 kOhm*cm 2, corresponding to an initial current of
3.3 [tAmps, was considered damaged and was discarded, and was subsequently replaced
with an intact skin sample.22
2.4.4 Ultrasound Pre-Treatment Protocol
Ultrasound, in the presence of a coupling medium containing 1% (w/v) SLS in PBS, was
applied to the intact human full-thickness skin samples based on previously published
methods. 1' 0' 24 Ultrasound (VCX 400, Sonics and Materials, Inc., Newtown, CT) was
applied to the skin samples at the following conditions: frequency - 20 kHz, intensity -
7.2 W/cm2, pulse length - 5 sec on, 5 sec off, and tip displacement - 3 mm,'0. 24 until the
measured skin electrical current reached values between 25 - 30 pAmps for the low
ultrasound-SLS dose and between 250 - 300 pAmps for the high ultrasound-SLS dose.
As stated in Section 2.1, these skin electrical current values will enable us to study how
the porosity, the tortuosity, and the aqueous pore radii change as the skin structural
perturbation is increased due to the ultrasound treatment. After each minute of
ultrasound exposure, the coupling medium was changed to minimize the impact of
thermal effects on the permeation enhancement of the skin,10,24 and measurements of the
skin electrical current were conducted to determine if the target skin electrical current had
been reached. Once the desired skin electrical current was attained, the skin sample was
removed from the diffusion cell and was rinsed to remove the excess coupling medium
from the skin surface in preparation for the dual radiolabeled diffusion experiments.
2.4.5 Dual Radiolabeled Diffusion Experiments
Dual radiolabeled diffusion experiments were carried out using vertical Franz diffusion
cells. In each experiment, urea, which is carbon-14 labeled, was paired with a tritium-
labeled permeant - mannitol, raffinose, or inulin. For the untreated skin samples, 2 ml of
a solution containing 10 gpCi/ml of urea and 10 ýpCi/ml of one of the three tritium-labeled
permeants was placed in the donor chamber, while for the ultrasound-treated skin
samples and the dermis samples, 2 ml of a solution containing 1 p~Ci/ml of urea and 1
giCi/ml of one of the three tritium-labeled permeants was placed in the donor chamber. A
higher concentration of the radiolabeled permeants was used in the untreated skin
samples relative skin samples treated with ultrasound and SLS and the dermis samples to
ensure that enough permeant was delivered through the untreated skin samples to be
detected by the scintillation counter. Aliquots (-400 pL) of the receiver chamber were
taken at predetermined time points over a period of 48 hours to ensure transition into the
steady-state domain for each of the permeants and skin sample types considered. The
radioactivity of these aliquot samples was then measured using the dual radiolabeled
counting mode in a scintillation counter (Packard, Tri-Carb®, 2200 CA). Plots of Q(t)
versus time were then generated from the results of the scintillation counting of the
aliquots taken from the receiver cell.
2.4.6 Regression Analysis of the Dual Radiolabeled Diffusion Experimental
Data using Eq. (2.31) to Evaluate the Porosity, the Tortuosity, and the
Aqueous Pore Radii
In the dual radiolabeled diffusion experiments, a 14C-labeled hydrophilic permeant and a
3H-labeled hydrophilic permeant are delivered simultaneously using the same skin
sample. This allows Eq. (2.31) to be utilized to model the amounts of '4C-labeled
hydrophilic permeant (Q(t) 14c) and of 3H-labeled hydrophilic permeant (Q(t)3H) delivered
across the skin, as follows:
Q(t) 14 (4C =CdL)14([DH(A) 1 2 (-1)" 11 DH(A) 22 (2.35a)I4( V 2  exp n r2
(L)2 14( 6 r ,n=1 n- (rL)2  14(
Q(t) 3H =(CdrL)3 H
D"H(A)r 1 2 (-) D("H(A)) (2.35b)
t -exp n 72(rL)2 31 6 2 ,=1 2 (IL)2 31
The quantities, (;CdTL) and [D'H(0)/(tL) 2], in Eqs. (2.35a) and (2.35b) can be evaluated
for both the 14C-labeled hydrophilic permeant and the 3H-labeled hydrophilic permeant
from the experimental data using non-linear regression methods. Specifically, non-linear
regression was conducted with DataFit 8.1 (Oakdale Engineering) with (ECdrL) and
[D'H(k)/(rL) 2] for both the 14C-labeled and the 3H-labeled hydrophilic permeants
selected as the regression parameters. DataFit 8.1 uses the Levenberg-Marquardt method
as the algorithm to adjust the values of the initial estimates of the regression parameters
to improve the fit of the nonlinear regression model. This regression analysis yields the
following four equations:
(C )14- R, (2.36a)
SD"H(1)L R2  (2.36b)
(D H() =R4 (2.36d)
L 3H
where R1, R2, R3, and R4 are the values of the four expressions above obtained from the
non-linear regression analysis. For both the 14C-labeled hydrophilic permeant and the
3H-labeled hydrophilic permeant, the donor concentration, Cd, and the bulk diffusion
coefficient, D , are known. In addition, the thickness of the skin, L, is also known.
Therefore, Eqs. (2.36a) - (2.36d) can be simplified as follows:
S-=a (2.36a)d,14(L
) 14( D14(
(er -) = - c (2.36c)
Cd,3H
H__ R4L2
- = d (2.36d)
where a, b, c, and d are known quantities, as defined in Eqs. (2.36a) - (2.36d). The
tortuosity for both the 14C-labeled hydrophilic permeant and the 3H-labeled hydrophilic
permeant may be eliminated from Eqs. (2.36a) - (2.36d) as follows:
(.6 )2( _ 2 H(Ai))11_ a2 b (2.37a)
14(C
(rY) 3= , 2 H(A))_, =c 2 d (2.37b)
At first glance, Eqs. (2.37a) and (2.37b) appear as if there are now two equations
for the four unknowns - l14C, H(X)14c, F3H, and H(X)3H. However, for the case of a single
average aqueous pore radius, as implemented by Peck et al.9 and by Tang et al.,'0 Eqs.
(2.2) and (2.3) show that H(X) is a function of rpore, while Eq. (2.19a) shows that s is also
a function of rpore, as well as of the total number of aqueous pore channels in the skin, N.
Therefore, there are two equations and two unknowns (rpore and N), indicating that a
unique solution is possible. Furthermore, for the case of a single average pore radius, the
porosity of the skin for the 14C-labeled permeant (6l4C) is equal to the porosity of the skin
for the 3H-labeled permeant (s3H). Therefore, Eqs. (2.37a) and (2.37b) can be combined
as follows:
)H -d (2.38)
H(A•) 14 . a2b
Equation (2.38) can then be solved for rpore, the average aqueous pore radius (see Eqs.
(2.2) and (2.3)). The porosity of the skin, 6l4C = E3H = c, can then be determined using
either Eqs. (2.37a) or (2.37b). Finally, the tortuosity of the aqueous pore channels for the
14C-labeled hydrophilic permeant (CI4c) and for the 3H-labeled hydrophilic permeant (-3H)
can be determined using Eqs. (2.36a) or (2.36b) and Eqs. (2.36c) or (2.36d), respectively.
For the case of a distribution of aqueous pore radii in the skin, as proposed by
Tezel et al.," Eqs. (2.37a) and (2.37b) can again be reduced to a system of two equations
with two unknowns. Specifically, if Eqs. (2.9) and (2.19b) are used to define the
hindrance factor, H(,p), and the porosity, Ep, respectively, characterizing the distribution
of aqueous pore channels in the skin, two unknowns remain, N and y(rpore). Once again,
this results in a system of two equations for the two unknowns, N and y(rpore), which can
be solved by substituting Eqs. (2.9) and (2.19b) in Eqs. (2.37a) and (2.37b), and
subsequently taking the ratio to eliminate the total number of aqueous pore channels
present in the skin, N, to obtain:
f)y(pore )r 2 drpore f y( pore )H(,A) drpore
r,, r-, - 2b (2.39)yf7(rp)re V 2 dr or f) y(rpore. )H(A)drpore a
r14( r,4 ,
If a normalized distribution function of the form:'1
(r, 2 r
7(r ) 2 exp pore (2.40)
is used for y(rpore), as proposed by Tezel et al.,'l there is only one unknown parameter, (,
the standard deviation of the normalized distribution function, to solve for in Eq. (2.39),
which can done numerically. Once a is determined in this manner, Eq. (2.9) can then be
used to determine H(X) for both the 14C-labeled hydrophilic permeant and for the 3H-
labeled hydrophilic permeant. With H(Q) evaluated in this manner, the porosities of the
14C-labeled and the 3H-labeled hydrophilic permeants, 814C and S3H, can then be
determined using Eqs. (2.37a) and (2.37b), respectively. Finally, the tortuosity
corresponding to the 14C-labeled hydrophilic permeant, T14C, can be evaluated using
either Eqs. (2.36a) or (2.36b), and the tortuosity corresponding to the 3H-labeled
hydrophilic permeant, T3lH , can be evaluated using either Eqs. (2.36c) or (2.36d).
In addition, the steady-state permeability of both the '4C-labeled and the 3H-
labeled hydrophilic permeants can be calculated from the two regression parameters,
(ECdTL) and [D°H(,)/(rL)2], using the following equation:
1 TZ D 1H(A)
Cd (&n H(2) (2.41)
which, upon simplification, is equal to Eq. (2.1).
2.5 Results and Discussion
2.5.1 Dual Radiolabeled Diffusion Experimental Data
Figure 2-3 shows the cumulative amount of radiolabeled permeant delivered across the
skin, Q(t), as a function of time for each of the four hydrophilic permeants used in the
diffusion experiments (Figure 2-3a: mannitol, Figure 2-3b: raffinose, Figure 2-3c: inulin,
and Figure 2-3d: urea). In each of the plots, the black diamonds correspond to data
obtained using the dermis as the model skin membrane, the open squares correspond to
data obtained using full-thickness skin treated with a high dose of low-frequency
ultrasound, the open triangles correspond to data obtained using full-thickness skin
treated with a low dose of low-frequency ultrasound, and the grey diamonds correspond
to data obtained using untreated full-thickness skin. Each data point represents an
average of 3 - 6 skin samples. Representative error bars, corresponding to + 1 S.D., have
been included to provide an estimate of the error in the average value (note that in Figure
2-3d for the delivery of urea, the error bars have been omitted for clarity). For data
corresponding to delivery in skin treated with low-frequency ultrasound, multiple data
points are presented because there was a difference in sampling times between the
experimental runs. In Figure 2-3d, the shaded regions for data corresponding to the
delivery in skin treated with a high dose of ultrasound and SLS, with a low dose of
ultrasound and SLS, and in untreated skin have been included to increase clarity.
Several trends may be observed from an examination of Figures 2-3a through 2-
3d. In each of the figures, in the period from 0 to 20 hours, the amount of permeant
delivered through each of the skin samples follows the expected permeability trend - the
dermis (black diamonds) is the most permeable, followed by full-thickness skin treated
with a high US-SLS dose (open squares), then by full-thickness skin treated with a low
US-SLS dose (open triangles), and finally by untreated full-thickness skin (grey
diamonds). Also, for each skin type (dermis, a high US-SLS dose, a low US-SLS dose,
and untreated), the amount of hydrophilic permeant delivered across the skin decreases as
the radius of the permeant increases (urea < mannitol < raffinose < inulin). However, by
48 hours, the results presented in Figures 2-3a through 2-3d indicate that the total amount
of permeant delivered, Q(t), in the untreated skin (grey diamonds) is greater than in some
of the skin samples treated with a low dose of ultrasound and SLS (open triangles).
There is some speculation that the observed increase in the permeability of untreated skin
after exposure to an aqueous solution for a long time may be attributed to a skin
hydration effect, 25 in which water acts as a chemical enhancer to perturb the structure of
the skin. According to the aqueous pore pathway models proposed by Tang et al.'0 and
by Tezel et al." , since the permeability of the untreated skin increases after 20 hours of
exposure to an aqueous solution, it should also follow that there would be a
corresponding increase in the skin electrical current.l 0"11 However, in the untreated skin
samples used in these experiments, no large increase in the skin electrical current was
t
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Figure 2-3: Plots of the cumulative amount of hydrophilic permeant, Q(t), delivered
through the skin as a function of time, t, normalized by the initial donor concentration,
Cd. (a) mannitol, (b) raffinose, (c) inulin, and (d) urea. Key: Untreated skin - grey
diamonds, low dose of US-SLS treatment - open triangles, high dose of US-SLS
treatment - open squares, dermis - black diamonds. Sample error bars correspond to + 1
S.D.
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Figure 2-3 (continued): In (d), the error bars have been replaced with shaded regions to
aid the reader in identifying the domains for the delivery of urea through untreated skin,
through skin treated with a low dose of ultrasound, and through skin treated with a high
dose of ultrasound.
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observed during the 48 hour experiment, suggesting that the increased perturbation in the
skin due to the exposure to water for more than 20 hours cannot account for the increased
permeation observed in the untreated skin case.
Another possible explanation of the untreated skin data presented in Figures 2-3a
and 2-3d is that the untreated skin may possess a large amount of diffusion sinks, such as
binding sites in the skin,' a branched network of aqueous pore channels in the skin,'5 or
diffusion into the skin cells themselves.' These diffusion sinks would initially decrease
the rate of delivery of the hydrophilic permeants through the skin, due to the hydrophilic
permeants being retained in the skin. Once the diffusion sinks have reached equilibrium,
such that they are no longer sinks to the diffusive transport process, the hydrophilic
permeants are then free to diffuse through the skin, resulting in a rapid increase in the
observed amount of hydrophilic permeant delivered through the skin and in the observed
onset of steady-state diffusion. The application of ultrasound and SLS appears to reduce
the impact of these diffusion sinks on the overall transport process, since there is no
corresponding increase in the permeability in skin samples treated with a high dose of
ultrasound and SLS in Figures 2-3a - 2-3d. For example, if the aqueous channels exist as
a branched network of interconnected channels, rather than the unbranched channels
assumed for the transport model presented in this paper (see Figure 2-2), ultrasound and
SLS may make these channels less branched. This would then provide a more direct
route of transport through the skin membrane (i.e. decrease t,).
The data in Figures 2-3a through 2-3d also suggest that the lag time to reach
steady-state delivery of the hydrophilic molecules decreases as the stratum corneum is
physically perturbed. Using the regression analysis of the diffusion data described in
Table 2-1: Values of the Lag Time to Reach Steady-State, tiag, Calculated using Eq.
(2.33) and the Data Presented in Figures 2-3a through 2-3d. a b c
Skin Type Urea
Untreated 63.4 + 5.4
Low US-SLS Dose 2.45 + 0.04
High US-SLS Dose 1.75 + 0.15
Dermis 1.41+ 0.10
a - Errors are presented as + 1 S.D.
b - The reported values have units of hours.
c - US stands for ultrasound.
Mannitol
37.3 + 1.7
7.90 + 3.47
4.23 + 0.22
2.07 + 0.05
Raffinose
70.9 + 10.2
15.2 + 2.9
5.48 + 0.37
3.17 + 0.13
Inulin
33.3 + 1.0
2.36 + 0.93
6.00 + 0.42
3.73 + 0.20
Section 2.4.6, it was possible to evaluate the parameter, [D'H(kp)/(TL)2], for each
hydrophilic permeant in each of the skin samples used in the dual radiolabeled diffusion
experiments. By substituting the values of [D H(0kp)/(TL) 2] in Eq. (2.33), it was
possible to determine the lag time to reach steady-state, tlag, for each permeant and skin
type used in this investigation. These values are reported in Table 2-1. As Table 2-1
shows, tlag decreases in skin which is physically perturbed by ultrasound, or by heat-
stripping, relative to tlag in untreated skin for each hydrophilic permeant examined. These
results for tlag differ from those Tezel et al., which suggested that the tortuosity of the
aqueous pore channels in the skin, t, and, therefore, through Eq. (2.33), that the lag time
to reach steady-state, tlag, both increase with an increase in the skin perturbation induced
by ultrasound."
2.5.2 Evaluation of the Average Aqueous Pore Radii from an Analysis of
Log P3H vs. Log Purea Plots using Steady-State Analysis Methods
Figure 2-4 shows plots of the permeability data from the three dual radiolabeled systems
examined in this experimental study. The 3H-mannitol - 14C-urea permeability data is
presented in Figure 2-4a, the 3H-raffinose - 14C-urea permeability data is presented in
Figure 2-4b, and the 3H-inulin- 14C-urea permeability data is presented in Figure 2-4c.
Note that each data point in Figures 2-4a through 2-4c represents a single diffusion
experiment. The values of the permeability for both the tritium-labeled permeant and
urea were calculated from the regression parameters, (cpCdtpL) and [DP H(•,)/(-,L) 2], by
using Eq. (2.41) in the time interval from 0 - 20 hours to avoid any contribution from the
"hydration effect" which was observed for untreated skin in Figures 2-3a through 2-3d.
Note that for the cases corresponding to the delivery of mannitol-urea and to the delivery
of inulin-urea in untreated skin, the values of the regression parameters were not
significantly different from zero, and, therefore, according to Eq. (2.41), the permeability
was also not different from zero. Consequently, no permeability values for the mannitol-
urea and for the inulin-urea delivery systems using untreated skin have been reported in
Figures 2-4a through 2-4c.
The permeability data were then linearly regressed using Eq. (2.4b) to determine
if a slope of 1 passed through the permeability data presented in Figures 2-4a through 2-
4c. For the mannitol-urea data, the regressed value of the slope was 1.06 + 0.06, with an
R2 value of 0.99. For the raffinose-urea data, the regressed value of the slope was 1.00 +
0.08, with an R2 value of 0.97. For the inulin-urea data, the regressed value of the slope
was 1.03 + 0.09, with an R2 value of 0.98. In Figures 2-4a through 2-4c, then, the solid
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Figure 2-4: Log P of the tritium-labeled permeants plotted against log P of urea, the
carbon-14 labeled permeant. (a) Mannitol-Urea, (b) Raffinose-Urea, and (c) Inulin-Urea.
Key: data points - open diamonds, ideal slope of 1 - solid line, and limiting case of
infinitely large aqueous pore channels - dashed line.
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lines, corresponding to the ideal slope of 1 through the data, have been added to
demonstrate that the data are indeed in agreement with the expression in Eq. (2.4b).
In addition to the solid lines corresponding to the ideal slope of 1 through the
data, dashed lines have also been added to Figures 2-4a through 2-4c, which represent a
limiting case where: 1) the aqueous pores in the skin are infinitely large, such that the
ratio of the hindrance factors for the tritium-labeled permeant and urea is equal to unity,
and 2) the porosity and the tortuosity values are not permeant dependent, such that the
porosity and the tortuosity ratios are also equal to unity. When (1) and (2) are satisfied,
Eq. (2.4b) reduces to:
D30log P•t = log 3H + log PUrea (2.42)
As can be seen from a comparison of the position of the data points in Figures 2-4a
through 2-4c relative to the dashed line representing Eq. (2.42), it would seem that the
radii of the aqueous pore channels in the human skin samples used in these studies may
be considered infinitely large, since many of the data points lie near or above the dashed
line, which represents the limiting case of infinitely large aqueous pore channels. This
observation may be confirmed from an evaluation of the average aqueous pore radii in
each type of skin sample used for the three dual permeant delivery systems. If it is
assumed that the porosity and the tortuosity ratios are unity (as was done by Peck et al.,
and by Tang et al.),9' 10 it is then possible to determine the value of the hindrance factor
ratio using Eq. (2.4b), from which the average available pore radii, rpore, may be
determined. The values of the hindrance factor ratio and of the average available pore
radii are reported in Tables 2-2 through 2-4 for the mannitol-urea system, for the
raffinose-urea system, and for the inulin-urea system, respectively.
Table 2-2: Values of the Hindrance Factor Ratio and of the Average Available Pore
Radii Calculated from the Permeability Data Obtained from the Mannitol-Urea Delivery
System.
Hindrance Factor Ratioa Average Available Pore Radiib (A)
Skin Type [H(,)mannitol/ H(,)urea] Low Average High
Low US-SLS Dose 0.78 + 0.20 21 41 450
High US-SLS Dose 0.84 + 0.09 36 57 130
Dermis 1.01 + 0.11 91 00 00
a- Errors correspond to + 1 S.D.
b - The high and the low values reported correspond to I standard deviation from the average value of the
aqueous pore radii.
An examination of the values of the hindrance factor ratios in Tables 2-2 through
2-4 reveals that these are very close to unity (for example, see the low US-SLS dose skin
and the high US-SLS dose skin values in Table 2-2), or are not significantly different
from unity (for example, see all the skin types in Table 2-3). Using Eqs. (2.2) and (2.3),
these high values of the hindrance factor ratios lead to the prediction of very large values
of the average available pore radii. The range of average values of the aqueous pore radii
reported in Tables 2-2 through 2-4 (41 A - infinitely large pores) are also much larger
than the values reported by Peck et al. (20 + 5 A)9 or by Tang et al. (25 + 20 A)' 0 for
similarly-sized permeants. This result suggests, physically, that the particular human full-
thickness skin samples used in these skin permeation studies possessed much larger
aqueous pore channels than those present in those present in the pig fidl-thickness skin
samples used by Peck et al. and by Tang et al. In addition, due to the amount of scatter
in the permeation data reported in Figures 2-4a through 2-4c, several of the average
values of the hindrance factor ratios reported in Tables 2-2 through 2-4 have very large
100
Table 2-3: Values of the Hindrance Factor Ratio and of the Average Available Pore
Radii Calculated from the Permeability Data Obtained from the Raffinose-Urea Delivery
System.
Hindrance Factor Ratioa Average Available Pore Radiib (A)
Skin Type [H()ramffnose/ H(X)urea] Low Average High
Untreated 1.09 + 0.70 25 00 00
Low US-SLS Dose 0.80 + 0.31 32 88 o0
High US-SLS Dose 0.82 + 0.21 43 98 00
Dermis 1.01 + 0.09 225 o0 co
a - Errors correspond to + 1 S.D.
b - The high and the low values reported correspond to 1 standard deviation from the average value of the
aqueous pore radii.
Table 2-4: Values of the Hindrance Factor Ratio and of the Average Available Pore
Radii Calculated from the Permeability Data Obtained from the Inulin-Urea Delivery
System.
Hindrance Factor Ratioa Average Available Pore Radiib (A)
Skin Type [H(,)inulin/ H(X)urea] Low Average High
Low US-SLS Dose 0.67 + 0.28 48 111 800
High US-SLS Dose 0.62 + 0.05 82 95 111
Dermis 0.71 + 0.04 111 128 151
a - Errors correspond to + 1 S.D.
b - The high and the low values reported correspond to 1 standard deviation from the average value of the
aqueous pore radii.
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standard deviation values. This results in several of the values of the hindrance factor
ratios being insignificantly different from unity (i.e. the error bars include unity). This, in
turn, leads to infinitely large aqueous pores being included in the range of values for the
average available pore radii (see Tables 2-2 and 2-3), which suggests that hindrance may
not have contributed significantly to the transport of hydrophilic permeants in the skin
samples used in this study. The large standard deviations in the average values of the
hindrance factor ratios also leads to the conclusion that there is no significant increase, or
decrease, in the hindrance factor ratio as a function of skin perturbation, reconfirming
that, based on the steady-state analysis methods used here, the radius of the aqueous pore
channels in the skin samples utilized in these studies does not increase with ultrasound
treatment of the skin. This result further confirms the results of Tang et al. and of Tezel
et al. that ultrasound treatment likely creates new aqueous pore channels which are
similar in radius to the aqueous pore channels present in untreated skin. 10,11
It should be noted that while there was no significant change in the slope of the
best-fit line through the data in Figures 2-4a through 2-4c from the predicted value of 1 as
a function of permeant size, this does not imply that the conventional porous pathway
hypothesis proposed by Peck et al. (for two uncharged hydrophilic permeants) 9 and by
Tang et al. (for one uncharged hydrophilic permeant and one charged hydrophilic
permeant)' 0 performs better than the modified porous pathway model proposed by Tezel
et al. (which incorporates the possible existence of a distribution of pore radii).'" In their
study, Tezel et al. were able to observe a significant increase in the slope of -1, predicted
by the conventional porous pathway hypothesis (see Eq. (2.7)), using hydrophilic
permeants which ranged in radius from (4.4 A - 26 A) combined with skin electrical
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current measurements." Because of the large average radius of the aqueous pore
channels in these skin samples (see Tables 2-2 through 2-4), the range of permeant radii
used in this investigation (2.6 A - 12 A) may not be sufficiently large to observe a
significant decrease in the value of the slope from 1, predicted by Eq. (2.4b), in Figures
2-4a through 2-4c as the radius of the hydrophilic permeant was increased. In order to
evaluate the distribution of aqueous pore channels in the skin samples used in this
investigation, in the following section, I utilize the theoretical techniques presented in
Section 2.3.3 to evaluate the standard deviation in the hypothesized distribution of pore
radii, as well as the porosity and the tortuosity, as a function of both the radius of the
hydrophilic permeant and the extent of skin perturbation induced by ultrasound and by
heat-stripping of the stratum corneum.
2.5.3 Evaluation of the Distribution of Pore Radii, the Porosity, and the
Tortuosity as a Function of Both the Radius of the Hydrophilic
Permeant and the Extent of Perturbation Induced in the Skin
The average values of the hindrance factor, the porosity, and the tortuosity are presented
as a function of the skin electrical resistivity, a quantitative measure of the extent of skin
perturbation, in Figures 2-5a through 2-5c, respectively. In each figure, the black
diamonds correspond to the data for urea, the open squares correspond to the data for
mannitol, the open triangles correspond to the data for raffinose, and the open circles
correspond to the data for inulin. Error bars represent + 1 standard deviation
corresponding to the average of 5 or 6 six diffusion experiments.
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Due the large size of the error bars associated with the values of the hindrance
factor reported in Figure 2-5a, the hindrance factor does not significantly depend on the
extent of perturbation induced in the skin by ultrasound. Since the hindrance factor does
not vary significantly with ultrasound treatment, one may conclude that the average
available pore channel radius also does not vary significantly with ultrasound treatment.
However, there is evidence that the value of the hindrance factor corresponding to the
larger hydrophilic permeants, raffinose and inulin, is significantly increased (p<0.05,
using the t-statistic for the difference in the two means26) when the epidermis is removed
from the skin, suggesting that the average radii of the aqueous pore channels in the
dermis may be larger than the average radii of the aqueous pore channels in the
epidermis.
Figure 2-5a also demonstrates that there is a significant dependence of the
hindrance factor on the radius of the permeant, as expected from Eqs. (2.2) and (2.3).
Specifically, the values of the hindrance factor for inulin are significantly lower (p<0.05)
than the values of the hindrance factor for urea and mannitol. Figure 2-5a also shows that
the average value of the hindrance factor of raffinose is lower than that of urea and
mannitol and higher than that of inulin, but, due the large values of the standard
deviations (see the error bars in Figure 2-5a) the observed differences cannot be viewed
as being significant. However, because of the small difference in the radii of urea (2.6
A) and mannitol (4.4 A), there is no significant difference in the values of the hindrance
factors of urea and mannitol. Therefore, based on the data presented in Figure 2-5a, the
following trend is observed in values of the hindrance factor as a function of the radius of
the permeant: urea and mannitol > raffinose > inulin.
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Figure 2-5: Plots of (a) the hindrance factor, H(X), (b) the porosity, c, and (c) the
tortuosity, t, as a function of skin perturbation as quantified by the skin electrical
resistivity, RA, measurements. Key: urea - black diamonds, mannitol - open squares,
raffinose - open triangles, and inulin - open circles. Error bars correspond to + 1
standard deviation. A dashed line has been added in (c) to indicate the location of the
lower bound value of t = 1.
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Figure 2-5b shows that the porosity of the skin increases as the extent of skin perturbation
increases, as quantified by the decreasing values of the skin electrical resistivity, RA.
This observation suggests that increased perturbation of the skin due to ultrasound
treatment, or due to heat-stripping, of the skin results in an increase of the fraction of the
skin surface area occupied by the aqueous pore channels. According to Eqs. (2.19a) and
(2.19b), this increase in the porosity may result from: (i) an increase in the average
available aqueous pore radii (either through an increase in rpore or an increase in c for a
distribution of pore radii (see Eq. 2.40)), (ii) from an increase in the number of aqueous
pore channels, N, or (iii) from both. However, based on an examination of Figure 2-5, it
was just concluded that there is no significant increase in the hindrance factor, and,
therefore, in the average available aqueous pore radius, as a function of increased
perturbation of the skin due to ultrasound treatment. Accordingly, the increase in the
porosity of each of the four permeants observed in Figure 2-5b must be due to the
formation of additional aqueous pore channels having similar radii to the aqueous pore
channels present in untreated skin.
In addition, at each level of skin perturbation, or RA value, there is no significant
difference in the values of the porosities reported in Figure 2-5b for the four permeants
considered, indicating that the value of the porosity is independent of the radius of the
permeant over the range of permeant radii considered. This result suggests that the
porosity may be properly modeled as a physical property of the skin membrane rather
than as a permeant-dependent property, over the range of permeant radii considered here,
as suggested previously by Tezel et al." It should also be noted that the values of the
porosity in untreated skin are similar to the fractional area of the skin occupied by hair
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follicles and by sebaceous glands (2-3*10-3).' While this observation does not imply that
the aqueous pore channels in untreated skin may be represented by the hair follicles and
by the sebaceous glands, it does imply that the fraction of the skin surface occupied by
the aqueous pore channels in ultrasound-treated skin, both at a low dose and at a high
dose, is much larger than the fraction of the skin surface occupied by hair follicles and
sebaceous glands, further suggesting that new aqueous pore channels are formed in the
skin as a result of the ultrasound treatment.
In Figure 2-5c, values of the tortuosity of the aqueous pore channels are presented
as a function of the skin electrical resistivity for each of the four permeants considered.
A dashed line corresponding to - = 1 has been included in Figure 2-5c to mark the lower
bound for the physically realizable value of the tortuosity. As can be seen, in most cases,
the tortuosity of the aqueous pore channels does not depend on the extent of skin
perturbation, as quantified by the RA values. One notable exception is the tortuosity of
the aqueous pore channels for the delivery of urea (see the black diamonds in Figure 2-
5c) in untreated skin relative to the dermis and to skin treated with a low and a high dose
of ultrasound, which may suggest that ultrasound treatment may reduce the tortuosity of
the aqueous pore channels present in the skin for small hydrophilic permeants like urea.
In addition, the results presented in Figure 2-5c do demonstrate that the tortuosity does
not increase as the skin electrical resistivity decreases, as suggested previously by Tezel
et al. "
Similar to the results for the hindrance factor presented in Figure 2-5a, the data
reported in Figure 2-5c does show that there is some dependence of the tortuosity on the
radius of the hydrophilic permeants. Specifically, the values of the tortuosity of inulin
108
are significantly lower (p<0.05) than the values of the tortuosities of urea, mannitol, and
raffinose. In addition, the value of the tortuosity of raffinose is also significantly lower
(p<0.05) than the values of the tortuosities of urea and mannitol in untreated skin and in
skin treated with a high dose of ultrasound. These results would seem to confirm the
assumption of Tezel et al. that the tortuosity of the aqueous pore channels in the skin may
decrease as the radius of the permeant increases."
However, there is some concern about the inulin tortuosity values reported in
Figure 2-5c, since the calculated values of the tortuosity of inulin obtained using the
methods presented in Section 2.3.3 are all statistically significantly lower than unity (see
the upper range of the error bars corresponding to the open circles does not include
unity). Tortuosity values lower than unity, in the context of the aqueous pore pathway
hypothesis, are not physically realizable, since this result suggests that inulin diffuses
across the skin barrier along a diffusion path that is shorter than the measured skin
thickness. Examining the term, [H(X)/t 2] in Eqs. (2.36b) or (2.36d), the tortuosity may be
increased if the hindrance factor is increased, such that the value of [H(X)/T2] remains
constant. Since the values of the average available pore radius determined from the
steady-state analysis (see Section 2.5.2) were very large for each of the three permeant
pairs studied (i.e. urea-mannitol, urea-raffinose, and urea-inulin) such that the value of
the hindrance factor was close to unity, it is instructive to evaluate the porosity and the
tortuosity of the aqueous pore channels as a function of the extent of skin perturbation
and of the permeant radii for the limiting case of infinitely large pores, for which
rpore--co, and H(k) = 1 (see Eqs. (2.2) and (2.3)).
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2.5.4 Evaluation of the Porosity and the Tortuosity as a Function of Both
the Radius of the Hydrophilic Permeant and the Extent of Skin
Perturbation for the Limiting Case of Infinitely Large Aqueous Pores
Figure 2-6 presents the values of the porosity (Figure 2-6a) and the tortuosity (Figure 2-
6b) as a function of the extent of skin perturbation for each of the four permeants
considered for the case where rpore- -- co and H(X) = 1. In each figure, the black diamonds
correspond to the data for urea, the open squares correspond to the data for mannitol, the
open triangles correspond to the data for raffinose, and the open circles correspond to the
data for inulin. Error bars represent + 1 standard deviation corresponding to the average
of 5 or 6 six diffusion experiments.
Similar to the case corresponding to a distribution of pore sizes (see Figure 2-5b),
Figure 2-6a reveals that the skin porosity increases as the extent of skin perturbation
increases, as quantified by decreasing values of the skin electrical resistivity, RA, for
each of the four permeants considered. This observation suggests that increased skin
perturbation due to ultrasound treatment, or due to heat-stripping, results in an increase of
the fraction of the skin surface area occupied by the aqueous pore channels. Since it has
been assumed that H(X) = 1, the observed increase can be attained by an increase in the
number of aqueous pore channels. However, there seems to be a slight dependence of the
porosity on the radius of the permeants considered for the case where H(X) = 1.
Specifically, the values of the porosities corresponding to inulin (open circles) are
significantly lower (p<0.05) than the values of the porosities corresponding to urea (black
diamonds), mannitol (open squares), and raffinose (open triangles) in the dermis, and also
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Figure 2-6: Plots of (a) the porosity, F, and (b) the tortuosity, T, as a function of the
extent of skin perturbation quantified by the skin electrical resistivity, RA, values, for the
limiting case where rpore - co and H(A) = 1. Key: urea - black diamonds, mannitol -
open squares, raffinose - open triangles, and inulin - open circles. Error bars represent +
1 standard deviation. A dashed line has been added in (b) to indicate the value of t = 1.
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significantly lower (p<0.05) than the values of the porosities corresponding to urea (black
diamonds) and raffinose (open triangles) in skin treated with a high dose of ultrasound.
In Figure 2-6b, in the absence of hindered transport (H(k) = 1), the values of the
tortuosity exhibit some dependence on both the size of the permeant and on the extent of
skin perturbation. Similar to the case corresponding to a distribution of pore radii (see
Figure 2-5c), the tortuosities of inulin (open circles) are significantly lower (p<0.05) than
the tortuosities of urea (black diamonds), mannitol (open squares), and raffinose (open
triangles) for the case where H(k) = 1. In addition, the values of the tortuosities of inulin
are now larger than unity, the lower bound for a physically realizable value of the
tortuosity. Furthermore, similar to the case corresponding to a distribution of pore radii
in the skin, the values of the tortuosities of raffinose (open triangles) are significantly
lower than those of urea (black diamonds) and mannitol (open squares) for untreated skin
and for skin treated with a high dose of ultrasound. These results again would seem to
confirm the assumption made by Tezel et al. that the tortuosity of the aqueous pore
channels in the skin may decrease as the radius of the permeant increases.' 1 Contrary to
the case corresponding to a distribution of pore radii in the skin, when hindered transport
is neglected, there is an observable decrease in the values of the tortuosities of each
permeant as the extent of skin perturbation is increased. Specifically, for urea (black
diamonds), the value of the tortuosity in untreated skin is significantly larger (p<0.05)
than in ultrasound-treated skin, which is also significantly larger (p<0.05) than the
tortuosity in the dermis. For raffinose (open triangles), the value of the tortuosity in
untreated skin is significantly larger (p<0.05) than in skin treated with a high dose of
ultrasound, which is also significantly larger (p<0.05) than the tortuosity in the dermis.
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For mannitol (open squares) and inulin (open circles), the values of the tortuosities in
ultrasound-treated skin are significantly larger (p<0.05) than the values of the tortuosities
in the dermis.
The results of this analysis, where it has been assumed that the aqueous pore
channels are infinitely large, suggest that as the extent of skin perturbation increases, new
aqueous pore channels, possessing a lower tortuosity than those present in untreated skin,
are formed in the skin. For urea, mannitol, and inulin, based on the data in Figure 2-6a,
one may also conclude that the porosity can be modeled as an intrinsic property of the
skin membrane, similar to the case corresponding to a distribution of pore radii.
However, the decreased value of the porosity of inulin relative to those of the other three
permeants appears to imply that there are some aqueous pore channels present in the skin
which inulin, due to its larger radius, cannot access. This result would seem to contradict
the assumption made in the analysis presented in this section, that the aqueous pore
channels in the skin are infinitely large, such that H(k) = 1. Since the transdermal
transport of inulin is not well explained for the case where H(X) = 1, or for the case
corresponding to a distribution of pore radii of the form given by Eq. (2.40), additional
studies are required to better understand the transdermal transport of large molecular
weight hydrophilic permeants, such as inulin, in the context of the aqueous pore pathway
hypothesis. As a first step, future studies may focus on a more realistic distribution of
pore radii, rather than the simple distribution given by Eq. (2.40).
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2.6 Conclusions
In this chapter, the aqueous pore pathway hypothesis was extended to model the transient
domain of the transdermal transport of hydrophilic permeants, in addition to the
previously-investigated steady-state domain, to verify assumptions regarding the
behavior of the hindrance factor, the tortuosity, and the porosity as a function of both
permeant radius and the extent of skin perturbation. Diffusion experiments were
conducted with 14C-urea combined with tritium-labeled mannitol, tritium-labeled
raffinose, or tritium-labeled inulin as the model permeants. An analysis of the
cumulative amount of the permeant delivered per unit area, Q(t), showed that the lag time
to reach steady-state was 10- to 40-fold lower in the dermis than in untreated full-
thickness skin, indicating that the tortuosity of the aqueous pore channels does not
increase with increasing skin perturbation, contrary to a suggestion made previously by
Tezel et al. 1
Analysis of the steady-state permeability data by linear regression revealed that
the slope of the best-fit through the steady-state permeability data was statistically similar
to the predicted slope of I over the range of permeant radii investigated in this study (rp =
2.6 A- 12 A). Using steady-state analysis methods, I determined that the average
available aqueous pore radius ranged in size from 41 A to infinity. Given the large range
of values for the average available aqueous pore radius, as well as the large size of the
standard deviation in the average available pore radius (in some cases varying from 21 A
to infinity), it is questionable whether the inclusion of a hindrance factor improves the
overall modeling of transdermal transport of hydrophilic permeants.
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To further investigate the need to include the hindrance factor, as well as to
investigate how the porosity and the tortuosity vary as a function of the permeant radius
and the extent of skin perturbation, the Q(t) data were analyzed with the proposed model
equations describing the transdermal transport of hydrophilic permeants in the transient
and the steady-state domains. For the case where a distribution of pore radii exists in the
skin, as proposed by Tezel et al.,'1 my results indicated that: 1) the value of the hindrance
factor depends on the radius of the permeant delivered through the skin, while there is
little change in the value of the hindrance factor as a function of the extent of skin
perturbation, 2) the value of the porosity does not depend on the radius of the permeant
delivered, while the value of the porosity increases as the extent of skin perturbation
increases, and 3) the value of the tortuosity decreases as the radius of the permeant
increases, while there is little evidence that the tortuosity depends on the extent of skin
perturbation. These trends would seem to suggest that ultrasound treatment of the skin
results in the formation of aqueous pore channels that are structurally similar to those
found in untreated skin.
Because the tortuosity values of inulin were found to be statistically significantly
lower than unity, and because of the large standard deviations in the hindrance factor
values of urea, mannitol, and raffinose, the values of the porosity and the tortuosity were
also evaluated in the limiting case of infinitely large aqueous pores (rpore - oo). This
analysis showed that, similar to the previous case where a distribution of aqueous pore
channels was assumed to exist in the skin, the tortuosity exhibited some dependence on
the radius of the permeant, while the porosity of urea, mannitol, and raffinose were found
to be statistically similar. In addition, a significant decrease in the tortuosity of each
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permeant was observed as a function of the extent of skin perturbation. While the use of
infinitely large pores resulted in tortuosity values of inulin which were greater than unity,
the value of the porosity for inulin was found to be significantly lower than those of the
other three permeants considered, suggesting that there were some aqueous pore channels
which could not be accessed by inulin due to its larger radius. These results indicate that
additional studies are needed to improve the model for the distribution of the aqueous
pore radii in the skin to better understand the transdermal transport of inulin, and other
large hydrophilic permeants, in the context of the aqueous pore pathway hypothesis.
Having developed a new theoretical analysis technique to further investigate the
transport of hydrophilic permeants across the skin, it is next appropriate to further
investigate the transport of hydrophobic permeants through the skin. With this in mind,
in the next chapter, then, a novel, first-principles model describing transdermal transport
of hydrophobic permeants through the intercellular regions of the stratum corneum is
derived for the purpose of providing a simpler and more accurate method of evaluating
the vehicle-bilayer partition coefficient, Kb, and the bilayer diffusion coefficient, Db, for
hydrophobic permeants solely using transdermal permeability experiments. The transport
model proposed for hydrophobic permeants in the next chapter will also be applicable in
both the transient and the steady-state domains, similar to the model developed in this
chapter for the transport of hydrophilic permeants. A major challenge that will be
encountered in the development of a model to describe the transdermal transport of
hydrophobic permeants involves the modeling of branched, parallel transport pathways.
As will be shown in the next chapter, this additional feature associated with the
transdermal transport of hydrophobic permeants will require the introduction of two
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tortuosity factors in the model equations, one to account for the total volume of the
hydrophobic transport pathways and the second to account for the flux of the
hydrophobic permeants through these pathways. Since the hydrophilic permeants
considered in this chapter were assumed to traverse the skin solely across unbranched
transport pathways, only a single tortuosity factor was needed in the model equations
developed in this chapter to account for: (i) the total volume of the hydrophilic transport
pathways, and (ii) the flux of hydrophilic permeants through these pathways.
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Chapter 3
Fundamental Structure-Based Modeling of Drug
Transport through the Intercellular Regions of the
Stratum Corneum
3.1 Introduction
The development of skin permeation models is an important area of continuing research
in the field of transdermal drug delivery. A major portion of this research is focused on
modeling the transport of drugs through the outermost layer of the skin, the stratum
comeum (SC). As discussed in Chapter 1, the SC provides the major resistance barrier to
transdermal drug delivery,' even though it is the thinnest layer of the skin (-10-20 ýtm
thick). The SC derives its high resistance to drug transport from a highly organized
brick-and-mortar structure of highly impermeable corneocyte cells (the bricks) and
intercellular lipid lamellar bilayers (the mortar).2 Due to the highly impermeable nature
of the corneocyte cells of the SC, researchers have shown that passive drug permeation in
the SC, especially for lipophilic drugs, occurs through the intercellular lipid lamellar
bilayers.3 7
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Over the past thirty years, several researchers have proposed permeation models
for the transport of drugs solely through the intercellular regions of the SC which are
heavily based on the structure and the geometric parameters of the SC.8- 12 The general
form of the intercellular permeation model, for the steady-state transport phase, can be
represented by Eq. (3.1):
P=C Khh (3.1)r L
where P is the steady-state permeability, Kb is the permeant vehicle-bilayer partition
coefficient, Db is the bilayer diffusion coefficient of the permeant, and L is the SC
thickness. The porosity, F, and the tortuosity, c, are transport parameters that can be
evaluated from the structural parameters of the SC (see section 3.2 for definitions).
These structural parameters include (see Figure 3-1): 1) the number of corneocyte layers
in the SC (N), 2) the diameter (d) of the corneocytes, 3) the height (h) of the corneocytes,
4) the length of the intercellular gap between the corneocyte cells (g), and 5) the
corneocyte offset (o). defined as the longer lateral diffusion path, dL, divided by the
shorter lateral diffusion path, ds, that is. o = d1/ds. Michaels el al. proposed the first
model for the SC geometry (see Figure 3-1a) using symmetrically offset (o = dl/ds = 1)
square corneocyte bricks and the physical path length of a molecule through the SC to
estimate of the tortuosity factor.8 Subsequent refinements to the SC geometry in the
context of modeling intercellular transport incorporated: i) infinitely long corneocytes
(see Figure 3-lb),9 ii) circular corneocytes (see Figure 3-1c),1' iii) separate regions for the
hydrophobic and the hydrophilic regions within the lipid lamellar bilayers with infinitely
long corneocytes (similar to Figure 3-lb)." and iv) asymmetrically offset corneocytes
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Figure 3-1: Previously-proposed brick-and-mortar models of the stratum comeum: (a)
model of Michaels et al. (symmetrically offset square comeocytes), (b) models of Cussler
et al. and of Edwards and Langer (symmetrically offset semi-infinite comeocytes), 8' 9'11
where N - number of comeocyte layers, d - comeocyte characteristic length, h -
comeocyte thickness, g - intercellular space thickness (occupied by the lamellar lipid
bilayers), and ds and dL - short and long comeocyte diffusion path lengths, respectively.
The dashed arrows in (b) and (d) indicate that the comeocytes are modeled as being
infinite in the direction of the arrows.
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Figure 3-1 (continued): (c) model of Lange-Lieckfeldt and Lee (symmetrically offset
circular corneocytes), and (d) model of Johnson et al. (asymmetrically offset semi-
infinite corneocytes). 1'0 12
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(see Figure 3-ld).12 Currently, the model presented by Johnson et al. (see Figure 3-1d) is
the most widely accepted representation of the 2D structure of the SC. Also, due to the
presence of the parallel lateral diffusion paths in the SC geometry, Cussler et al.
introduced the concept of an effective lateral diffusion path length, modeled analogously
to electrical resistors in parallel, which has been used by subsequent researchers, 12 for the
evaluation of the tortuosity factor.9
It is essential that an adequate skin permeation model be able to predict both the
steady-state permeability and the lag time to steady-state for a desired drug, as both of
these quantities are critical to attain proper clinical drug delivery. While Eq. (3.1) is able
to acceptably describe the steady-state permeability of a lipophilic drug through the
intercellular regions of the SC, attempts to predict the lag time required to reach steady-
state, (tlag = (zL)2/6Db), based on the values of Db, L, and z used in Eq. (3.1), have been
less successful for a broad class of lipophilic permeants. 12 Recently, Frasch and Barbero
have overcome this difficulty by demonstrating that it is possible to evaluate both the
steady-state permeability and the lag time for a drug transporting through the intercellular
regions of the SC by using the complete solution to Fick's Second Law for the
accumulation of mass of a permeant, Q(t), diffusing through a homogeneous membrane. 13
Since the intercellular regions of the SC are not a homogeneous membrane due the brick-
and-mortar structure of the SC, Frasch and Barbero introduced parameters for the
effective diffusion coefficient, D*, and for the effective membrane thickness (or the
effective diffusion path length), L*, as shown in Eq. (3.2):' 3
Q(t)= KbCL*[Dt 1 2 e K(-1)" -D*t j]Qt [ K L "  1 2  2  2 exp( - 2  n2 _2 (3.2)
=6 L*
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where C is the concentration difference across the membrane and Kb was assumed to be 1
for simplicity. Frasch and Barbero obtained estimates of D* and L* by regressing data
obtained from finite element method (FEM) simulations of drug permeation through
model SC geometries using Eq. (3.2). 13 Having obtained R2 values in excess of 0.999 for
a wide range of SC geometries, Eq. (3.2) seems to have the proper form for describing
the transport of drugs through the complex SC intercellular geometry. 13
However, the dependence of Eq. (3.2) on the effective values of D and L, and not
on the intrinsic values of both the diffusion coefficient and the membrane thickness,
provides an excellent opportunity for further model refinement. In Section 3.2, I will
analyze five previous structure-based models for the purpose of: 1) highlighting the
subtle differences between the five previous models, and 2) using the results of the
analysis of the previous structure-based models to guide the proposed refinements to
model the barrier properties of the skin. In Section 3.3, I will derive, from first principles,
a new 2D model for the diffusion of a drug through the intercellular regions of the SC.
The new model will use the intrinsic values of the diffusion coefficient and the
membrane thickness, rather than the effective values, by explicitly incorporating the
structure and geometry of the intercellular regions of the SC into the model equations. In
Section 3.5, I will then demonstrate how predictions using the new model compare with
finite element simulations of drug transport through the SC over a wide range of SC
geometric parameter values both in the transient and in the steady-state transport phases.
Finally, I will use the new 2D model to evaluate, for the first time, both the SC
lipid bilayer diffusion and partition coefficients, Db and Kb, for two hydrophobic
permeants directly from permeation experiments (see Section 3.5 for details). Currently,
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Kb can be determined indirectly from octanol-water partitioning experiments using the
Potts and Guy correlation, Kb = Ko/w0.71 14 of the Flynn permeation database,' 5 where Ko/w
is the permeant octanol-water partition coefficient. Once Kb has been evaluated, Eq.
(3.1) can be utilized to estimate Db from permeability experiments. However, to evaluate
Kb and Db for an unknown drug, this approach requires both an octanol-water partition
experiment and a skin permeation experiment. Another potential drawback to this
method is that the value of Db obtained from Eq. (3.1) is directly based on the value of Kb
obtained indirectly from octanol-water partition experiments. Any inaccuracies in the
experimental value of Kb would then be added directly to inaccuracies in the deduced
value of Db through the use of Eq. (3.1). Another approach for evaluating Kb and Db
using both permeation experiments and solute release experiments was demonstrated by
Mitragotri. 16 While this approach deduces the values of Kb and Db directly from the SC,
it still requires two sets of experiments. Using the new 2D model, I will demonstrate that
both Kb and Db can be evaluated directly solely from skin permeation experiments,
thereby greatly simplifying the experimental procedure, and providing a more direct
measure to deduce these critical drug transport parameters.
3.2 Review of Previously Developed Structure-Based Models
Describing Transport in the Intercellular Regions of the
Stratum Comeum
In this section, the five models discussed in the previous section will be analyzed for the
purpose of: 1) highlighting the subtle differences between the five previous models,
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illustrating how the modeling of the skin structure for the purpose of estimating
transdermal drug permeabilities has evolved over the past thirty years, and 2) using the
above information to guide the proposed refinements to model the barrier properties of
the skin. Before carrying out an analysis of the previously-developed models, it is useful
to derive some simple expressions for e and T based on the geometric structure of the
stratum corneum for comparison with the expressions for E and - used in each of the five
previously-developed models. This comparison will provide some insight into the model
assumptions and techniques used by the previous researchers, as well as allow a
determination of which of these assumptions and techniques should be employed in the
newly-proposed model. Regarding the porosity of the stratum corneum, which is a
measure of the lipid bilayer fraction at the stratum corneum surface, both 2-D and 1-D
expressions can be derived as follows:
e = (2-D) (3.3)
•orneocvl. + lipids
e = (l-D) (3.4)
Lcorneocye
s + lipids
where Alipids and Acoreocytes are the areas of the lipids and the corneocytes at the stratum
corneum surface, respectively, used in the 2-D model for the porosity, and Llipids and
Leomeocytes are the lengths of the intercellular lipid region and the corneocytes,
respectively, used in the 1-D model for the porosity. Note that Eqs. (3.3) and (3.4) are
necessarily valid whether one considers a single comeocyte surrounded by a half-width
of lamellar lipid bilayers or the total areas (or lengths in the 1-D case) of the corneocytes
and the lamellar lipid regions at the stratum corneum surface.
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The tortuosity, -c, is generally defined as follows:' 8
Total diffusion distance traveled by the permeant molecule
r = (3.5)Stratum corneum membrane thickness
For a stratum corneum membrane sample of thickness, h, containing N layers of
corneocytes, Eq. (3.5) can be rewritten as follows (see Figure 3-1, a - d):
Nh + (N - I)g + (N - 1)di , (r = (3.6)
L
where h is the thickness of the corneocyte cells, g is the thickness of the lipid bilayers
between the layers of comeocytes in the stratum corneum (which is equal in both the
horizontal and the vertical directions' 9), and dlat is the distance traveled by the permeant
molecules laterally in a given layer of the stratum corneum before descending to the next
stratum corneum layer, which can be evaluated from the SC structural parameters shown
in Figure 3-1. While h and g are physical dimensions of the stratum corneum that can be
measured, 16,19 the calculation of dlat is as yet unresolved, as the following comparative
analysis of the five previous models available in the literature will highlight. By
examining Figure 3-1, it is noteworthy that the term Nh + (N-I)g is equivalent to the
stratum corneum thickness, L. Therefore, the value of the tortuosity is very sensitive to
the value of diat (see Eq. (3.1)), stressing the need for the availability of an accurate model
equation, based on the structural parameters of the skin, to evaluate diat. Having derived
Eqs. (3.3), (3.4), and (3.6) for E and r, it is now possible to effectively analyze the five
previously-developed models.
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3.2.1 Model of Michaels et al.
In the model of Michaels et al. (based on symmetrically offset, impermeable, square-
shaped corneocyte bricks, see Figure 3-la), the equation for the permeability through the
intercellular regions of the stratum corneum is given by:12
2g
P d KDh (3.7)
dg
-+ h))
=+ h h (3.8b)
Equation (3.8a) for w can be derived by using Eq. (3.3) for the two-dimensional geometry
(d + g)2 -d 2  2gd + g2
If it is assumed that d>>g, which is valid for typical dimensions of the corneocytes and
the intercellular lipid bilayers in the stratum corneum, 16,19in the23 Eq. (3.9) reduces to Eq.
the intercellular lipid bilayers in the stratum corneumn, 16,19-23 Eq. (3.9) reduces to Eq.
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(3.8a). To effectively compare Eq. (3.8b) with Eq. (3.6), Eq. (3.8b) needs to be
rearranged to yield a form similar to Eq. (3.6), as shown below:
(h + g)+ d+g
r = (3.10)
h+g
Then, multiplying the right-hand side of Eq. (3.10) by N/N yields:
Nh + Ng + N d+g
r = (3.11)
N(h + g)
Comparing Eq. (3.11) with Eq. (3.6) allows one to make several observations about the
assumptions made by Michaels et al. in the development of their model for T. First, these
authors made the assumption that for sufficiently large values of N, (N-1) in Eq. 3.6 can
be replaced by N without significantly affecting the value of T. While this is a good
approximation for the (N-1)g term in Eq. (3.6) and for the stratum corneum thickness, L,
since h>>g, it is not a good approximation for the (N-1)dlat term in Eq. (3.6), since
typically, (d+g)/2>>h, which could introduce a significant overestimation of t calculated
using Eq. (3.11). Second, a comparison of Eqs. (3.6) and (3.11) shows that dlat = (d+g)/2
in Eq. (3.11). An examination of Figure 3-1a reveals that this dlat value corresponds to
the physical diffusion path length that a solute must travel along a corneocyte to reach the
center of the next intercellular gap. In summary, the model of Michaels et al., which is
based on symmetrically offset, impermeable, square-shaped corneocyte bricks (see
Figure 3-1a), uses a 2-D calculation to determine E and the physical path length to
calculate diat in the expression for -.
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3.2.2 Model of Cussler et al.
In the model of Cussler et al. (based on symmetrically offset, impermeable, semi-infinite
corneocyte bricks, see Figure 3-1b), the equation for the permeability through the
membrane is given by:'13
P KhDh (3.12)
Lz*
where t* is given by:'13
_ _ _ _rd+g 2
r*=1+ In N (d ++ g)h +(N-1) 2 (3.13)L 2g gL gL
The four terms on the right-hand side of Eq. (3.13) describe the resistance of a membrane
without bricks, the resistance due to the constriction of the slit opening at the top and at
the bottom of the membrane, the resistance due to transport through the intercellular
spaces themselves, and the resistance due to the tortuous nature of the intercellular
spaces, respectively. 13 Comparing Eq. (3.12) with Eq. (3.1), it follows that 1/t* in Eq.
(3.12) must be equivalent to (si/) in Eq. (3.1), although the equivalence is not readily
apparent if Eq. (3.13) is compared directly with Eqs. (3.3), (3.4), and (3.6). However, by
substituting typical values of the physical parameters of the stratum corneum in Eq.
(3.13),16,19-23 one can show that the third and fourth terms are orders of magnitude larger
than the first and second terms, such that Eq. (3.13) can be approximated well as follows:
d+g 2
, N(d+g)h (N _1) (3.14)
gL gL
Noting that the term, (d+g)/g, can be factored out from both terms in Eq. (3.14), the
following further simplification of Eq. (3.14) can be made:
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(3.15)
By comparing Eq. (3.15) with Eqs. (3.4) and (3.6), one can identify the (d+g)/g term in
Eq. (3.15) as being equivalent to 1/k, and the second term as being similar in form to the
expression for T in Eq. (3.6). Therefore, -* in Eq. (3.12) is actually equal to (r/s), and Eq.
(3.12) has the same form as Eq. (3.1). It is now possible to make several observations
about the assumptions made by Cussler et al. in the development of their model. First, s
= g/(d+g) is calculated in Eq. (3.15) using the one-dimensional model given in Eq. (3.4).
This observation is confirmed by examining Figure 3-1b, which shows that the model of
Cussler et al. is a 1-D model. This is different from the model of Michaels et al. who
used a 2-D model for square corneocyte bricks. Second, a comparison of Eqs. (3.15) and
(3.6) shows that the diffusion distance contribution of the intercellular lipids between the
layers of the corneocytes (given by (N-1)g) has been neglected in Eq. (3.15), which,
based on the physical parameters of the stratum corneum, could lead to an
underestimation of t calculated using Eq. (3.15). Finally, dlat = (d+g)/4 in Eq. (3.15),
which is a factor of 2 smaller than the result of Michaels et al. for diat. The extra factor of
1/2 in the calculation of diat reflects the use of an effective diffusion path length. Cussler et
al. argue that a diffusing molecule has two parallel paths by which it may travel laterally
to diffuse around an impermeable corneocyte.' 3 Modeling the parallel diffusion paths
using the analogy of current flow through electrical resistors in parallel, the expression
for dlat used in Eq. (3.15) is obtained as follows (see Figure 3-1b):
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1 1 1 ( 2
- + 2 2 (3.16)
dia d+g (d+g d+g
2 ) 2)
Equation (3.16) clearly shows that the use of an effective diffusion path length, modeled
in terms of electrical resistors in parallel, will always result in a diffusion path length that
is smaller than the actual diffusion path lengths associated with either path.
3.2.3 Model of Lange-Lieckfeldt and Lee
In the model of Lange-Lieckfeldt and Lee (based on symmetrically offset, impermeable,
circular-shaped corneocyte bricks, see Figure 3-1c), the permeability equation for
permeation solely through the intercellular regions of the stratum corneum is given by:14
P =(+X 2) Khh (3.17)P L* A L
where the terms (L*/L) and (A/A*) are given by: 14
L+(N-1 dgg
V 2 (3.18a)L L
and
d+g d
A* 2 ((3.18b)
2
Comparing Eq. (3.18a) with Eq. (3.6), and recalling that L = Nh + (N-i)g, it follows that
(L*/L) is equivalent to r, and that it matches Eq. (3.6) exactly, for dlat = (d+g)/2, which
corresponds to the physical diffusion path length of a permeant traversing a circular
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corneocyte, originating from the center of the corneocyte (see Figure 3-1c). Comparing
Eq. (3-18b) with Eq. (3.3), it follows that (A*/A) is equivalent to E, with Alipids =
7t((d+g)/2)2 - 7c(d/2) 2 and Acorneocyte = 7t(d/2)2 for the two-dimensional geometry
corresponding to a circular corneocyte of radius (d/2) surrounded by a half-width of the
lipid bilayers of thickness (g/2) (see Figure 3-1c). In addition, it was assumed that
Acomeocytes >> Abilayers in the denominator of Eq. (3.18b), since d>>g. This should only
introduce a minor overestimation when , is calculated according to Eq. (3.18b).
3.2.4 Model of Edwards and Langer
In the model of Edwards and Langer (which is similar to the model corresponding to
Figure 3-1b), the permeability equation for the permeation of small hydrophobic solutes
through the intercellular regions of the stratum corneum is given by: 15
lP = (g,, )Lh )KD (3.19)
d + g 1, +1,, h + d L
where 10 and lw are the fractions of the intercellular lipid bilayer regions that are
hydrophobic and hydrophilic in nature, respectively. A comparison of Eq. (3.19) with
Eq. (3.1), keeping in mind Eq. (3.4) for this one-dimensional model of the stratum
comeum, shows that the term [g/(d+g)] on the right-hand side of Eq. (3.19) is equivalent
to , given in Eq. (3.4). The term [lo/(lw+lo)], from a structural standpoint, is a further
refinement to estimate F, where the actual fraction of the intercellular regions which are
hydrophobic is accounted for explicitly. Therefore, in the model of Edwards and Langer,
, is equal to the product of the first two terms on the right-hand side of Eq. (3.19).
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As part of the derivation of Eq. (3.19), in their work, Edwards and Langer
identified the tortuosity of the intercellular regions of the stratum corneum as given by
the third term on the right-hand side of Eq. (3.19), that is, they take - = (h+d)/h.'5 The
third term can be manipulated in the following manner to derive an expression similar in
form to that in Eq. (3.6):
h + d Nh + Nd
r- - (3.20)h Nh
Comparing Eq. (3.20) with Eq. (3.6), the following three observations can be made.
First, the thickness of the intercellular regions between the corneocyte layers, reflected in
the (N-1)g term in Eq. (3.6), has been neglected in the calculation of t according to Eq.
(3.20). Second, N layers are used for the contribution of the lateral diffusion path length,
diat, to the total diffusion path length of a solute permeating across the stratum corneum in
Eq. (3.20), instead of the (N-1) layers used in Eq. (3.6). Finally, diat is given by d, the
characteristic length of a corneocyte. This value of diat is different from that used in the
three previous models considered above and, physically, it appears less probable. While
the first two approximations may lead to a slight overestimation of r calculated using Eq.
(3.20), taking dlat = d will overestimate - calculated according to Eq. (3.20) by two-fold
as compared to the - values predicted by the models of Michaels et al. and of Lange-
Lieckfeldt and Lee, which use diat = (d+g)/2, and by four-fold as compared to the r value
predicted by the model of Cussler et al., which uses dlat = (d+g)/4.
137
3.2.5 Model of Johnson et al.
In the model of Johnson et al. (see Figure 3-1d), the permeability equation for the
diffusion of a hydrophobic solute through the intercellular regions of the stratum corneum
is also given by Eq. (3.12), 16 corresponding to the model of Cussler et al.'3 In their
model, however, Johnson et al. incorporated an asymmetric offset of the corneocyte
layers, which leads to the following modification of Eq. (3.13) for r*:16
I 2g (d+g N(d +g)h (N -1) w d 2
r =1+ 1 + + (3.21)L 2g ) gL O0+w)Y gL
where w is the offset ratio which is defined as (see Figure 3-1d): 16
d,
w = d (3.22)
d,
where dL and ds are the longer and shorter diffusion path lengths, respectively. As was
done with the model of Cussler et al., Eq. (3.21) can be simplified as follows:
r= N(d + (N - w (3.23)
gL (1+ w)2 gL
Since d>>g, Eq. (3.23) can be further simplified as follows:
(3.24)
As we already saw in the case of the model of Cussler et al., the first term on the right-
hand side of Eq. (3.24) corresponds to the expression for 1/6 in the case of a one-
dimensional model of the stratum corneum (see Eq. (3.4)). The second term corresponds
to an expression for t, where the contribution of the thickness of the lipid bilayers
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between the layers of corneocytes (reflected in the (N-1)g term in Eq. (3.6)) is again
neglected. For the model of Johnson et al., diat is now given by:
da, = d W)2  (3.25)
For the case of a symmetric offset corresponding to w = 1, diat = d/4, which is equal to the
value of diat in the model of Cussler et al. [(d+g)/4], when d>>g. Therefore, the model of
Johnson et al. also utilizes the concept of an effective diffusion path length, introduced
originally by Cussler et al., while making a significant contribution to the literature by
considering the observed asymmetric offset of the comeocyte layers in the stratum
corneum.
3.2.6 Summary of Key Aspects of the Previous Structure-Based Models
Aimed at Developing a First-Principles Intercellular Transport Model
In the next section, the derivation of a model for drug transport through the intercellular
regions of the stratum corneum, which utilizes the structural parameters of the skin to
determine the values of the porosity and the tortuosity, is presented. From the review of
the previous structure-based models presented in Sections 3.2.1 - 3.2.5, several key ideas
were incorporated into the derivation of this first principles transport model, including: 1)
the use of a model of the stratum corneum that best represents the observed physical
cross-section of the stratum corneum, in the direction of permeant flux through the
stratum corneum, 2) the use of the same model of the stratum corneum for the evaluation
of the porosity and the tortuosity factors, and 3) the realization that the use of an effective
diffusion path length to model diffusive flux through the parallel intercellular diffusion
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pathways in the stratum corneum always underestimates the total amount of intercellular
space present in the stratum corneum. From microscopic imaging of the stratum
comeum, the model of Johnson et al. (see Figure 3-1d), which incorporates the existence
of asymmetrically offset comeocytes, seems to be the most accurate representation of the
cross-section of the stratum corneum, in the direction of permeant flux. In addition, it is
necessary to maintain consistency of the stratum corneum model in the evaluation of the
porosity and the tortuosity factors. While it is possible to evaluate the porosity of the
stratum corneum surface in two dimensions using hexagonal-shaped corneocytes, it is not
currently possible to analytically evaluate the tortuosity in a three-dimensional section of
the stratum corneum, since it is not clear how the parallel diffusion pathways should be
treated in three-dimensions. (At first glance, it appears that there exist an infinite number
of paths a molecule can choose to travel along the surface of a comeocyte to move from
the center of the corneocyte to the edge of the corneocyte. Following the analogy with
electrical circuits, the effective diffusion path length for an infinite number of finite
diffusion paths would be zero, indicating that the stratum corneum would provide no
resistance to transdermal diffusion. Clearly, this conclusion does not agree with
experimental data, requiring more in depth study of parallel diffusion pathways in three
dimensions.) For the purpose of the derivation presented in Section 3.3, therefore, a two-
dimensional cross-section of the stratum corneum, oriented in the direction of permeant
flux, was used to evaluate the tortuosity, while the porosity was evaluated from the one-
dimensional "surface" corresponding to the two-dimension model of the stratum corneum
cross-section. Finally, the review of the previous models has revealed that either the
physical diffusion path length or the effective diffusion path length, modeled analogously
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to electrical resistors in parallel, has been used in the past to estimate the tortuosity of the
intercellular regions of the stratum corneum. It has been shown that the use of the
effective diffusion path length in the expression for the tortuosity represents the best
model to describe the flux of material through the intercellular region of the stratum
corneum. 12,13 However, the use of the effective diffusion path length model always
underestimates the total amount of space occupied by the intercellular regions of the
stratum corneum, which could significantly underestimate the time required to reach
steady-state diffusion in the stratum corneum. On the other hand, the actual physical
space occupied by the intercellular regions of the stratum corneum can be well
represented when the physical diffusion path length is used in the expression for the
tortuosity of the intercellular diffusion pathways. However, use of the physical diffusion
path length will lead to some underestimation of the steady-state diffusive flux. As the
theoretical derivation presented next demonstrates, these modeling difficulties can be
overcome if two unique tortuosity factors, one accounting for the physical space
occupied by the intercellular regions of the stratum corneum and the second accounting
for the diffusive flux through the intercellular regions of the stratum corneum, rather than
a single tortuosity factor, are used to model the transport of drugs through the
intercellular regions of the stratum corneum.
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3.3 Theory
3.3.1 Derivation of Fick's Second Law for the Intercellular Regions of the
Stratum Corneum
Figure 3-2 represents a horizontal repeating slice of the SC. Assuming that drug
transport is restricted to the intercellular region of the SC, the following mass balance can
be written on the thin slice of SC shown in Figure 3-2:
_m
hin - mhou, = (3.26)
at
where rh in and rh out are the drug mass flow rates into, and out of, the thin slice of SC.
The mass, m, which accumulates in the intercellular region of the SC can be defined as
the product of the intercellular volume, Vlipids, and the drug concentration, C(z,t), where z
denotes the direction perpendicular to the SC slice (see Figure 3-2). In the absence of
hydration (swelling) effects in the SC during the course of a permeation experiment,
Vlipids constant with time, and Eq. (3.26) can be rewritten as follows:
8C(z,t)
rh,, - rho,, = ac;,(, (3.27)
at
Based on the geometry of the SC in Figure 3-2, Vlipids can be defined as follows:
Vl,,a , = Wg (h + g + d) (3.28)
The volume of the entire SC slice is given by:
VT. = W(d + g)(h + g) (3.29)
The ratio of Vlipids to Vsc is then given by:
=1 fi = _l'OlUer (3.30)Vsc· d+g h+g ,oirone
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Figure 3-2: Repeating lateral slice of the stratum corneum, corresponding to the model of
Johnson et al. (see Figure 3-1d), used for the derivation of Fick's Second Law of
diffusion through the intercellular regions of the stratum corneum. The grey regions
represent the impermeable corneocytes and the white regions represent the intercellular
lipid lamellar regions. The dashed arrows indicate that the corneocytes are modeled as
being infinite in the direction of the arrows. Note that the two intercellular regions at the
inlet of the slice are each half of the intercellular gap width, (g/2), to maintain equality
with the width of the intercellular region at the outlet of the slice.
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Comparing the first term in parentheses in Eq. (3.30) to Eq. (3.4), it follows that it
corresponds to the porosity, 6, in 1-D. Comparing the second term in parentheses in Eq.
(3.30) to Eq. (3.6), it follows that Eq. (3.30) has a form similar to the expression for the
tortuosity, r, for the case of a single corneocyte and a single intercellular region, where
diat is given by d. Since this tortuosity factor in Eq. (3.30) accounts for the total amount
of lipids in the SC slice, it is subsequently denoted as tvolume. Substituting Eq. (3.30) into
Eq. (3.27) yields:
8C(z,t)hin - ho, = rvoune m C(eVzS ) (3.31)
at
Dividing Eq. (3.31) by the cross-sectional area of the SC slice, W(d+g), and using Eq.
(3.29) for Vsc yields:
mi, mi =C(z,t)Min = Ervolume (h + g) - (3.32)
W(d + g) W(d + g) at
Noting that mass per unit area and per unit time is the flux, F, and that (h+g) = Az (see
Figure 3-2), Eq. (3.32) can be rearranged as follows:
F a (3.33)
rvolume Az t
For the SC that has many layers of corneocytes, Az can be assumed to be small compared
to the entire SC thickness. In that case, the square-bracketed term in Eq. (3.33)
corresponds to a derivative, and Eq. (3.33) reduces to:
1 F(z, t) =ac(z,t) (3.34)
r volu,•e az at
It now remains to evaluate F(z,t) in terms of C(z,t) to obtain a model equation for
the partial differential form of Fick's Second Law of diffusion. The mass flow rate of
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drug delivered through the intercellular regions of the thin slice of the SC (see Figure 3-
2) can be modeled as follows:
rhlipid, =Dh (Wg) C(z + Az,t) - C(z,t) (3.35)
h + g + dia,
where (Wg) is the cross-sectional area of the lipids available to the drug at the inlet and
the outlet of the SC slice, and (h+g+dlat) is the effective intercellular diffusion path length
through the thin slice of SC. Since there are two parallel lateral diffusion pathways, dL
and ds, that the diffusing molecule may chose, diat may be evaluated using the techniques
of Cussler et al. and of Johnson et al., as follows:
1 1 1
I-- I + - (3.36)
d/a, di, ds
where djl and ds represent the long and the short diffusion paths (see Figure 3-2 for the
corresponding expressions, and recall that (o = dL/ds). The expressions for dL and ds
represent the average physical diffusion path lengths for the long and the short parallel
diffusion pathways, respectively. Substituting the expressions for dL and ds given in
Figure 3-2 into Eq. (3.36) and simplifying yields:
dd, 0) d (3.37)
(1 + e-)
The mass flow rate through a homogeneous lipid membrane that has the same thickness,
(h+g), and cross-sectional area, W(d+g), as the slice of SC shown in Figure 3-2 can be
expressed as follows:
r,, = Dh, [W(d + g)]C(z + Az, t) - z,t) (3.38)h+g
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Taking the ratio of Eqs. (3.35) and (3.38) yields:
rhilipids g 1S g1 (3.39)
sL h + g + Jd co Zh+g+ -- -- d(1+ 0)2
h+g
As in Eq. (3.30), the first term in parentheses in Eq. (3.39) corresponds to the porosity, .,
in I-D, and the second term in parentheses in Eq. (3.39) is similar to the expression for
the tortuosity, r, where diat is given by [o/(l+o)2]d. Since this tortuosity factor in Eq.
(3.30) accounts for the effect of the parallel, intercellular lateral diffusion pathways
shown in Figure 3-2 on the flux of material through the slice of SC, it is subsequently
denoted as nflux. Substituting Eq. (3.38) into Eq. (3.39) and dividing by the cross-
sectional area of the SC to obtain the flux yields:
m liPas C(z + Az, t) - C(z,t)F - =- Dh (3.40)[W(d + g)]- ix  h + g
Noting again that (h+g) = Az, where Az represents a thin slice of the SC, Eq. (3.40) can
be further simplified to yield Fick's First Law of diffusion for the intercellular regions of
the SC:
F = T FDb (z (3.41)
Substituting Eq. (3.41) into Eq. (3.34) yields the form of Fick's Second Law of diffusion
through the intercellular regions of the SC.
C Dh a2caC = Dl D ' 2C (3.42)
at r luxrvolume az 2
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3.3.2 Obtaining Expressions for the Lag Time and for the Steady-State
Permeability Corresponding to the Intercellular Regions of the
Stratum Corneum
Equation (3.42) can be solved for the general case with the following boundary and initial
conditions:
C(z = L,t) = Kh,inC 2  (3.43a)
C(z = O,t)= Kb,outCI (3.43b)
C(z,t = 0)= Co (3.43c)
where Kb is the vehicle/lipid bilayer partition coefficient, C2 is the bulk concentration on
the donor side of the SC, C1 is the bulk concentration on the receiver side of the SC, and
Co is the initial concentration of the drug within the intercellular lipids of the SC. Note
that in the z-direction, z = 0 corresponds to the outlet of the stratum corneum, rather than
to the inlet of the stratum corneum, in order to simplify the solution of Eq. (3.42).
Following the solution procedure of Fick's Second Law of diffusion through a
homogeneous membrane, 2 0 the solution to Eq. (3.42) with the above initial and boundary
conditions, is given by:
C(z,t)=Kh, u + (K,,C, - K ,C,
+2 K,,,CC, cos nr - Kb,ouCi sinn= exp Dh n2/7u2 t (3.44)
n n L T T L 2
-7 n=1x flux volume
4C- o 1 ((2m+1)7 Db (2m + 1)2 ;2t)
+ - sin ex- b27 m=0 2m +1 L r Tfluxrvolume L
The total amount of mass per unit area delivered across the SC, Q(t), is given by a time
integral over the flux, that is, by:
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IE IC(z,t)
Q(t) = JF(z = O,t)dt = f- - Dh -'D, dt (3.45)
0 0 fZtlx z z=0O
where Eq. (3.41) has been used for the definition of the flux in the SC. Substituting Eq.
(3.44) into Eq. (3.45) and carrying out the integration over time yields:
Q(t) = Dht (Kh,,, C - Kh0,, C. )
.fluxL
2 Ec volumeL Kh, C 2 cos n - Kh,,,, C , ex - D 2 2(3.46)
m=0 (2m +1) ux volume L
For the special case when C1 = Co = 0, which is applicable for most permeation
experiments, Eq. (3.46) can be further simplified by noting that cos(nmt) = (-1)n and that
(--- .r2  This yields:
n=l n2  12
Q) ~Kh,,C2 vomL f Dht 1 2 (-)n (- Dhn 2;2t lQLt = (cKhinx2volume L 2lL 6 2 =l 2 VXp L2  (3.47)S.tr vwlumeL 6 n ,,( 1 .lux Tvolume L
Equation (3.47) describes the cumulative amount of mass delivered through the
intercellular regions of the SC at time, t, while using both the intrinsic values of the drug
vehicle/lipid bilayer partition coefficient and the diffusion coefficient. At steady-state
(for large t), Eq. (3.47) simplifies as follows:
Q(t) = (eKh,inC 2TvolumeL D 2D 1 (3.48)L fUx r volume L 6
From Eq. (3.48), the lag time for diffusion through the intercellular regions of the SC can
be evaluated by setting Q(t) in Eq. (3.48) equal to zero and solving for tlag,20 which
yields:
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t/ag = T volume (3.49)
6Db
Equation (3.49), which describes the lag time to steady-state in the intercellular regions
of the stratum corneum, has two unique tortuosity factors, rather than the single tortuosity
factor present in the expression for the lag time, (tlag = (CL)2/6Db), presented in Section
3.1. Finally, the steady-state permeability, P, for drug transport through the intercellular
regions of the SC can be evaluated by dividing Eq. (3.48) by C2 and evaluating the time
derivative to obtain:
P = (t) = c Kb•L (3.50)(C, a t -r L
Equation (3.50) has a form similar to Eq. (3.1), where t and Kb in Eq. (3.1) are now given
by Tfnux and Kb,in, respectively, for steady-state diffusion through the intercellular regions
of the stratum corneum. Note that for the case of a homogeneous membrane where E,
tEvolume, and flux are equal to 1, Eqs. (3.44) - (3.50) reduce to the equations describing
transport through a homogeneous membrane. 2 0
Application of Eqs (3.47) - (3.50) to human SC samples of the type shown in
Figure 3-Id requires slight modifications to the expressions used for zvol,,m and nflux to
account for the presence of N corneocyte layers and (N-1) intercellular lateral lipid layers
in the SC model presented in Figure 3-1d. The expressions for tvolume and Tnux
corresponding to this case are:
Nh + (N - 1)g + (N - 1)d
r,,ohl, (3.51a)Nh + (N - 1)g
and
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Nh + (N- I)g + (N - 1) -2 d
= ( (3.51b)
x =Nh + (N - 1)g
Equations (3.51a) and (3.51b) have the same general form as the expression for the
tortuosity given in Eq. (3.6), which accounts for the actual number of layers of
corneocytes (N) and intercellular lateral lipid bilayers (N-1), where diat is equal to d for
Tvolume and equal to [0/(1+C) 2]d for tflux, and L = Nh+(N-I)g. By including these two
tortuosity factors in the model equations, it is now possible to separate the effect of the
volume of the stratum corneum intercellular domain on the time required to reach steady-
state in the intercellular domain and the effect of the parallel pathways in the intercellular
domain on the diffusive flux of hydrophobic molecules through the stratum corneum.
Previous structure based models, restricted by the use of a single tortuosity factor, were
unable to distinguish these separate effects on diffusive transport that arise from the
physical arrangement of the stratum corneum intercellular domain.
3.4 Theoretical and Experimental Methods and Materials
3.4.1 Finite Element Method Simulations
Finite Element Method simulations were conducted using FEMLAB 3.0a (Comsol, Inc.).
2D geometric models of the SC, similar to the one presented in Figure 3-1d, were
generated in FEMLAB. The assumptions built into the model included: 1) no diffusive
flux into or out of the corneocytes, 2) zero concentration of the permeant on the receiver
side of the SC (note that while permeant does accumulate in the receiver chamber in an
actual permeability experiment, if the concentration of the permeant in the receiver
chamber is much lower than that in the donor chamber, one can safely assume that the
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permeant concentration in the receiver chamber is zero, relative to that in the donor
chamber), 3) a non-zero value of the bulk concentration, Co, on the donor side of the SC
(a value of 0.1 g/L was used in the simulations), and 4) periodic boundary conditions
equating the values of the permeant concentrations on the left edge and on the right edge
of the intercellular regions within the SC. Values of 1 and 1*10 -9 m2/s were chosen as
inputs in the simulations for Kb and Db, respectively. The following SC geometric
parameters were varied (over the listed range of values): the corneocyte diameter, d (20,
30, 40, 50 and 60 ýpm); the ratio, g/h, which measures the amount of intercellular space in
the SC relative to the amount of space in the SC occupied by the corneocytes (0.02, 0.1,
0.5); and the corneocyte layer offset, o (1, 3, 8, 19, 37, and infinity). 13 These values were
selected to examine the robustness of Eq. (3.47) over a range of SC structural parameters,
centered around the structural parameter values corresponding to native SC, listed in bold
above. 12,13 The chosen values of g/h vary from the case of swollen corneocytes (g/h =
0.02) to the case of a swollen intercellular region (g/h = 0.5), while the native SC
structure is represented by g/h = 0.1. In each of the above cases, the volume of the
intercellular region was assumed to be constant during the simulation of each permeation
experiment, even though the volume of the intercellular region did vary between each
case examined. The values of o were varied from the case corresponding to
symmetrically offset corneocyte layers (co = 1) to the case corresponding to aligned
corneocyte layers which have no offset (co = infinity). Each simulation was run for 100
seconds of simulation time to ensure that the FEMLAB simulations reached the steady-
state diffusion phase. Time steps were taken every 0.4 seconds to minimize numerical
errors, while keeping the simulation solution time on the order of minutes. Plots of Q(t)
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vs. time were generated by exporting the flux vs. time data corresponding to the lipid
bilayer edge located on the receiver side of the SC model generated in FEMLAB into an
Excel spreadsheet, and then performing the numerical integration required by Eq. (3.45)
to obtain Q(t). Note that increases, or decreases, in the values of Kb and Co used in the
FEMLAB simulations relative to the values reported above result directly in proportional
increases, or in decreases, of Q(t), and, thus, will have no impact on the calculated values
for % error in the regressed values of Kb and Db. In addition, decreases in the values of
Db used in the FEMLAB simulations can impact whether the FEMLAB simulation
reaches the steady-state regime, but this can easily be addressed by increasing the
simulation time, such that the term, Dbt, remains constant.
3.4.2 Permeability Experiments with Human SC Membranes
Two radiolabeled hydrophobic permeants - Naphthol (MW = 144.2 Da, log Ko/w = 2.84)
and Testosterone (MW = 288.4, log Ko/w = 3.31) - were selected to demonstrate how Eq.
(3.47) can be used to simultaneously evaluate Kb and Db from the permeability
experiments. Both permeants were selected because of their previous use as model
hydrophobic permeants. 12,16  These chemicals were obtained from American
Radiolabeled Chemicals, Inc. (St. Louis, MO). Phosphate Buffer Saline was obtained
from Fluka Chemical (St. Louis, MO).
Full-thickness human cadaver skin was obtained from the National Disease
Research Institute (Philadelphia, PA) and stored at -800 C until use. The full-thickness
human skin was submersed in 600 C water for 2 minutes to heat strip the epidermis from
the dermis. 17 The heat-stripped epidermis was then placed, with the stratum corneum
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side up, in a phosphate buffer saline (PBS) solution containing 0.1% (w/v) trypsin (Sigma
Chemical, St. Louis, MO) for 24 hours at 25 oC to remove the epidermis. The SC was
rinsed in PBS and any residual epidermis was gently scrapped from the SC. The SC was
then transferred to a nylon mesh for support and stored at 40C, 95 % humidity for up to
14 days prior to use.' 8
Diffusion experiments were carried out using side-by-side diffusion cells. The
structural integrity of the SC samples was tested using electrical resistivity measurements
according to previously published methods. 19 Any SC sample with an initial electrical
resistivity below 30 kOhm*cm 2 was considered damaged and was replaced with a new
SC sample. The hydrophobic permeants were rotary evaporated to remove the solvent,
and were subsequently redissolved in PBS to obtain a donor solution concentration of 1
tiCi/ml. Aliquots of the receiver chamber were taken at predetermined time points, and
their radioactivity was measured using a scintillation counter (Packard, Tri-Carb®, 2200
CA). Permeability experiments were conducted for 2 hours for naphthol, and for 8 hours
for testosterone to ensure transition into the steady-state regime for the two hydrophobic
permeants considered. Note that more time was required for testosterone to reach steady-
state, because testosterone has a larger molecular weight than naphthol (see Figure 3-4).
Plots of Q(t) versus time were then generated from the results of the scintillation counting
of the aliquots taken from the receiver cell.
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3.4.3 Regression Analysis of FEMLAB and of the Experimental Diffusion
Data using Eq. (3.47) to evaluate Kb and Db
The Q(t) versus time data generated from the FEMLAB simulations and from the human
SC diffusion experiments were analyzed using DataFit 8.1 (Oakdale Engineering).
Equation (3.47) was used as the model equation for the nonlinear regression analysis, and
Kb and Db were selected as the regression parameters for analysis of both data sets.
DataFit 8.1 uses the Levenberg-Marquardt method as the algorithm for adjusting the
values of the initial estimates of the regression parameters to improve the fit of the
nonlinear regression model. For the FEMLAB data, the initial values of Kb and Db for
the regression analysis were set at 1 and 1*10 -9 m2/s, respectively, which were the chosen
input values of Kb and Db used in the FEMLAB simulations. For the human SC diffusion
experimental data, the initial values of Kb and Db for the regression analysis were 100 and
1*10 -8 cm 2/s, respectively. These initial values of Kb and Db were selected as
representative values of Kb and Db for hydrophobic permeants based on previously
published data.12,16
3.5 Results and Discussion
3.5.1 Comparison of the Kb and Db Inputs for the FEMLAB Simulations
with the Values of Kb and Db Obtained from the Regression Analysis
of the FEMLAB Data Using Eq. (3.47)
Figures 3-3a and 3-3b present the absolute % error in the regressed values of Db and Kb,
respectively, compared to the FEMLAB input values of Db (1 * 10-9 m2/s) and Kb (1) over
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the range of SC geometric parameters studied. Note that the R2 values for all the
regressions of the FEMLAB data using Eq. (3.47) exceeded 0.9999. In both figures, the
white blocks correspond to the swollen corneocyte case (g/h = 0.02), the light grey blocks
correspond to the native SC case (g/h = 0.1), and the dark grey blocks correspond to the
swollen intercellular region case (g/h = 0.5). For each individual case, the data are
plotted by decreasing corneocyte length, d, on the x-axis and by increasing corneocyte
offset, o, on the y-axis (recall that for o = 1, the corneocytes are symmetrically offset,
while for o = infinity, the corneocytes are aligned such that there is no offset). Absolute
% error values in Db and Kb for SC models similar to the native SC skin structure (d = 40
itm, h = 1 pm, g = 0.1 ptm, w = 3 - 8) are denoted by the asterisks (*).
Based on the results in Figures 3-3a and 3-3b, it appears that Eq. (3.47) performs
better (i.e. the absolute % error decreases) as: 1) the ratio, g/h, approaches zero, 2) the
corneocyte length, d, increases, and 3) the corneocyte offset, o, approaches 1. Therefore,
one may conclude, based on comparisons with the finite-element data generated by
FEMLAB, that Eq. (3.47) approaches the exact solution describing transient diffusion
through the intercellular regions of the SC membrane as the intercellular regions of the
SC become infinitely thin (g/h approaches 0), and when the corneocytes are
symmetrically offset (oa approaches 1). While Eq. (3.47) compares very well to the
FEMLAB data at these idealized conditions, Eq. (3.47) also performs very well over the
wide range of SC geometries that were analyzed. In Figures 3-3a and 3-3b, absolute %
errors greater than 5% correspond to the highlighted blocks. In Figure 3-3a, Eq. (3.47)
was able to reproduce the value of Db to within less than 5% of the FEMLAB input value
for over two-thirds of the SC geometries sampled. In addition, in Figure 3-3b, Eq. (3.47)
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Figure 3-3: Absolute % errors in the values of (a) Db and (b) Kb from the FEMLAB
simulations regressed using Eq. (3.47). The white bars correspond to a (g/h) ratio of
0.02, the light grey bars correspond to a (g/h) ratio of 0.1, and the dark grey bars
correspond to a (g/h) ratio of 0.5, where g/h is the ratio of the intercellular region in the
SC to the comeocyte region in the SC. Values of (o vary from 1, corresponding to the
case of symmetrically offset comeocyte layers, to infinity, corresponding to the case
where the comeocyte layers have no offset. Values of the comeocyte diameter, d, vary
from 20 p.m to 60 ptm. The asterisks (*) correspond to stratum comeum geometries
found in native human stratum comeum samples. Columns having values larger than 5%
are highlighted in bold.
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was able to reproduce the value of Kb to within less than 5% of the FEMLAB input value
for over 90% of the SC geometries sampled. Most importantly, perhaps, Figures 3-3a
and 3-3b indicate that Eq. (3.47) can be used to obtain values of Kb and Db to within
approximately 2-3% of the actual value of these parameters for a drug permeating
through the intercellular regions of a native human SC sample (see the asterisked
columns).
One source for the observed errors between the regressed values of Kb and Db and
the FEMLAB input values of Kb and Db is the inability of the current model to predict the
initial exit of permeant from the SC. Equation (3.47) assumes that all permeants will
travel along a diffusion path which is proportional to the effective lateral diffusion path,
diat. However, in the FEMLAB simulations, permeants that physically travel along the
shorter lateral diffusion path length, ds, will exit from the SC earlier than predicted by Eq.
(3.47), which results in decreased diffusion lag times. As o approaches infinity and ds
approaches 0, this error in the diffusion lag times increases. Since L, tflux, and tvolume are
fixed quantities in Eq. (3.47), the decrease in the lag time is compensated for by
increasing the value of Db. This increase in Db is then coupled with a corresponding
decrease in Kb to increase the goodness of the fit corresponding to the steady-state
regime. This may explain why the errors in Kb and Db increase as o increases and as d
decreases (see Figures 3-3a and 3-3b), since both result in a decrease of the value of ds.
A second source of error may be attributed to the presence of increased 2-D diffusion as
the ratio, g/h, increases. As g/h approaches zero, the intercellular region becomes
infinitely thin and diffusion in the intercellular region can adequately be modeled as 1-D
diffusion. As g/h increases, the thickness of the intercellular regions increases, which
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may cause 2-D diffusion to become significant. This may explain why the errors in Db
when g/h = 0.5 are much larger than the errors in Db when of g/h = 0.1 and 0.02, without
a corresponding increase in the errors in Kb over the same range of g/h values (see the d =
40 and the d = 60 columns in Figure 3-3a and 3-3b). When d = 20, corresponding to the
largest errors in Db and Kb, both sources of error discussed here are likely to contribute to
the observed errors in Db and Kb.
The errors in Db and Kb reported here between the regressed values of Db and Kb
using Eq. (3.47) and the values of Db and Kb used in the FEMLAB simulation are still
small when compared to the values of Db and Kb regressed from the five previous
structure-based SC permeability models discussed in Section 3.2 that utilize the intrinsic
values of Db and Kb in the model equations. Table 3-1 summarizes the expressions for
the porosity and the tortuosity used in these five models, which were presented in Section
3.2. These expressions for the porosity and the tortuosity can be used in the following
equation:
t= L(rL)2  6 2r 2 n (=L)_
Equation (3.52) was derived using the methods presented in Section 3.3.2, but where Eq.
(3.42) would have a single tortuosity factor for the flux and the volume of intercellular
space in the SC, rather than separate tortuosity factors for the flux and the volume of
intercellular space in the SC. Equation (3.52) can be used in place of Eq. (3.47) as the
regression equation, with Db and Kb as the regression parameters, to compare with the
FEMLAB Q(t) vs. time data. The results of this analysis for three SC geometries are
presented in Table 3-2. The SC geometries selected include: 1) symmetrically offset,
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Table 3-1: Expressions for the Porosity, E, and the Tortuosity, t, from the Five Previously
Published Structure-Based Models for Transport through the Intercellular Regions of the
Stratum Comeum.
Model
Michaels et al.8
Porosity, E
2g
d
Tortuosity, r
dg
-+
h
Cussler et al. 9
Lange-Lieckfeldt and Lee' 0
Edwards and Langer''
Johnson et al. 2
g
d+g
d + g ) _(d ) 22 2K~ d(d l 1 
1
2
dg 1 +1d+g )( +() ,
g
d+g
Nh + (N- d+
L 4
L
d+h
h
Nh + (N -1 )
L
swollen corneocytes (d = 60, h = 5, g = 0.1, and co = 1), 2) native SC structure (d = 40, h
= 1, g = 0.1, and co = 3), and 3) asymmetrically offset corneocytes with swollen lipids (d
= 20, h = 1, g = 0.5, and co = 37). These three SC geometries were selected as examples
of a native SC geometry and extreme cases of the SC geometries considered for the
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Table 3-2: Comparison of the Regressed Values of Kb and Db from the FEMLAB Q(t)
versus Time Data Using Eq. (3.47) (the Two-Tortuosity Model) and Eq. (3.52) (the five
models presented in Section 3.2, each having a single tortuosity factor).a
d = 60, h = 5, d = 40, h = 1, d= 20, h = 1,
g = 0.1, o= 1 g = 0.1, co = 3 g = 0.5, co = 37
Model Kb Db*109  Kb Db*10 9  Kb Db*10 9
Two-Tortuosity Model 0.995 1.002 0.986 1.017 0.932 1.210
Michaels et al. 4.086 0.048 0.913 1.419 1.085 2.489
Cussler et al. 14.91 0.014 3.661 0.351 4.381 0.642
Lange-Lieckfeldt and Lee 4.261 0.044 0.953 1.286 1.104 2.344
Edwards and Langer 40.30 0.017 7.967 6.390 7.709 17.89
Johnson et al. 14.93 0.014 4.742 0.209 4.807 0.145
a = The chosen input values of Kb and Db for the FEMLAB simulations were 1 and 1*10 -9 m2 /s,
respectively.
FEMLAB experiments. As can be seen from Table 3-2, the values of Kb and Db obtained
with Eq. (3.47) for these three SC geometries are closer to the FEMLAB input values (Kb
= 1, Db = 1* 10-9 m2/s) than the values of Kb and Db obtained using any of the other five
structure-based SC permeability models considered here. The observed improvement is
due to accounting for the impact of the volume of the SC intercellular region on
intercellular transport through the SC in Eq. (3.47), captured in the term, Tvolume. As
discussed in Section 3.3, this tortuosity term was obtained directly from first-principles
by using a mass balance to describe the accumulation of the drug within the intercellular
regions of the SC.
It is noteworthy that the expression for the ratio of the lag time from the Two-
Tortuosity Model (see Eq. (3.49)) to the lag time for a similar sized homogeneous
membrane (tlago = L2/6Db), given by:
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tag = u = flux + 1+(N-)
tago un ux - Nh + (N - I)g (3.53)
is very similar, assuming that N - (N-1), to the expression for the ratio of the lag time
through the SC membrane to the lag time of a similar sized homogeneous membrane
presented by Frasch and Barbero:13
t d
tagO 1+ 1+g
trago h + g
(3.54)
where tiag is the lag time through the SC, tlgo is the lag time through a similar sized
homogeneous membrane. While the first-principles derivation of Eq. (3.47) presented in
this chapter yields similar expressions for the lag time ratio to those presented by Frasch
and Barbero, the model equation described in Eq. (3.47) utilizes the intrinsic values of
the SC membrane thickness, L, the intercellular lipid diffusion coefficient, Db, and the
vehicle/lipid bilayer partition coefficient, Kb. By including a second tortuosity factor into
the diffusion model equation, Eq. (3.47) properly accounts for the geometric factors
influencing the SC tortuosity, which, in turn, allows for the use of the intrinsic values of
L, Db, and Kb in the model equation. When only one tortuosity factor is used to describe
the SC diffusion length, as in Eq. (3.2), it then becomes necessary to use the effective
values of L and Db to describe permeation data through the SC, as stated by Frasch and
Barbero. 13 Having demonstrated the ability of Eq. (3.47) to extract values of Db and Kb
from FEMLAB SC permeability simulations for SC structures similar to native human
SC structures to within 2-3% of the intrinsic values of Kb and Db, Eq. (3.47) can now be
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used as a tool to simultaneously deduce the intrinsic values of Kb and Db for hydrophobic
permeants directly from permeability experiments.
3.5.2 Simultaneous Evaluation of Kb and Db for Hydrophobic Permeants
from SC Permeability Experiments with Hydrophilic Molecules Using
Eq. (3.47)
The delivery of the hydrophobic permeants - naphthol and testosterone - through human
SC as a function of time is presented in Figure 3-4a and Figure 3-4b, respectively. The
experimental data, as shown by the black circles, in Figure 3-4 represents the average of
5 experiments. The error bars represent the standard deviation of the experimental data
for the 5 experiments conducted. For naphthol (Figure 3-4a), the solid line represents the
best-fit curve (R2 = 0.9975) of the experimental data using Eq. (3.47). The intrinsic
values of Kb and Db obtained from the regression analysis are 233 (+44) and 1.6*10 -7
(+0.3*10 -7) cm 2/s, respectively. For testosterone (Figure 3-4b), the solid line represents
the best-fit curve (R2 = 0.998) of the experimental data using Eq. (3.47). The intrinsic
values of Kb and Db obtained from the regression analysis are 100 (+14) and 1.8*10 -8
(+0.2*10-8) cm 2/s, respectively. These values for Kb and Db for naphthol and testosterone
compare well with the values of Kb and Db obtained using permeation experiments
combined with octanol-water partition experiments, 12 as well as using permeation
experiments combined with solute release experiments,16 as shown in Table 3-3. Again,
the great practical advantage of the new method to obtain Kb and Db is that it requires
only permeability experiments to evaluate these parameters, while all the previous
methods require two types of experimental measurements.
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Figure 3-4: Delivery of hydrophobic permeants through human SC: (a) Naphthol, (b)
Testosterone. Key: Black circles - experimental data (n = 5), solid lines - best-fit curve
of the experimental data using Eq. (3.47). Error bars: + 1 S.D.
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Table 3-3: Comparison of Kb and Db Values Obtained using the Two-Tortuosity Model
with Values of Kb and Db Obtained Using Previously Published Techniques.
Naphthol Testosterone
Kb Db (cm 2/s) Kb Db (cm 2/s)
Two-Tortuosity Model 233 1.6*10-7 100 1.8*10.8
(ONLY permeation experiments) (±44) (+0.3 * 10-) (+14) (+0.2*10 -8)
Permeation experiments AND 144 1.910 7  328 1.610-8
octanol-water partition experiments'2  144
Permeation experiments AND solute 519 0.5*1 7  10 2.0*108
release experiments6 519 0.5
The value of Db for testosterone obtained with the Two-Tortuosity Model was
also in good agreement with the expected value of Db based on FRAP (fluorescence
recovery after photobleaching) measurements in extracted human stratum corneum lipids.
Johnson et al. measured the value of the lateral diffusion coefficient for permeants having
a molecular weight in the range of 223 to 854 Da in three model membranes,
dimyristoylphosphatidylcholine (DMPC), DMPC/cholesterol (40% mol), and human
stratum corneum lipids extracted with chloroform/methanol (2:1).21 Based on the results
of Johnson et al., the expected values for testosterone in DMPC, DMPC/cholesterol, and
extracted stratum corneum are 12.5*10-8, 3.2*10-8, and 1.0*10-8 cm 2/sec. 2 1 The value of
Db obtained from permeability experiments in the SC with the two-tortuosity model
(1.8*10 -8 cm2 /sec) is closest to the FRAP measurements conducted with extracted human
stratum corneum lipids. The difference in the values of Db for testosterone with the two-
tortuosity model and the expected value in extracted human stratum corneum could be
due to the lipid extraction and bilayers formation processes. The extraction and
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deposition of the stratum corneum lipids could result in a bilayer structure that is different
from what is found in native human SC samples. Still, comparison of the value of Db
from the two-tortuosity model and the value expected in with FRAP does support the
accuracy of the two-tortuosity method, since, as previously mentioned, the value obtained
from permeability experiments in the SC with the two-tortuosity model is closest to the
FRAP measurements conducted with extracted human stratum corneum lipids.
In addition to being able to more accurately and more easily determine the values
of Kb and Db associated with drug transport in the intercellular regions of the stratum
corneum, the new method of analysis presented in this chapter would allow determination
of the enhancement mechanism induced by chemical enhancers. Specifically, by
comparing the values of Kb and Db for a desired drug in untreated and chemically-treated
skin, one could determine whether the chemical enhancer increases the partitioning of the
drug into the skin (by increasing the value of Kb), or whether it perturbs the highly-
ordered structure of the lipid bilayers to increase the permeability of the drug (by
increasing the value of Db), or both.
3.6 Conclusions
From first principles, a new theoretical model that describes Fickian diffusion of
hydrophobic permeants which diffuse through the intercellular lipid domains of the
stratum corneum has been developed. This new theoretical model utilizes the structural
parameters of the stratum corneum to evaluate the porosity and the tortuosity parameters.
The new feature of the model is the presence of two tortuosity factors in the model
equations, which account for: 1) the total amount of lipid in the SC, and 2) the impact of
166
parallel diffusion pathways on the diffusive flux through the SC. Based on a regression
analysis of the data obtained from the simulated stratum corneum diffusion experiments
performed with FEMLAB, the new transport model deduced Kb and Db to within a 2-3%
error for native stratum corneum structures, out-performing all the five previous
structure-based transport models considered. The regressed values of Kb = 233 (+44) and
Db = 1.6*10-7 (+0.3*10-7) cm 2 /s for naphthol and Kb = 100 (+14) and Db = 1.8*108
(+0.2*10-8 ) cm2 /s for testosterone, obtained using the new transport model, are
comparable to the Kb and Db values obtained using previously published experimental
techniques. This result demonstrates that Kb and Db values for hydrophobic permeants
can be evaluated solely from permeation experiments using the new theoretical model,
which should greatly simplify the experimental method used to evaluate Kb and Db for
hydrophobic permeants.
In the next chapter, the impact of localized transport regions on the transport of
hydrophilic drugs through ultrasound-treated skin is examined. As part of this
examination, the results of this chapter are used to establish whether drugs permeate
through the LTRs via an intercellular or via a transcellular pathway. Specifically, the
equations for (E/nflux) for the intercellular domain of the stratum corneum obtained in this
chapter are used to determine a threshold value for the presence of hydrophilic
intercellular pathways in the LTRs. If the value of (e/inux) for the hydrophilic pathways
is greater than the threshold value, then this would suggest that transcellular permeation
pathways are formed in the LTRs present in the ultrasound-treated skin.
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Chapter 4
Experimental Demonstration of the Existence of
Highly Permeable Localized Transport Regions in
Low-Frequency Sonophoresis
4.1 Introduction
As discussed in Chapter 1, transdermal drug delivery offers several advantages over
traditional methods of drug delivery. However, due to the structure and function of the
skin, specifically of the stratum comeum, successful application of transdermal delivery
methods has been restricted to a few, small (MW < 400 Da), hydrophobic (positive
octanol-water partition coefficients, log Koiw) compounds (see Table 1-1 in Chapter 1).1-4
To deliver larger hydrophobic molecules, as well as hydrophilic compounds of any size,
four primary methods have been developed to make the skin more permeable to drug
transport - (i) electroporation, 5-1o (ii) iontophoresis," - 17 (iii) chemical enhancers, 17-22 and
(iv) sonophoresis 22-28 (see Chapter 1 for details).
While the mechanistic details associated with methods (i), (ii), and (iv) to enhance
transdermal drug delivery are not yet fully understood, there is some evidence that
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enhanced transport of model permeants occurs by means of highly permeable, localized
pathways. These so-called localized transport regions (LTRs) have been observed in the
fields of electroporation and iontophoresis in several studies. 11 Using heat-stripped
human cadaver skin with the hydrophilic, fluorescent probes sulforhodamine B (SRB)
and calcein, LTRs (diameter 40-80 pm) were observed in electroporation for applied
voltages which were greater than 75 V. 5 In an attempt to deliver DNA antisense
oligonucleotides with electroporation, the DNA delivery was localized to 30-ptm diameter
LTRs.6 Further work determined that the size of the LTRs was much larger (-1 mm2)
when long pulses (100 - 300 ms) of medium-voltage (>30 V), rather than short pulses (1
ms) of high-voltage (100 V), were applied.7 However, the total number of LTRs formed
on the skin was higher for the short pulse, high-voltage case. 7 All the LTRs observed in
electroporation and iontophoresis exhibited a characteristic ring structure, in which the
LTR was highlighted by high concentrations of residual fluorescent probe bordering the
outer edge of the LTR.5 sa8 1
A recent discovery in the field of sonophoresis, made independently by Tang29
and by Tezel et al.,2325 unveiled the possible existence of LTRs on the surface of full-
thickness human skin and full-thickness pig skin as a result of exposure to low-frequency
ultrasound (20 - 76 kHz). Using the red-colored hydrophilic probe SRB, Tang observed,
with the naked eye, a single red spot, indicating the location of the hypothesized LTR, at
the center of the surface of sonicated (frequency - 20 kHz, intensity - 1.6 W/cm 2, duty
cycle - 0.1:0.9 sec, time - 20 hrs, transducer displacement - 0.8 cm) full-thickness human
skin.29 Tezel et al., using both SRB and sodium lauryl sulfate (SLS) (a surfactant used to
enhance the effects of sonophoresis), observed, also with the naked eye, a heterogeneous
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pattern of red spots on full-thickness pig skin (frequency - 20 kHz, intensity - 7.5 W/cm 2,
duty cycle - 5:5 sec, time - 15 min, transducer displacement - 3 mm). 23 Unlike the
microscopic ring structure observed in electrophoresis, the hypothesized LTRs observed
in low-frequency sonophoresis are more macroscopic structures, on the order of
millimeters in diameter.22-25,29 In addition to these initial observations, some microscopic
visualization of the hypothesized LTRs has been attempted by Tang29 and by Alvarez-
Roman et al.28 Using SRB as the fluorescent probe, Tang imaged sonicated (frequency -
20 kHz, intensity - 1.6 W/cm2, duty cycle - 0.1:0.9 sec, time - 20 hrs, transducer
displacement - 0.8 cm) full-thickness human skin using two-photon microscopy and
observed that a higher concentration of SRB was present within the single observed LTR
as compared to that found in the surrounding regions of the skin (the non-LTRs).29 Using
calcein as the fluorescent probe, Alvarez-Romain et al. imaged sonicated (frequency - 20
kHz, intensity - 15 W/cm 2, duty cycle - 0.1:0.9 sec, time - 2 hrs, transducer displacement
- 0.5 cm) full-thickness pig skin using confocal microscopy and observed that a single,
discrete region of the SC, located within an area of 1 cm 2 beneath the ultrasound probe,
had been perturbed, while the surrounding regions of the SC were less affected by the
ultrasound exposure. 28
While these observations appear to suggest that regions of increased permeability
do exist in sonicated skin samples, there has not yet been a direct, quantitative
demonstration that the hypothesized LTRs produced by low-frequency sonophoresis are
indeed regions of increased transdermal drug permeability. Also, no attempt has yet been
made to incorporate the existence of highly permeabilized regions of the skin into current
models of transdermal drug permeation to obtain a more accurate estimate of ultrasound
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enhancements, a need that has been emphasized recently by Alvarez-Romain et al.28 With
all of the above in mind, in this chapter, we pursue the following objectives: 1)
demonstrating quantitatively that the hypothesized LTRs that are produced in full-
thickness pig skin by low-frequency sonophoresis are indeed regions of higher
transdermal drug permeability (see Section 4.4), and 2) developing model equations to
describe skin samples having two regions with differing transdermal drug permeabilities
(see Section 4.3). To accomplish the first objective, we first pre-treat skin samples with
ultrasound in the presence of SLS using the constant skin electrical resistivity protocol,
which was developed by Tang et al.26 The constant skin electrical resistivity protocol is
an excellent technique for ensuring high reproducibility in the transdermal permeability
values of hydrophilic permeants delivered across skin samples perturbed by ultrasound.
This is because increases in transdermal permeability of hydrophilic solutes across the
skin are proportional to decreases in the skin electrical resistivity (or to increases in the
skin electrical conductivity, since resistivity and conductivity are inversely related),
which are both a result of the increased structural perturbations in the skin induced by the
exposure to ultrasound. Using the constant skin electrical resistivity protocol, we
prepared three groups of pig full-thickness skin samples that have unique skin electrical
resistivity values, and therefore, have unique transdermal permeability values, unique
skin electrical conductivity values, and unique structural perturbation levels. Note that
three groups with unique structural perturbation levels (and therefore, with unique skin
electrical conductivity values) were chosen so that the effect of increasing the structural
perturbation levels (and therefore, of increasing the skin electrical conductivity values) on
the size and on the transport properties of the LTRs and the non-LTRs could be
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examined. After pre-treatment with ultrasound, we conducted a series of diffusion
masking experiments, in which skin samples are masked for permeation of a model
hydrophilic drug through select portions of the skin (see Section 4.2). Based on the
permeability results of these diffusion masking experiments, as well as on skin electrical
resistivity measurements, we show that the hypothesized LTRs experience greater
structural perturbation than the surrounding non-LTRs due to ultrasound exposure,
confirming that the hypothesized LTRs are indeed regions of high localized transport (see
Section 4.4). Finally, we address how the results of the proposed experimental analysis
may impact our understanding of both the enhancing mechanisms, including the nature of
the transdermal transport pathways generated, in ultrasound-mediated transdermal drug
delivery (see Section 4.5). To accomplish the second objective, we start with mass
balances to develop the equations that relate the permeability of the LTRs and the non-
LTRs to the permeability of the entire skin sample (see Section 4.3). These equations are
then used to validate the permeability data obtained from the diffusion masking
experiments (see Section 4.4).
4.2 Materials and Methods
4.2.1 Chemicals
Phosphate buffer saline (PBS; 0.01 M phosphate, 0.137 M NaC1) was obtained from
Fluka Chemical (St. Louis, MO). Sulforhodamine B (SRB) was obtained from Molecular
Probes (Eugene, OR). Calcein (absorbance at X = 494 nm) and Sodium Lauryl Sulfate
(SLS) were obtained from Sigma Chemical Company (St. Louis, MO). All these
chemicals were used as received.
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4.2.2 Skin Preparation
Skin samples were prepared following previously published methods,30 which are briefly
summarized next. Pig full-thickness skin samples were obtained from the back and flank
of female Yorkshire pigs. Excess hair was carefully removed from the skin, which was
subsequently harvested within 1 hour after the animal was sacrificed. The subcutaneous
fat was removed from the skin, which was then sectioned into strips and stored at (-80 0C)
for up to 12 months. Before use in the permeation experiments, the skin was thawed for
an hour prior to being placed in vertical Franz diffusion cells (15-mm inner diameter)
obtained from Permegear (Bethlehem, PA) (see Figure 4-1). The receiver cell was filled
with PBS, and the donor cell was filled with a solution of PBS containing 0.5 % (w/v) of
SRB and 1.0 % (w/v) SLS.
Dc
Ce
Skin
Rece
Cell
Figure 4-1: Experimental setup of the vertical Franz diffusion cell used in the diffusion
masking experiments.
176
4.2.3 Skin Electrical Resistance Measurements
The electrical resistance of the skin was measured according to previously published
methods, 30 which are summarized next. A 100 mV AC voltage source at 10 Hz was
generated using a signal generator (Hewlett-Packard, model HP 33120A) and applied
across the skin membrane using two Ag/AgCl electrodes (In Vivo Metrics, Healdsburg,
CA) for 5-10 seconds. The skin electrical current was measured using a Fluke
Multimeter (Model 139, Fluke Corporation). The skin electrical resistance was obtained
from the skin electrical current using Ohm's Law. Since this measurement also includes
the resistance of the donor and the receiver cell solutions, a background electrical
resistance measurement of just the PBS solution was made separately and was then
subtracted from the electrical resistance of the skin in the diffusion cell to determine the
actual skin electrical resistance.
Prior to ultrasound exposure, the electrical resistance, R, of all the skin samples
was measured and multiplied by the skin area available to ultrasound exposure in the
diffusion cell (A = 1.77 cm2 ). Any skin sample with an initial RA value of <50
kOhm*cm 2 was considered damaged and was discarded, and was subsequently replaced
with an intact skin sample.31
4.2.4 Ultrasound Pre-Treatment Protocol
Ultrasound was applied to the intact pig full-thickness skin samples following previously
published methods. 23'30 Ultrasound (VCX 400, Sonics and Materials, Inc., Newtown,
CT) was applied to the skin samples at the following conditions: frequency - 20 kHz,
intensity - 7.2 W/cm 2, pulse length - 5 sec on, 5 sec off, and tip displacement - 3 mm,
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until the skin electrical current measured reached values of 225, 275, or 325 pLAmps. As
stated in Section 4.1, these three skin electrical current values will enable us to study the
role of the LTRs at three unique transdermal permeability values and three unique
structural perturbation levels. Moreover, these three skin electrical current values were
selected to ensure visible LTR formation with the naked eye, which is necessary to
effectively mask the surface of the skin in order to carry out the masking experiments
(see below). The skin electrical resistances corresponding to these three electrical
currents are 380, 240, and 150 Ohms, respectively. After each minute of ultrasound
exposure, the SRB/SLS/PBS coupling medium was changed to minimize the impact of
thermal effects on the permeation enhancement of the skin,2 5 and measurements of the
skin electrical current were conducted to determine if the target skin electrical current had
been reached. Once the desired skin electrical current was attained, the skin sample was
removed from the diffusion cell and was rinsed for 15 minutes in PBS to remove all
excess coupling medium from the skin surface in preparation for the digital imaging and
the analysis of the hypothesized LTRs.
4.2.5 Digital Imaging and Analysis of the LTRs
After the PBS wash, the skin sample was blotted dry and was then imaged using a digital
camera (Kodak DC4800, 3.1 Megapixels, F-stop - 2.8, shutter speed - 1/15 second). To
correct for any color infidelity of the CCD (charged coupled device) chip of the camera,
as well as for any fluctuations in the laboratory lighting, an orange-colored strip of tape
was included in the digital image of the skin (see Figure 4-2, image 1). (Note: the color
of the strip of tape is not critical. Any color strip of tape could have been used, as long as
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Figure 4-2: Sequence of steps in the method used to analyze the digital skin images. In
step A, the original digital image (1) is standardized (to eliminate lighting variations) and
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then cropped to isolate the ultrasound exposed region of the skin (2). In step B, the
cropped digital image (2) is separated into the green (3), the blue (4), and the red (5)
channel images (which are displayed as grayscale images). By examining the three
channel images separately, the dark regions in the blue channel image (4) are very close
in size to the LTRs in the cropped image (2). In step C, the dark regions (LTRs) in the
blue channel image (4) are quantified using the threshold function (threshold = 75 blue
pixel count), which counts all pixels with a blue pixel count at, or below, 75 (6). From
this information, the area of the LTRs (in cm 2) can then be readily determined (see the
text for a detailed explanation). In images (1) - (6), the scale bar represents 5 mm.
the same color tape is used in all the digital images.) Also, three repeat images of each
ultrasound-treated skin sample were taken for statistical certainty. The digital skin
images were then analyzed using the Corel Photo-Paint 11 Software Package (Corel
Corporation) according to the following method, which is outlined in Figure 4-2. (Note:
digital color variation is defined by the number of bits used to store different levels of
color. In 24-bit color, which is the depth of color used in this analysis, there are 224
levels of color variation that can be described digitally. The 224 shades of color in a
single pixel are determined by the combination of the levels of the individual red, green,
and blue channels, which each have 28 levels of color. Therefore, any 24-bit digital color
image can be decomposed into its individual 8-bit red, green, and blue channel digital
images.) First, the orange-colored tape strip included in the digital image of the
ultrasound-treated skin (see Figure 4-2, image 1) is isolated from the rest of the image to
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determine the average blue channel color count (scale from 0 - 255 for 8-bit color, 28) of
the orange colored tape strip (see the following paragraph for the rationale behind using
the blue channel). This average blue channel color level is then compared to the standard
average blue channel color level of the orange-colored tape strip, which is 32 for the
orange-colored tape strip used in these experiments, obtained from the average blue color
levels of 40 digital images of the orange-colored tape strip. The blue channel color levels
from the entire ultrasound-treated skin image are then shifted so that the average blue
channel color level for the colored tape strip matches the standard average blue channel
color level for the colored tape strip. For example, suppose that the colored tape strip in a
skin image has an average blue channel color level of 39. In order to match the standard
average blue channel color level for the colored tape strip, which is 32 for the orange-
colored tape strip, the entire skin image needs to have all the blue channel color levels
decreased by 7. This standardization procedure was accomplished with the function
named "Contrast Enhancement" in Corel Photo-Paint 11.
After standardization of the ultrasound-treated skin sample digital images, the
digital images are cropped down to the diameter of the ultrasound-treated skin region
(diameter = 1.5 cm) (see Figure 4-2, step A). To determine the size of the LTRs from the
cropped digital image (see Figure 4-2, image 2), the Threshold function in Corel Photo-
Paint 11 is used to calculate the number of pixels having a blue channel color level of 75
or less. The blue channel image (see Figure 4-2, image 4) was selected for the
determination of the LTR size, since the blue channel image seems to offer a better
definition of the LTR region over the red channel image (see Figure 4-2, image 5) or the
green channel image (see Figure 4-2, image 3) of the skin sample (see Figure 4-2, step
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B). (Note: the red channel, the green channel, and the blue channel images are displayed
by Corel Photo-Paint in grayscale.) A blue color level threshold of 75 was selected to
define the LTRs of the ultrasound-treated skin since a blue color level threshold of 75
closely matches the dark red regions of the ultrasound-treated skin (compare Figure 4-2,
images 2 and 6), indicating that the entire area of the LTRs has been quantified (see
Figure 4-2, step C). If the value of the blue color level threshold was higher, or lower,
than 75, a larger, or smaller, LTR area would be estimated by this method, which would
lead to different values for the estimated area of the LTRs (see the Appendix, Section
4.7). By knowing the number of pixels with a blue color level at, or below, 75, the total
number of pixels in the cropped digital image, and the total area of the cropped digital
image (2.25 cm 2), it is possible to calculate the area of the hypothesized LTRs formed on
the ultrasound-treated skin. The reader should again note that these calculated LTR area
values are directly based on the blue pixel threshold value of 75.
4.2.6 Masking Experiments
Following digital imaging of the skin, the ultrasound-treated skin samples were divided
into four groups: A) Control, B) non-LTRs, C) LTRs, and D) Total (see Figure 4-3). In
the Control group (see Figure 4-3A), we determined the background absorbance of the
solution in the receiver cells by masking the entire skin surface with vacuum grease
(High Vacuum Grease, Dow Coming, Midland, MI), which prevents calcein permeation
across the entire ultrasound-treated skin samples. The effectiveness of the vacuum grease
to prevent transdermal permeation of calcein in the Control group was confirmed in two
ways: 1) an absorbance spectrum of the contents of the receiver cells after calcein
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Figure 4-3: Sample setup of the diffusion masking experiments. (A) Control group - no
transport of calcein. (B) Non-LTR group - only the non-LTRs are available for calcein
transport. (C) LTR group - only the LTRs are available for calcein transport. (D) Total
group - the entire skin surface is available for calcein transport. Key: Masking material
- (0), LTRs - (0), and non-LTRs (0).
exposure showed no peak at 494 nm (the absorbance peak of calcein; data not shown),
and 2) skin electrical resistance measurements revealed that after application of the
vacuum grease mask, the RA values were higher than 300 kOhm*cm 2 , well above the
threshold RA value for the intact skin samples (50 kOhm*cm2). In the non-LTR group
(see Figure 4-3B), we determined the permeability of the non-LTRs in the skin by
masking the surface of the LTRs with vacuum grease to prevent calcein permeation
through the LTRs. In the LTR group (see Figure 4-3C), we determined the permeability
of the LTRs in the skin by masking the surface of the non-LTRs with vacuum grease to
prevent calcein permeation through the non-LTRs. (See the Appendix, Section 4.7, for a
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brief discussion of the possible experimental errors associated with the mask application
for the LTRs and the non-LTRs.) In the Total group (see Figure 4-3D), we determined
the permeability of the entire skin sample since no vacuum grease was applied to these
ultrasound-treated skin samples. These four sub-groups of ultrasound-treated skin
samples were utilized for each of the three current conditions listed above.
After masking, the ultrasound-treated skin samples were placed in another vertical
Franz diffusion cell with fresh PBS in the receiver cell and 2 ml of 0.2 % (w/v) calcein in
PBS in the donor cell. Passive diffusion through the ultrasound-treated skin samples was
conducted for a total of 30 hours to ensure that enough calcein was delivered to obtain an
accurate measurement of the absorbance of calcein in the receiver cell solution.
Measurements of the skin electrical resistance were made at the beginning and at the
conclusion of the 30-hour permeation experiments to determine if there was any
significant change in the electrical resistance properties of the skin during the masking
experiments (no significant difference was observed). The amount of calcein that
diffused through the available regions of the ultrasound-treated skin was determined by
measuring the absorbance of a I-ml aliquot of the receiver cell solution exposed to 494-
nm light with a UV-Vis spectrophotometer (Cary, Bio 50). The absorbance measurement
of the receiver cell solution was used in conjunction with a standard curve to determine
the mass concentration of calcein in the receiver cell. The steady-state skin permeability,
P, of calcein was determined using the following equation:32
V ACP = (4.1)
AC, At
where V is the volume of the receiver cell (12 ml), A is the cross-sectional skin area
available for transport, Co is the initial mass concentration of the permeant (calcein) in
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the donor cell (2 mg/ml), AC is the change in mass concentration of the permeant in the
receiver cell, and At is the total time allowed for permeant diffusion through full-
thickness pig skin minus the lag time (which is approximately 13 hours, see Figure 4-4).
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Figure 4-4: Sample plot of the cumulative amount of calcein transported across the skin
into the receiver compartment as a function of time. The solid line is shown to guide the
eye. The dashed line represents the linear regression of the data points in the steady-state
phase (18 - 30 hrs). The lag time is determined from the intercept of the dashed line with
the x-axis (n = 3, error bars = + 1 S.D.).
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4.3 Theory
4.3.1. Relating the Total Skin Permeability to the Permeabilities of the Non-
LTR and the LTR Skin Regions
As indicated in Materials and Methods (Section 4.2), Eq. (4.1) can be utilized to calculate
transdermal drug permeabilities in a diffusion cell experiment. Equation (4.1) may be
applied to the non-LTR, the LTR, and the Total groups of diffusion masking experiments
to determine Pnon-LTR, PLTR, and PTotal (which are the permeabilities of the non-LTR, the
LTR, and the Total skin regions, respectively), as follows:
V AC
Pnon- V non-I7. 1  (4.2a)C At Anon-LTf
COAt A 
_TIn
V At ATota
Pr•,oa= nrai (4.2c)
CAt A,,,,
where ACnon-LTR, ACLTR, and ACTotal are the changes in the mass concentrations of the
permeant (calcein) measured in the receiver cell over the duration of the diffusion
masking experiments, and Anon-LTR, ALTR, and ATotal are the measured areas of the skin
available for transport for the non-LTR, the LTR, and the Total skin regions,
respectively. Noting that the quantity (VAC) is equal to the mass of calcein delivered in
each diffusion masking experiment, the following mass balance must hold:
VACT,,,o = VAC,,,,,_17 + VACLIJn (4.3)
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Equation (4.3) states that the mass of calcein delivered across the non-LTR and the LTR
skin regions must be equal to the mass of calcein delivered across the Total skin region.
Substituting Eqs. (4.2a)-(4.2c) in Eq. (4.3) yields the following result:
P1 oal Aroial CoAt = P,,-,ni .R Anon-, 7 CO At + P.•7,AL 7 CO At (4.4)
Since the diffusion masking experiments have been designed such that Co and At are
identical for each set of masking experiments, Co and At can be eliminated from Eq.
(4.4). By further dividing both sides of Eq. (4.4) by ATotal, the following equation is
obtained to calculate the total skin permeability, PTotal:
Poa,,l = Pnon,,,,-L7 anon-,-R + Pan a,.7 (4.5)
where canon-LTR = Anon-LTR/ATotal and GCLTR = ALTR/ATotal are the area fractions of the non-
LTR and of the LTR skin regions, respectively.
4.3.2 Evaluating the Skin Electrical Resistivity from the Skin Electrical
Resistance Measurements
The electrical resistivity, p, of a resistor is defined as follows:
RAp = (4.6)
Ax
where R is the electrical resistance, A is the cross-sectional area of the resistor, and Ax is
the thickness of the resistor. If the skin is modeled as an electrical resistor, Eq. (6) can be
used to determine the skin electrical resistivity for each region of the skin from
experimental measurements of the skin electrical resistance (R), the area available for
transport (A), and the thickness of the stratum corneum (Ax = 13.1 ýpm). 2 The skin
electrical resistivity is preferred in our analysis over the skin electrical resistance because
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the skin electrical resistivity is an intrinsic electrical property of the skin membrane,
while the skin electrical resistance is an extensive electrical property of the skin
membrane. Consequently, by using the skin electrical resistivity, it will be easier to
compare differences in the electrical properties of the sonicated regions of the skin - the
LTRs, the non-LTRs, and the Total group - with those of the untreated skin samples.
Since the skin electrical resistivity is an almost instantaneous measure of the structural
integrity of the skin,30 a comparison of the skin electrical resistivity within the LTRs and
the non-LTRs will shed light on the extent of structural perturbation generated in the
LTRs and in the non-LTRs as a result of the exposure to ultrasound, in the presence of
SLS.
4.3.3 Evaluating the Structural Parameter, (s/r), to Characterize the
Transdermal Pathways in the LTR and the non-LTR Regions of the
Skin
It is possible to determine the ratio of the fraction of the stratum corneum surface
available for transport (i.e. the porosity), s, to the tortuosity, -, of the hydrophilic
transport pathways, within the LTR, the non-LTR, and the Total regions of the skin using
the following equation based on the Porous Pathway Theory (which is a theory that has
been previously proposed to model the transport of hydrophilic solutes across the SC
through aqueous tortuous pathways, see Chapter 2 for details):30
,(4.7)
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where pi is the measured skin electrical resistivity of the LTR group, the non-LTR group,
or the Total group, and asol is the electrical conductivity of the PBS coupling medium
(0.012 Q-lcm-').30 The hindrance factor for the transport of the principal ions in the
solution (in the present case, the sodium ions), H(ion,), is defined, for k<0.4, as follows:33
H(A,,, ) = (1 - i,,on,) ( -2.104,,,, + 2.09A1,,, - 0.95A,,, ) (4.8)
where kion is defined as: 33
Aion r, (4.9)
rpore
where rion,, is the hydrodynamic radius of the solute (2.2 A for sodium ions)30 and rpore is
the average radius of the aqueous pore pathways available for transport. The value of
rpore in each region of the skin may be determined from the transdermal permeability, P,
the skin electrical resistance, R, and the area available for transport, A, using the
following equation based on the Porous Pathway Theory: 30
kT DpH(A,)PRA = P (4.10)2z'2 Fc,,eo D,,H( ,,,, )
where k is the Boltzmann constant (1.38 x 10-23 J/K), T is the absolute temperature (298
K), z (= 1) is the valence of the principal ion in the solution, F is the Faraday constant
(9.648 x 104 C/mol), Cion is the electrolyte molar concentration (0.137 M), eo is the
electronic charge (1.6 x 10-19 C), D,, and Dp are the diffusion coefficients of the
sodium ions (1.33 x 10-5 cm 2/s) 3 1 and of calcein (3.63 x 10-6 cm 2 /s, estimated using an
empirical correlation based on molecular weight), respectively, at infinite dilution, and
H(Xp) is the hindrance factor of calcein. Since P, R, and A are experimentally
determined, Eq. (4.10) may be used to determine rpore in each region of the skin. Once
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rpore is determined, Eq. (4.7) may be used to determine the value of (s/t) for each region
of the skin from the values of the skin electrical resistivity (p) obtained from Eq. (4.6).
From knowledge of the values of (s/z) for each region of the skin, we can then gain
useful insight about the type of transport pathways present in the LTRs and the non-LTRs
(see Discussion, Section 4.5).
4.4 Results
4.4.1 Determining the Permeabilities of the LTRs and the Non-LTRs
The amount of calcein transported across the skin and the skin permeability to calcein in
the diffusion masking experiments, as determined from measurements of the absorbance
of 494-nm light in the receiver cell solution, are presented in Figure 4-5. Figure 4-5A
shows the results of the calcein absorbance measurements for each of the four groups of
diffusion masking experiments conducted (Control, non-LTR, LTR, and Total skin
regions) at each of the three specified skin electrical current conditions (225, 275, and
325 pAmps). Since no peak was observed for calcein in the absorbance spectrum of the
Control group, the results of the Control group serve as a measurement of the background
absorbance of the receiver cell solution. Therefore, the absorbance values corresponding
to the Control group can be subtracted from those corresponding to the non-LTR, the
LTR, and the Total groups to obtain the actual amount of calcein transported across the
skin in each of these three groups of masking experiments, as shown in Figure 4-5B. As
Figure 4-5B reveals, within the experimental uncertainty, the amount of calcein that
permeates across the LTRs is comparable to the amount of calcein that permeates across
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Figure 4-5: Results of the diffusion masking experiments: (A) receiver cell absorbance
measurements (at 494 nm), (B) mass of calcein transported across the skin in each
masking group, and (C) calcein permeability of each masking group. Key: Control
group (m), non-LTR group (0), LTR group (m), Total group (M). Error bars = + 1 S.D.
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Table 4-1: Summary of Experimental Results and Calculated Values from the Diffusion
Masking Experiments.a
Skin Diffusion Area Available
Electrical Masking for Transport,
Current Group A (mm 2)
Area Fraction,
xi = Ai/ATotal
Skin Electrical
Resistance, R
(kOhm)
Calcein Skin
Permeability, P
(*104 cm/hr)
Skin Electrical
Resistivity, pb
(kOhm*cm)
(E/T) c
(* 10 )
Total 177 I 0.347 + 0.062 6.89+ 1.11 469+77 2.47+0.21
225
LTR 11.4+4.4 0.064 + 0.024 0.461 + 0.083 81.8+29.4 40.1 + 14.1 29.5+7.64ýtAmps
Non-LTR 159.6 + 11.9 0.902 + 0.067 1.00 + 0.43 0.97 + 0.98 1220 + 520 1.29 + 0.21
Total 177 I 0.250 + 0.041 10.4 + 3.86 338 + 55 3.29 + 0.57
275
Amps LTR 19.3 + 4.6 0.110 + 0.026 0.244 + 0.029 87.5 + 26.3 35.9 + 9.9 32.2 + 4.44Non-LTR 152.710.8 0.8630.061 1.080.58 0.960.81 1520440 1.470.2Amps
Non-LTR 152.7+ 10.8 0.863 + 0.061 1.08+0.58 0.96+0.81 1520+440 1.47+0.23
Total 177
325
Amps LTR 38.9 + 9.0tAmps
Non-LTR 143.6 + 7.2
aErrors in the data + 1 SD.
bCalculated using Eq. (4.6).
cCalculated using Eq. (4.7).
1
0.220 + 0.051
0.811 + 0.041
0.216 + 0.040
0.212 + 0.042
1.39 + 0.39
14.3 + 3.1
63.0 + 21.6
0.67 + 1.25
292 + 59
63.0+ 17.0
1520 + 437
3.62 + 0.56
17.0 + 4.14
1.02 + 0.25
the total skin sample (compare the second and third columns), indicating that most of the
calcein permeates through the LTRs.
Using Eqs. (4.2a)-(4.2c), the experimental data in Figure 4-5B, and the values of
the areas corresponding to the non-LTR, the LTR, and the Total regions of the skin (see
Table 4-1), we can now calculate the permeability through these three regions of the skin.
The results of these calculations are presented in Figure 4-5C, which shows that the LTRs
are almost two orders-of-magnitude more permeable than the non-LTRs (compare the
second and the first columns). In addition, over the range of skin electrical currents
examined (225 - 325 pAmps), the permeabilities of the non-LTRs and of the LTRs are
almost constant based on a statistical analysis of the data (95% confidence). Based on
this finding and Eq. (4.5), it follows that the increase in the total skin permeability, as the
skin electrical current increases from 225 ptAmps to 325 pAmps, observed in Figure 4-5C
192
(see the third column), is likely due to the observed increase in the size of the more
permeable LTRs (see Table 4-1), as the skin electrical current increases from 225 ptAmps
to 325 gAmps. It is also worth noting that the Total calcein permeability is less than the
LTR calcein permeability, but greater than the non-LTR calcein permeability, at each
skin electrical current condition. This is because the Total calcein permeability is a
quantitative measure of the combined calcein permeability of both the more permeable
LTR and the less permeable non-LTR skin regions. Since the Total calcein permeability
combines both the high and the low calcein permeability regions, it is not surprising to
find that the Total calcein permeability lies between the calcein permeabilities of the LTR
and the non-LTR skin regions.
To ensure that our experimental data set is accurate for the analysis presented
above, we verified that the calcein mass balance in Eq. (4.3) is satisfied. The results of
this verification are presented in Figure 4-6, where we compared the mass of calcein
transported in the Total group (see the first column) with the combined masses of calcein
transported separately through the non-LTRs (from the first column of Figure 4-5B) and
through the LTRs (from the second column of Figure 4-5B) at the three current
conditions examined (see the second column). As Figure 4-6 shows, a mass balance is
attained for each of the three electrical current conditions examined (95% confidence). In
addition, we can also use the data in Figure 4-5C to determine if Eq. (4.5) is satisfied.
These results are presented in Figure 4-7, where we compare the experimentally-obtained
value of the calcein permeability corresponding to the Total group (the third column of
Figure 4-5C) with the value of the calcein permeability of the entire skin sample, which
was predicted using the measured calcein permeabilities of the non-LTR (the first column
193
225 pAmps 275 pAmps 325 iAmps
Figure 4-6: Verification that the calcein mass balance in Eq. (4.3) is satisfied at the three
skin electrical current conditions studied. Key: Total group (0), non-LTR group + LTR
group (0). Error bars = + 1 S.D.
194
,4A• "
c
t-Cn
0
0C)
100
80-
60
40
20
0
I Jl I
Z.UIt-U•
1.8E-03 -
E 1.6E-03
E
o 1.4E-03 -
1.2E-03 -
U) 1.OE-03E
U,
n 8.OE-04
( 6.OE-04
O 4.OE-04
2.OE-04
n nI=+nf
If
T
225 pAmps 275 jAmps 325 VAmps
Figure 4-7: Comparison of the experimentally measured Total calcein skin permeability
with that predicted from the experimentally measured values of the calcein permeability
and the area fraction available for transport of the non-LTRs and the LTRs, as reported in
Table 4-1, at the three skin electrical current conditions examined. Key: Total group -
experimental measurement (0), Total group - calculated from Eq. (5) (0). Error bars = +
1 S.D.
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in Figure 4-5C) and the LTR (the second column in Figure 4-5C) skin regions in
conjunction with the measured values of anon-LTR and aLTR (see Table 4-1) in Eq. (4.5).
Similar to the verification of the mass balance shown in Figure 4-6, Figure 4-7
demonstrates that the measured values of the calcein permeabilities of the non-LTR and
the LTR skin regions can be utilized in conjunction with the LTR and the non-LTR area
fractions (@LTR and anon-LTR, respectively) to predict the calcein permeability of the entire
skin sample using Eq. (5) (95% confidence).
4.4.2 Comparison of the Skin Electrical Resistivity (p) Data based on the
Masking Experiments
Figure 4-8 presents the skin electrical resistivity, p, data for the untreated skin samples
(the first column, n = 30), the non-LTR group (the second column, n = 10), the LTR
group (the third column, n = 10), and the Total group (the fourth column, n = 10) for each
of the three current conditions (225, 275, and 325 pAmps) used in the masking
experiments. By comparing the columns for the LTRs and the non-LTRs at the three
current conditions, it follows that the p value corresponding to the LTRs (46.4
kOhm*cm, which is the average of the three Figure 8 values) is approximately 30-fold
lower than the p value corresponding to the non-LTRs (1330 kOhm*cm, which is the
average of the three Figure 4-8 values). Since the p data is a quantitative measure of the
structural integrity of the skin membrane, 3" the non-LTRs are more structurally intact
than the LTRs. Hence, based on the p measurements, the non-LTRs are less permeable
than the LTRs, thereby confirming the results of the permeability measurements.
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Figure 4-8: Skin electrical resistivity data from the masking experiments.
Untreated skin (0), non-LTR group (0), LTR group (n), Total group (0). Error bars = +
1 S.D. For the untreated skin data, n = 30 samples, while for all the other groups, n = 10
samples.
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Figure 4-8 also shows that the p values for the Total group decrease as the current
increases from 225 ptAmps to 325 giAmps (this can also be seen in Table 4-1), and
consistently fall between the p values for the LTR group and for the non-LTR group.
Similar to the nature of the permeability of the Total group, the p value for the Total
group is a combined measure of regions with high electrical resistance and low current
flow (the non-LTRs) and regions with low electrical resistance and high current flow (the
LTRs). Therefore, the p value for the Total group will always fall between the p values
of the non-LTRs and the LTRs. The decreasing trend in the p values for the Total group
as the current increases from 225 IAmps to 325 pAmps can be attributed to the increase
in the skin surface area fraction of the LTRs, OaLTR, as the current increases. Since the p
values of the LTRs are much lower than the p values of the non-LTRs, an increase in the
area of the LTRs will lead to an overall decrease in the p values of the entire skin sample,
as is observed for the Total group in Figure 4-8. These results are consistent with the
observed trends in the permeability data of the Total group presented in Figure 4-5C.
4.4.3 Determining the Structural Parameter, (E/r), for the Transdermal
Pathways in the LTR and the Non-LTR Regions of the Skin
Finally, using the values of p reported in Table 4-1, we can calculate values of (s•/) for
each of the three skin regions at each of the three current conditions examined using Eq.
(4.7). These values are listed in the last column of Table 4-1. An examination of these
values shows that the values of (s,/) corresponding to the LTR group are approximately
30-fold higher than the values of (/-c) corresponding to the non-LTR group at the three
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current conditions examined. In addition, the values of (si) corresponding to the Total
group consistently fall in between the values of (s/t) corresponding to the LTR group and
to the non-LTR group, similar to the behavior exhibited by the permeability data and the
skin electrical resistivity data corresponding to the Total skin region relative to the
permeabilities and the skin electrical resistivities of the LTR and the non-LTR skin
regions. In the Discussion section, we describe how useful conclusions can be reached
about the nature of the transport pathways present in the LTRs and in the non-LTRs
based on the values of (si) reported in Table 4-1.
4.5 Discussion
4.5.1 Analysis of the Results of the Diffusion Masking Experiments
As the results presented in Figure 4-5 show, most of the transdermal delivery of calcein
occurs through the LTRs. Indeed, Figure 4-5C clearly shows that the permeability of the
LTRs to calcein is nearly two orders-of-magnitude greater than the permeability of the
non-LTRs to calcein. These observations provide explicit proof that the red spots
observed by previous authors when full-thickness pig skin or full-thickness human skin
was treated with ultrasound in the presence of SRB, a red-colored permeant, 22-25.29 are,
indeed, markers of localized regions of extremely high transdermal permeability. In fact,
the average measured calcein permeability in the LTRs for the three skin electrical
currents examined (77 x 10 4 cm/hr, see Table 4-1) is of the same order-of-magnitude as
the permeability of the dermis for small molecular weight hydrophilic permeants (100 x
104 cm/hr), 2 5,3 0 indicating that the formidable barrier to transdermal transport of small,
hydrophilic molecules exhibited by the SC has been successfully bypassed in the LTRs.
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Interestingly, the results of the diffusion masking experiments also reveal that the
non-LTRs formed on skin sonicated in the presence of SLS also undergo a significant
structural perturbation when compared to untreated skin due to the exposure to low-
frequency ultrasound and SLS. A comparison of the skin electrical resistivity data in
Figure 4-8 and in Table 4-1, which quantifies the structural integrity of the skin, for the
non-LTRs (p = 1330 kOhm*cm, average of the three Table 4-1 values) and for the LTRs
(p = 46.4 kOhm*cm, average of the three Table 4-1 values) with the skin electrical
resistivity data for all the skin samples prior to ultrasound treatment (p = 2.35 x 105
kOhm*cm, average of the three Figure 4-8 values) shows that the non-LTR and the LTR
skin regions experience a -170-fold and a -5000-fold enhancement, respectively, over
untreated skin due to the exposure to ultrasound and SLS. This would suggest that the
observed enhancement in the skin electrical resistivity of full-thickness pig skin is due to
two distinct levels of ultrasound exposure in the presence of SLS. A high level of
ultrasound enhancement likely results in the formation of the highly permeable LTRs,
while a lower level of ultrasound enhancement results in the formation of the less
permeable non-LTRs. While it is known that transient cavitation events near the skin
surface, which are triggered by ultrasound exposure, are the primary mechanism
responsible for the observed enhancements in the skin electrical resistivity of pig full-
thickness skin,27 further study is required to better understand how this mechanism is
responsible for the apparent dual-level of enhancement in the skin electrical resistivity of
pig full-thickness skin samples treated with ultrasound in the presence of SLS.
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4.5.2 Quantitative Prediction of Intercellular versus Transcellular
Transdermal Transport Pathways for Hydrophilic Permeants Using
the Calculated (c/T) Values
In the field of transdermal drug delivery, it is typically assumed that most hydrophilic
permeants diffuse across the SC primarily through the intercellular lipid bilayers. This
assumption, based on the results of several visualization studies,3,4 '3 537 has been a key
aspect of many previous studies addressing the modeling of both hydrophilic and
hydrophobic drug transport through the stratum corneum.2'38-4 1 For typical physical
dimensions of the stratum corneum, 2,42 -44 the threshold value of (E/i) corresponding to
steady-state transport in the intercellular regions of the stratum corneum was estimated to
be 3.6*10 -4 using the equations for porosity, E, and the tortuosity for the flux, Tflx,
obtained in Chapter 3 (see Section 3.3 for details). By comparing this threshold value of
(sE/) for the intercellular regions of the SC with the calculated values of (e/T) presented in
Table 4-1, it follows that the values of (Est) for the more permeable LTRs (26.2 x 10-4,
average of the Table 4-1 values) are an order-of-magnitude (-7-fold) higher than this
threshold value of (E/t) for the intercellular regions of the SC (3.6 x 10-4). This 7-fold
increase in (E/i) could be the result of a 7-fold increase in E, of a 7-fold decrease in t, or
of a combination of an increase in E and a decrease in r. Physically, such a 7-fold
increase in E, or a 7-fold decrease in -, above the threshold value of (E/t) for the
intercellular regions would require the formation of some transcellular transdermal
pathways, either in the corneocytes at the SC surface (resulting in an increase in e) or in
the corneocytes within the SC itself (resulting in a decrease in -r). Interestingly, the
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presence of transcellular transdermal transport pathways within LTRs has been visualized
recently near the SC surface by Tang using two-photon microscopy. 29 Furthermore, Tang
observed that, in the non-LTR regions of the SC, intercellular transdermal transport
pathways were the dominant pathway. 29 Since the values of (c//) for the non-LTR
regions (1.26 x 10-4 , average of the Table 4-1 values) are lower than the threshold value
of 3.6 x 10-4 , one may conclude that transcellular transdermal transport regions are not
the primary route of transport through the non-LTRs, which is consistent with the results
of Tang.29 Since the previous two-photon microscopy studies examined skin samples
sonicated in the absence of SLS, future two-photon microscopy studies will be conducted
to confirm whether or not transcellular transdermal transport pathways are present in the
more permeable LTRs and in the less permeable non-LTRs of skin samples sonicated in
the presence of SLS.
4.6 Conclusions
A series of diffusion masking experiments have been performed for the purpose
of demonstrating quantitatively that the patterns of red spots observed on the skin when
the red-colored permeant SRB and the chemical enhancer SLS are used in the ultrasound
coupling medium are, indeed, markers for localized regions of high transdermal
permeability on ultrasound-treated full-thickness pig skin. The results of these
experiments, carried out over a range of skin electrical currents, have shown that the
transdermal permeability of the LTRs is 80-fold higher, on average, than the transdermal
permeability of the less permeable non-LTRs. Although most of the transdermal delivery
occurs in the more permeable LTRs, an analysis of the skin electrical resistivity data also
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indicates that there is a significant enhancement in both the highly permeable LTRs and
in the less permeable non-LTRs when compared to untreated skin (-5000-fold and -170-
fold, respectively). This indicates that the skin may be experiencing two levels of
structural perturbation in the ultrasound/SLS system. Finally, an analysis of the (s/t)
values for the less permeable non-LTRs and the highly permeable LTRs reveals that,
while the transdermal transport pathways in the less permeable non-LTRs may be entirely
intercellular, the transdermal transport pathways in the more permeable LTRs are likely
to be both intercellular and transcellular. Further studies need to be conducted to confirm
the presence of transcellular transdermal transport pathways in the more permeable LTRs
and to better understand how two levels of structural perturbation may be induced in skin
samples treated with low-frequency ultrasound in the presence of SLS.
In the next chapter (Chapter 5), then, two-photon microscopy will be used to: 1)
confirm the presence of transcellular permeation pathways in the LTRs as a result of
exposure to low frequency ultrasound, and 2) evaluate the enhancements in the partition
coefficient and the diffusion gradient in the skin for a model hydrophilic permeant (SRB)
and a model hydrophobic permeant (RBHE) diffusing in SLS-treated, ultrasound-treated,
and ultrasound/SLS-treated skin samples as compared to untreated skin.
4.7 Appendix
In this appendix, three possible sources of error in the experimental procedure for the
diffusion masking experiments are examined: 1) the choice of 75 as the blue color
threshold value for determining the LTR area, 2) skin variability, and 3) the placement of
the masking material on the skin samples prior to calcein diffusion. To give the reader a
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quantitative sense of how the estimated LTR area would vary with changes in the blue
color level threshold value, estimates of the LTR area were made at blue color level
threshold values of 60, 65, 70, 75, 80, 85, and 90 on a randomly-selected skin sample.
The results of this analysis are presented in Table 4-Al. As the table shows, there is
approximately a 10% increase in the estimated LTR area for every 5-pixel increase in the
value of the blue color level threshold. For the LTR data in Table 4-Al, the relative error
in the average LTR area for 10 samples is roughly 20% - 35% over the range of skin
electrical currents examined, due solely to the second source of error- the high variability
of the skin samples themselves. Comparing these sources of error in the LTR area
estimate, we can conclude that the error that arises from skin sample variability (20% -
35%) will have a greater influence on the total error in the deduced average LTR area
than the error in the selection of the blue color level threshold value (10% increase per 5
pixel increase).
Table 4-Al: Estimated LTR Area at Different Blue Color Level Threshold Values for a
Randomly-Selected Skin Sample.
Blue Color Level Estimated LTR
Threshold Value Area (mm 2)
60 17.65
65 19.23
70 20.82
75 22.67
80 24.64
85 26.97
90 30.23
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The third possible source of error in the experimental procedure is the placement
of the masking material on the skin prior to calcein diffusion. While the ideal result
would be to place the masking material directly on the border between the LTRs and the
non-LTRs, this can be difficult in practice. In order to obtain the most accurate results
possible, it was initially assumed (correctly, based on our results) that the hypothesized
LTRs were regions of very high transport. Therefore, when applying the mask on skin
samples that would be used to measure transport through the LTRs, care was taken to not
partially cover the LTRs with masking material. This was achieved by including a thin
unmasked perimeter of the surrounding non-LTR with the unmasked LTR. Since the
non-LTR is a region of low transdermal transport, the inclusion of this perimeter would
not impact the results as much as if a fraction of the LTR had been unknowingly covered
during mask application. Likewise, for the measurement of the transport in the non-
LTRs, a thin perimeter of the non-LTR surrounding the LTRs was covered with masking
material along with the LTRs. This was done to ensure that the highly permeable LTRs
would be completely masked, and hence would be unable to introduce errors into the
measurement of the less permeable non-LTRs.
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Chapter 5
Investigation of Transdermal Transport Pathways and
Transport Mechanisms in Skin Treated with Low-
Frequency Ultrasound and with Chemical Enhancers
Using Two-Photon Microscopy
5.1 Introduction
5.1.1 Previous Applications of Two-Photon Microscopy in Transdermal
Drug Delivery: Chemical Enhancers and Low-Frequency Ultrasound
In Chapter 1, a brief overview was presented of the visualization techniques that have
been utilized in the past to determine the types of transdermal permeation pathways
present in the skin.'1 5 One such technique, two-photon microscopy (TPM), has been
used in the past to advance our understanding of the permeation pathways present in skin
samples treated with chemical enhancers, as well as in skin samples treated with low-
frequency sonophoresis.' 0-'5  Two-photon microscopy is an excellent visualization
technique for the analysis of transdermal permeation pathways for two primary reasons:
1) it is a non-invasive imaging technique, 14"16 and 2) it produces higher quality images at
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a greater depth into the tissue compared to similar microscopy methods, such as confocal
microscopy.' 14 17-19 Being a non-invasive technique, it is possible to keep the skin intact
while imaging with TPM. This is a significant consideration for the use of in vivo
imaging of biological tissues. Other imaging techniques used in previous transdermal
visualization studies, such as scanning electron microscopy4,6-8 and transmission electron
microscopy,2,9 require that the skin undergoes special preparations prior to imaging (i.e.
coating with gold-palladium; 4 exposure to osmium tertoxide, 6 8 lanthanum nitrate, 6,7 and
mercuric chloride;2 and staining with uranyl acetate ) that would be hazardous for in vivo
applications. In addition to being a safe imaging technique for the skin, TPM offers
improved imaging capabilities over confocal microscopy techniques. Specifically, TPM
involves a three-body collision of two photons and one fluorescent molecule to create an
excitation event, while confocal microscopy involves the collision of a single photon with
one fluorescent molecule to create an excitation event. 14 ,15,17  Because three-body
collisions occur with lower frequency than two-body collisions, imaging of fluorophores
is restricted to the focal plane of interest. 14 ,2 0,'2 In addition, the photon flux decreases
quadratically as the distance away from the focal plane increases, which allows for
discrimination of the fluorescence signal at increased tissue depths.'14 17 These attributes
of TPM have made it a useful tool for imaging the delivery of fluorescent permeants in
skin samples treated with chemical enhancers and with low-frequency sonophoresis. 10-15
In the area of chemical enhancers, TPM has been used extensively to further our
understanding of the mechanisms of chemically-enhanced transdermal transport. Yu et
al. used TPM to visualize (image) and to quantify the effect of a chemical enhancer (oleic
acid) on the delivery of a model hydrophilic fluorescent permeant, sulforhodamine B
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Table 5-1: Physical properties of the fluorescent hydrophilic probe, Sulforhodamine B
(SRB), and the fluorescent hydrophobic probe, Rhodamine B Hexyl Ester (RBHE),
examined with Two-Photon Microscopy.14
Probe Molecular Weight (Da) Absorbance/Emission (nm) Log KO/PBS
SRB 559 565/586 -0.45 + 0.0045
RBHE 627 556/578 2.49 + 0.18
(SRB), and of a model hydrophobic fluorescent permeant, rhodamine B hexyl ester
(RBHE) in 112 pm x 112 tm regions of heat-stripped human cadaver skin.'10 14 As Table
5-1 shows, SRB and RBHE are ideal choices since they have similar molecular weights
and absorbance/emission peak wavelengths. Through a novel analysis of the fluorescent
intensity profiles as a function of skin depth in the imaged skin regions, it was
demonstrated that oleic acid primarily enhances the transdermal transport of SRB and
RBHE by increasing the permeant vehicle-to-skin partition coefficient as compared to the
delivery of SRB and RBHE in untreated skin.'0, 14 Imaging studies conducted with High
Speed Two-Photon Microscopy (HTPM) demonstrated that a larger number of 112 pm x
112 p.m skin samples is required to obtain statistically meaningful data for the
hydrophilic permeant, SRB, (12-24 imaged skin sites) than for the hydrophobic permeant,
RBHE, (4-6 skin sites). 11,14 Further analysis of HTPM images corresponding to the
transdermal delivery of SRB and RBHE with and without oleic acid enhancement
demonstrated that the rate-limiting steps for transdermal transport of SRB and RBHE are
the vehicle-to-skin partitioning and the lateral diffusion through the lipid lamellar
bilayers, respectively.' 2,14
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A third TPM technique, dual-channel TPM, was used by Yu et al. to determine
the locations of the SRB and the RBHE probes relative to the intrinsic structure of the
stratum corneum. The stratum corneum contains intrinsic fluorophores, including
collagen, elastin, aromatic amino acids (such as tryptophan and tyrosine), nicotinamide
adenine dinucleotide, porphyrins, and flavin adenine dinucleotide, which have
fluorescence emission bands centered at 450 nm and 520 nm. 13,14 ,22 ,23 The emission
bands of the skin fluorophores are significantly lower than the emission bands of SRB
and RBHE (see Table 5-1). By adding filters to the two-photon microscope to capture
light emitted from the fluorescent permeants separately from the light emitted from the
intrinsic skin fluorophores, it is possible to simultaneously image the location of SRB and
RBHE relative to the intrinsic structure of the skin. Using this technique, Yu et al.
demonstrated that oleic acid increases the localization of RBHE in the intercellular
region, while it increases the penetration of SRB into the corneocytes of the stratum
corneum. 13' 14 These effects of oleic acid effectively reduced the diffusion lag time both
in the case of RBHE, by circumventing the corneocytes, which act as sinks to transdermal
diffusion, and in the case of SRB, by increasing the partitioning of SRB into the
corneocytes, such that the diffusion sinks were filled faster.'13 14
In the area of low-frequency sonophoresis, some preliminary investigations have
been conducted with conventional TPM techniques to understand the differences in
transdermal permeation between untreated skin samples and ultrasound-treated skin
samples. As part of her Ph.D. thesis work, Tang used TPM to demonstrate that the
hydrophilic probe SRB traverses the skin passively via an intercellular pathway. On the
other hand, in the presence of ultrasound only (i.e. no surfactant was included in the
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coupling medium during the ultrasound treatment), both intercellular and transcellular
pathways contribute to the overall transdermal transport of SRB.'5 Additionally, Tang
observed heterogeneity in the distribution of SRB on the surface of ultrasound-treated
skin."5 Specifically, a single region containing a large amount of SRB was observed (by
the naked-eye since SRB has a red color) beneath the ultrasound transducer.' 5 Because
of their appearances, these regions were referred to as localized transport regions (LTRs)
by Tang.'15 Preliminary investigations of the LTRs with TPM suggested that, near the
stratum corneum surface, both intercellular and transcellular permeation pathways were
formed as a result of the ultrasound-treatment, while only intercellular pathways were
observed in the deeper regions of the stratum corneum.' 5 In the surrounding regions of
the skin, referred to as inactive transport regions (ITRs) by Tang, TPM imaging
demonstrated that intercellular pathways were present, similar to those observed in
untreated skin samples.' 5 An analysis of the fluorescence intensity profiles as a function
of skin depth for untreated skin, the LTRs, and the ITRs: 1) confirmed that the ITRs and
the untreated skin samples were statistically similar, and 2) demonstrated that SRB
penetrated deeper into the skin within the LTRs as compared to the untreated skin
samples and the ITRs. '
Prior to the work presented in this chapter, there had been no previous studies
conducted with TPM to deduce the types of permeation pathways present in skin treated
simultaneously with low-frequency ultrasound and a chemical enhancer. In addition,
there has been no previous quantitative analysis of the enhancements of key transport
properties, such as the vehicle-to-skin partition coefficient, K, and the fluorescent
permeant intensity gradient in the skin, dI/dz, for skin treated with low-frequency
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sonophoresis (with or without the simultaneous application of a chemical enhancer), as
has been examined in the case of a chemical enhancer (oleic acid) by Yu et al.10-14
Finally, there have been no previous investigations with TPM to examine the permeation
pathways traversed by a hydrophobic permeant in skin treated with low-frequency
sonophoresis (with or without the simultaneous application of a chemical enhancer). In
the next section, the motivation for investigating these aspects of low-frequency
sonophoresis using TPM is provided.
5.1.2 Motivation for Additional Two-Photon Microscopy Studies of Low-
Frequency Sonophoresis
In Section 4.4.1, it was demonstrated that the LTRs formed during treatment of full-
thickness pig skin samples (an acceptable model for human skin) with low-frequency
ultrasound in the presence of a chemical enhancer - the surfactant, sodium lauryl sulfate
(SLS) - and a hydrophilic fluorophore, SRB, were indeed localized regions of high
permeability for the model hydrophilic permeant, calcein. 24 In addition, skin electrical
resistivity measurements were used in conjunction with the Aqueous-Pore Pathway
Hypothesis to determine the value of the aqueous-pore transport parameter, (//T), for each
region of the skin studied: the non-LTRs (note the change in wording from ITRs used by
Tang15 ), the LTRs, and the Total skin sample (see Sections 4.2.6 and 4.4.2). By
comparing the value of (E/) deduced for each region of the skin studied in Chapter 4
with the threshold value of (s/ttlux) for the intercellular regions of the stratum corneum
(see Chapter 3 for details), it was hypothesized that transcellular permeation pathways
217
were present within the LTRs formed in skin samples treated with low-frequency
ultrasound in the presence of SLS (see Section 4.5.2 for details).24
In this chapter, dual-channel two-photon microscopy (see Section 5.2.6 for an
explanation of this technique) was used to determine if, in fact, transcellular pathways are
present within the LTRs formed in skin treated simultaneously with low-frequency
ultrasound and with the chemical enhancer, SLS (see Section 5.3.3), in the presence of
the hydrophilic fluorescent permeant, SRB. In addition, the types of pathways present in
untreated, SLS-treated, and US-treated skin were also examined in an attempt to
understand the differences in the permeation pathways formed as a result of different
transdermal enhancing techniques (i.e. a chemical enhancer (SLS), low-frequency
sonophoresis (US), and a synergistic method (US combined with SLS)) (see Section
5.3.3). Furthermore, fluorescent intensity profiles as a function of skin depth were
generated from the TPM images of the model fluorescent permeant for each of the four
skin types listed above (see Section 5.2.7.1 for a discussion of this technique). From the
fluorescent intensity profiles, the enhancements in the skin surface partition coefficient,
K, and in the permeant intensity gradient, dI/dZ, were determined (see Section 5.3.2.4)
for the purpose of furthering our understanding of the mechanism of LTR formation in
ultrasound-treated skin (see Section 5.3.4).
The studies listed above were also conducted with RBHE, a hydrophobic
fluorescent permeant, in place of SRB. In Chapter 4, LTRs were observed in skin treated
simultaneously with ultrasound, a chemical enhancer (SLS), and the hydrophilic probe,
SRB. The motivation for using RBHE was to determine if the LTRs also form in the
presence of a hydrophobic probe, and, if so, what are the differences, if any, in the
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permeation pathways, or in the enhancements of the transdermal transport properties,
observed using dual-channel TPM imaging methods.
5.2 Materials and Methods
5.2.1 Chemicals
Phosphate buffer saline (PBS; 0.01 M phosphate, 0.137 M NaCi) was obtained from
Fluka Chemical (St. Louis, MO). Sulforhodamine B (SRB) and Rhodamine B Hexyl
Ester (RBHE) were obtained from Molecular Probes (Eugene, OR). Ethanol and Sodium
Lauryl Sulfate (SLS) were obtained from Sigma Chemical Company (St. Louis, MO).
All these chemicals were used as received.
5.2.2 Skin Preparation
Human full-thickness skin samples from the abdominal area were obtained from the
National Disease Research Institute (NDRI, Philadelphia, PA) and stored at -800C for up
to 3 months prior to use. Human skin was selected, rather than the pig skin model (see
Chapter 4), for this investigation since all previous work with TPM for transdermal
imaging in our group has used human skin samples.' 0 15 Since pig skin is used as a model
for human skin, results obtained with human skin are comparable to results obtained with
pig skin. In addition, human skin is preferred over pig skin, since human skin is more
relevant to the study of transdermal transport for future clinical applications. Prior to its
use in the fluorescent permeant diffusion experiments (see Section 5.2.4), the skin was
thawed and the subcutaneous fat was removed from the skin using a razor blade. The
skin was then sectioned and mounted in vertical Franz diffusion cells (15-mm inner
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diameter) obtained from Permegear (Bethlehem, PA). Finally, the initial electrical
resistivity of the skin was measured using methods described in Section 4.2.3. Any skin
sample with an initial resistivity lower than 50 kOhm*cm 2, which is indicative of the skin
sample being compromised, 15 was discarded and replaced with a new skin sample.
5.2.3 Preparation of the Fluorescent Permeant Solutions
For the visualization of SRB in human skin, the following solutions were prepared:
Formulation (S-1) - 0.05 mg/ml of SRB in PBS for the delivery of SRB through
untreated skin, Formulation (S-2) - 0.005 mg/ml of SRB in PBS for the delivery of SRB
through skin treated solely with ultrasound, and Formulation (S-3) - 0.005 mg/ml of SRB
in PBS containing 1% (w/v) SLS for the delivery of SRB through chemically-enhanced
skin, as well as for the delivery of SRB through skin treated simultaneously with
ultrasound and with a chemical enhancer (SLS). For a discussion of the selection of the
concentrations of SRB in the various formulations used, see below.
For the visualization of RBHE in human skin, the following solutions were
prepared: Formulation (R-l) - 0.05 mg/ml of RBHE in a 50/50 mixture of PBS and
ethanol for the delivery of RBHE through untreated skin, Formulation (R-2) - 0.005
mg/ml of RBHE in a 50/50 mixture of PBS and ethanol for the delivery of RBHE through
skin treated solely with ultrasound, and Formulation (R-3) - 0.005 mg/ml of RBHE in a
50/50 mixture of PBS and ethanol containing 1% (w/v) SLS for the delivery of RBHE
through chemically-enhanced skin, as well for the delivery of RBHE in skin treated
simultaneously with ultrasound and with a chemical enhancer. For a discussion of the
selection of the concentrations of RBHE in the various formulations used, see below.
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The concentrations of SRB and RBHE in formulation S-1 to S-3 and R-1 to R-3
were selected for the following reasons. For the enhanced delivery of SRB and RBHE in
the skin, a smaller concentration of 0.005 mg/ml was chosen to enable the detection of
both the fluorescent permeant and the intrinsic skin auto-fluorescence signals.' 3,14 For
the delivery of SRB and RBHE in untreated skin, a larger concentration of 0.05 mg/ml
was chosen to ensure that enough fluorescent permeant was present in the skin to be
detected with TPM. Ethanol was included in the RBHE solution to enable solubility of
RBHE, which is immiscible in PBS due to its relatively high level of hydrophobicity (see
Table 5-1). Finally, 1% (w/v) SLS was selected as the amount of chemical enhancer to
be consistent with the experiments conducted in Chapters 2 and 4.
5.2.4 Diffusion Experiments Using Fluorescent Permeants
Skin samples were divided into four groups: 1) untreated, 2) SLS-treated (chemical
enhancer only), 3) US-treated (low-frequency sonophoresis only), and 4) US/SLS-treated
(simultaneous application of low-frequency ultrasound and a chemical enhancer). For the
delivery of SRB and RBHE in untreated skin samples, the skin was exposed to
Formulation (S-1) and to Formulation (R-1), respectively, for 24 hours. For the delivery
of SRB and RBHE in chemically-enhanced skin samples, the skin was exposed to
Formulation (S-3) and to Formulation (R-3), respectively, for 24 hours. For the delivery
of SRB and RBHE in US-treated skin samples, the skin was exposed to Formulation (S-
2) and to Formulation (R-2), respectively, for 24 hours in the presence of ultrasound at
the following conditions: frequency - 20 kHz, intensity - 1.6 W/cm 2, duty cycle -
0.1:0.9 sec (ON:OFF), and tip displacement - 3 mm.'5 These ultrasound conditions were
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selected to be similar to those used in the preliminary investigation of LTRs with TPM. "
At the end of the 24-hour exposure period, the skin electrical resistivity was measured to
determine the extent to which each formulation had perturbed the structure of the skin.
For the delivery of SRB and RBHE in skin samples treated simultaneously with LFS and
a chemical enhancer (SLS), the skin was exposed to Formulation (S-3) and Formulation
(R-3), respectively, in the presence of ultrasound at the following conditions: frequency
- 20 kHz, intensity - 7.5 W/cm 2, duty cycle - 5:5 sec (ON:OFF), and tip displacement -
3 mm,24 until the skin electrical current reached a value of 225 ýtAmps, similar to the
conditions examined in Chapter 4. Note that this level of skin electrical current was
obtained after treating the skin simultaneously with ultrasound and SLS for 5 - 10
minutes.
5.2.5 Preparation of Skin Samples for TPM Imaging
After delivery of SRB and RBHE into the skin, the skin samples were removed from the
Franz diffusion cells, and excess formulation was removed from the skin surface. The
circular region of the skin exposed to the fluorescent permeants was removed using a
razor blade. A few drops of PBS were then added to an imaging chamber (2.5 mm
Coverwell, Grace Bio Labs, Bend, OR) covered with a No.1, 22 mm square glass cover
slip (VWR Scientific, Media, PA) to ensure good contact of the skin surface with the
cover slip. The skin was then inserted into the imaging chamber and subsequently
mounted onto a glass microscope slide (VWR Microslides, 25 mm x 75 mm).
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5.2.6 Dual-Channel TPM Imaging and Data Collection
Two-photon imaging of the skin samples prepared using the methods outlined in Sections
5.2.4 and 5.2.5 was conducted according to previously published methods,' 0-13 which are
briefly summarized here. Figure 5-1 shows a schematic illustration of the TPM imaging
system. 14 The laser source was provided by a femtosecond ti-sa laser (Tsunami, Spectra-
Physics, Mountain View, CA) pumped by 5W diode-pumped, solid state CW laser
(Millenia V, Spectra-Physics, Mountain View, CA). For all the dual-channel TPM
imaging, the laser power was set at 250 mW to ensure detection of the skin auto-
fluorescence signal, while minimizing damage to the skin from the laser. A modified
inverted microscope (Axiovert, 100TV, Ziess, Thornwood, NY) with an oil immersion
40X objective lens (Zeiss F Fluar, NA .13) was used to image the skin samples. X-Y
scans were made with a scanner unit (6350 Cambridge Technology, Watertown, MA).
The emitted photons from the laser excitation are collected by the microscope and then
passed through two filters, which split the signal into the red channel for the photons
emitted by the fluorescent permeant and the green channel for the photons emitted by the
intrinsic skin fluorophores. The red and green channels are then sent to a photomultiplier
and are discriminated against dark noise with a custom built high-speed photon
discriminator unit to obtain the final dual-channel TPM image.
In untreated and SLS-treated skin, six 120 Cim x 120 ýpm skin sites were imaged.
In US-treated and US/SLS-treated skin, twelve 120 ýpm x 120 ptm skin sites were imaged
- six sites for the non-LTRs and six sites for the LTRs. The depth of the TPM imaging
varied from a depth of 40 jtm, for skin samples where little to no fluorescent permeant
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Figure 5-1: Schematic illustration of the TPM imaging system.14
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penetrated deep into the skin, to a depth of 70 jtm, for skin samples where significant
fluorescent permeant penetrated deep into the skin.
5.2.7 Analysis of the TPM Images
The techniques that were used to analyze the dual-channel TPM images of both SRB and
RBHE are based on previously published methods,' 0-'5 which are described in this
section. These techniques include: 1) generating and analyzing the average fluorescence
permeant intensity profiles as a function of skin depth, 2) evaluating the enhancement of
the fluorescent permeant vehicle-to-skin partition coefficient, 3) evaluating the
enhancement of the fluorescent permeant intensity gradient, 4) evaluating the
enhancement of the effective diffusion path length, and 5) evaluating the existence of
transcellular permeation pathways in the stratum corneum. All the TPM image
processing reported in this section was carried out using MATLAB with the Image
Processing Toolbox (Version 7.0.4.365 (R14) Service Pack 2, The Mathworks, Inc.).
5.2.7.1 Generating and Analyzing the Fluorescent Permeant Intensity
Profiles as a Function of Skin Depth
The fluorescent permeant intensity profiles as a function of skin depth were generated
using an in-lab subroutine in MATLAB, which calculated an average value for the
fluorescence intensity, I, for each layer of the skin imaged in the z-direction (the direction
perpendicular to the skin surface). The surface of each skin sample, corresponding to z =
0 pm, was defined at the location of the first local maximum in the average value of the
intensity of the fluorescent probes as a function of increasing skin depth.1'0 14,15 The
average value of the fluorescence intensity at z = 0 was then averaged over the 5-7 skin
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sites imaged for each of the six types of skin samples examined in this study for delivery
of SRB and RBHE: 1) Untreated skin, 2) SLS-treated skin, 3) the non-LTRs of US-
treated skin, 4) the LTRs of US-treated skin, 5) the non-LTRs of US/SLS-treated skin,
and 6) the LTRs of US/SLS-treated skin. For the fluorescence intensity profiles of SRB
and RBHE in the untreated skin, the value of I was divided by 10 to account for the
difference in the donor concentration of the fluorescent permeant used for the untreated
skin samples (0.05 mg/ml) and for the enhanced skin samples (0.005 mg/ml).
To determine whether treatment of the skin with SLS, US, or US/SLS results in a
significant enhancement in the penetration of SRB and RBHE, the average value of the
fluorescence permeant intensity in the enhanced skin samples and in the untreated skin
samples were analyzed with the t-statistic, over the depth of skin imaged. The t-statistic,
to, which tests for the difference in two average values where the variances are not equal,
was calculated using the following formula: 25
to= xnhanced (- ntreated (5.1)2 2
S Enhanced UIntreated
nEnhanced nUntreated
where XEnhanced and XUntreated are the average values of the fluorescence intensity
corresponding to the enhanced skin samples (i.e. SLS-treated, US-treated, or US/SLS-
treated skin samples) and to the untreated skin samples, respectively, SEnhanced and SUntreated
are the standard deviations in the average values of the fluorescence intensity
corresponding to the enhanced skin samples and to the untreated skin samples,
respectively, and nEnhanced and nuntreated are the number of samples examined for the
enhanced skin samples and for the untreated skin samples, respectively. The value of to
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was then compared to the values of t in a standard t distribution table.25 For a specified
value of the number of degrees of freedom, v, defined by: 25
S Enhanced S Intreated
v nEnhanced lntreated (5.2)
1 Enhanced Enhanced )2 2SIntreated / Untreated 2
nEnhanced + I n(Inireated + 1
and the level of probability, p, there existed a corresponding value of t. For the case
where tv,p > to, XEnhanced and X Untreated are considered to be statistically similar. For the
case where t,,p < to, XEnhanced and x Untreated are considered to be statistically different. A
value of p = 0.05, corresponding to a 95% confidence, was selected for the analysis of the
fluorescent permeant intensity profiles in this study.
5.2.7.2 Evaluating the Enhancement in the Fluorescent Permeant Vehicle-
to-Skin Partition Coefficient
The fluorescent permeant vehicle-to-skin partition coefficient, K, is defined as follows: 14
C, (z = 0)K =  (5.3)
Cd
where Cs(z = 0) is the concentration of the fluorescent permeant at the skin (s) surface
and Cd is the concentration of the fluorescent permeant in the bulk donor (d) solution,
which is assumed to be constant since Cd / Cr >>1, where Cr is the concentration of the
fluorescent permeant in the bulk receiver solution. The enhancement in the fluorescent
permeant vehicle-to-skin partition coefficient, EK, is then calculated using the following
equation:
EK= Cs,l:nhancer (Z = O) Cd,Enhancer (5.4)
C d (z = 0) (4)Cs, lntreated (Z = O)/ Cd,tIntreated
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where Ci,Enhancer and Ci,Untreated (i = s and d) denote the concentrations of the fluorescent
permeant in the enhanced skin samples and in the untreated skin samples, respectively.
By assuming that the intensity of the fluorescent permeant, I, is directly proportional to
its concentration in the skin, EK can be approximated from the fluorescence intensity
profiles using the following equation:'1014
EK = iEnhancer (z = 0) (5.5)
IUIntreated (z = 0)
where IEnhancer(Z = 0) is the average value of the fluorescence intensity of SRB or RBHE
at the surface of the enhanced skin samples, and IUntreated(Z = 0) is the average value of the
fluorescence intensity of SRB or RBHE at the surface of the untreated skin samples.
Again, the difference in the concentrations of the fluorescent permeants in the donor
solutions has been accounted for in the value of IUntreated as described in Section 5.2.7.1.
5.2.7.3 Evaluating the Enhancement in the Fluorescent Permeant Intensity
Gradient
The fluorescent permeant intensity gradient, (dl/dz), in the stratum corneum was
evaluated by performing a linear regression using the average intensity values from the
first 12 scans from the surface into the stratum corneum, a region which exhibits a
significant decrease in the fluorescent probe intensity in the untreated skin, to which the
fluorescent probe intensities in the enhanced skin samples are then compared.10,14 The
fluorescent permeant intensity gradient serves as a good approximation of the
concentration gradient (dC/dz) of the fluorescent permeant in the skin, since the value of
the fluorescence intensity is directly proportional to the concentration of the fluorescent
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permeant present in the skin. To calculate the enhancement in the fluorescent permeant
intensity gradient, EG, the following equation was used:'10 14
E = (d / dz),nhanced (5.6)
W(d / dz)lIntreated
where (dI/dz)Enhanced and (dI/dz)Untreated are the fluorescent permeant intensity gradients
corresponding to the intensity profiles of the enhanced skin samples and of the untreated
skin samples, respectively.
5.2.7.4 Evaluating the Enhancement in the Effective Diffusion Path
Length
The steady-state flux, J, of permeant through the SC membrane is directly proportional to
the concentration gradient, dC/dz, of the permeant in the SC, as embodied in the equation
for Fick's First Law of diffusion in one dimension, given by:26
dC
J = -D (5.7)
dz
where D is the effective diffusion coefficient of the permeant within the SC. The steady-
state permeability, P, is then given by:2 7
P=J / AC (5.8)
where AC is the concentration difference across the SC membrane (i.e. AC = Cd - Cr). As
discussed in Section 5.2.7.2, Cd >> Cr, and, therefore, AC can be approximated by Cd.
The transdermal permeability can also be defined as follows: 27
KDP =KD (5.9)
L
where L is the effective diffusion path length. Equations (5.7) - (5.9) can be combined to
yield the following useful result:
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KC
L=- d (5.10)
dC / dz
Noting that KCd is equal to C(z = 0) (see Eq. (5.3)), and that the concentration of the
fluorescent permeant in the stratum corneum is directly proportional to the intensity of
the fluorescence signal, Eq. (5.10) can be written in terms of the fluorescence intensity, I,
as follows:
L =I(z = 0) (5.11)
dl / dz
The enhancement in the effective diffusion path length, EL, in enhanced skin samples as
compared to untreated skin samples is given by:
Ilinhanced (z = 0)
E L lnhanced (IUntreaed (z = ) EK (5.12)
L(ntreated dI/ dz)•inhanced E;
(dl / dz )ntreated
Accordingly, EL can be evaluated from the values of EK and EG, which can be obtained
from the fluorescence intensity profiles using Eqs. (5.5) and (5.6), respectively.
5.2.7.5 Evaluating the Existence of Transdermal Permeation Pathways in
the Stratum Corneum from the Dual-Channel TPM Images
Following previously published methods, 13"14 a slice, 5 pixels (width) x 256 pixels
(length), of the red channel (probe) and the green channel (skin auto-fluorescence) TPM
images was selected for analysis of the location of the fluorescent permeant relative to the
structure of the skin. At each position along the length of this slice (0 - 255), the
intensities of the corresponding 5 pixels along the width were averaged and then
normalized. These normalized average values, for both the red channel and the green
channel, were plotted as a function of the pixel number along the length of the slice.
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Previous studies utilizing this dual-channel TPM image analysis technique have
demonstrated that it is possible to determine whether there is an increase, or a decrease,
in the penetration of the probe into the corneocytes. 13,14 Specifically, by measuring the
width and height of peaks in the normalized average intensity profile of the fluorescent
probe in untreated skin, and comparing these values to the peak width and peak height of
the fluorescent probe in the enhanced skin samples, enhancements, or reductions, in the
penetration of the probe into the corneocytes were evaluated quantitatively. As the height
of the peaks increases and the width of the peaks decreases, there is less permeant present
inside the corneocytes, which serves as a qualitative indicator of the existence of
intercellular permeation pathways. Conversely, as the height of the peaks decreases and
the width of the peaks increases, there is more permeant present inside the corneocytes,
which serves as a qualitative indicator of the existence of transcellular permeation
pathways. The height of the peaks was determined by evaluating the difference between
the height of the peak and the average height of the two valleys that neighbor the peak.
The width of the peaks was determined by measuring the width of the peaks at half of the
peak height. The skin surface (z = 0 ptm) was selected as the skin layer to examine for
the existence of transcellular permeation pathways. The surface of the skin is the first
skin layer that is perturbed by SLS or US, since it is at the skin surface where the
enhancing transient acoustic cavitation events take place, 2 8-30 and where the skin contacts
the coupling medium. For samples with transcellular pathways present at z = 0 jým,
additional measurements were made to deduce the depth that the transcellular pathways
penetrate into the stratum corneum.
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5.3 Results and Discussion
5.3.1 Qualitative Analysis of the Dual-Channel TPM Images
Figures 5-2 through 5-13 show samples of the 120 rtm x 120 utm dual-channel TPM
images obtained for the delivery of the fluorescent permeants, SRB and RBHE, in each of
the six skin samples examined in this study: 1) untreated skin (see Figure 5-2 for SRB
and Figure 5-8 for RBHE), 2) SLS-treated skin (see Figure 5-3 for SRB and Figure 5-9
for RBHE), 3) the non-LTRs of US-treated skin (see Figure 5-4 for SRB and Figure 5-10
for RBHE), 4) the LTRs of US-treated skin (see Figure 5-5 for SRB and Figure 5-11 for
RBHE), 5) the non-LTRs of US/SLS-treated skin (see Figure 5-6 for SRB and Figure 5-
12 for RBHE), and 6) the LTRs of US/SLS-treated skin (see Figure 5-7 for SRB and
Figure 5-13 for RBHE). In each figure, the red channel images show the location of SRB
or RBHE in the skin, and the green channel images show the location of the intrinsic skin
fluorophores. The dual-channel TPM images are presented as a function of skin depth
(z). Specifically, TPM images are presented at z = 0 ptm (the skin surface), z = 5 gm, z =
10 ptm, z = 20 pm, z = 30 ýtm, and z = 40 pm to provide qualitative information on how
the amount and location of SRB and RBHE changes as a function of skin depth in each of
the six skin samples. Note that the thickness of the stratum corneum is, on average, 10 -
20 pm. Where appropriate, the location of a representative corneocyte in the stratum
corneum has been indicated with a "C", and the visualization of the stratum spinosum
layer of the viable epidermis has been indicated with a "SS". A horizontal white scale
bar in the image corresponding to z = 0 urm, representing a length of 24 jim, has been
included to aid the reader in approximating dimensions.
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5.3.1.1 Qualitative Analysis of SRB Penetration in SLS-Treated and
Untreated Skin
From a qualitative analysis of Figures 5-2 and 5-3, the dual-channel TPM images for
SRB delivery in untreated and SLS-treated skin, respectively, SRB does not appear to
penetrate deeper than 20 ýtm into the skin, which corresponds approximately to the
thickness of the stratum corneum. For the images corresponding to 20 ýtm, 30 tm, and
40 ltm, there is little evidence of appreciable SRB intensity, as well as of little skin auto-
fluorescence, indicated by the low values of the upper limits of the intensity scales
associated with the TPM images for 20 rtm, 30 ptm, and 40 um. In addition, from the
images corresponding to z = 0, 5, and 10 um, the shapes of the corneocyte cells, which
have a diameter of 30-40 ptm, are clearly observed. This observation suggests that the
penetration of SRB is restricted to the stratum corneum in both SLS-treated skin and
untreated skin.
While the depth of SRB penetration in SLS-treated skin and untreated skin
appears to be similar, there is a visible difference between the penetration of SRB into the
corneocytes of SLS-treated skin and of untreated skin. In untreated skin (see Figure 5-2,
z = 0, 5, and 10 jim), SRB does not penetrate deeply into the corneocytes of the stratum
corneum, since the intercellular and comeocyte domains are well defined. On the other
hand, in SLS-treated skin (see Figure 5-3, z = 0, 5, and 10 gm), SRB appears to be more
evenly distributed between the intercellular region and the interiors of the comeocytes.
This observation suggests that more SRB penetrates into the corneocytes in SLS-treated
skin relative to untreated skin.
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Figure 5-2: Dual-channel two-photon microscopy images of the hydrophilic probe
sulforhodamine B (SRB) in untreated skin as a function of skin depth. Key: red -
sulforhodamine B, green - skin auto-fluorescence, C - representative corneocyte. Image
size: 120 jtm x 120 jtm. The horizontal white bar in the figure corresponding to z = 0
represents 24 lam.
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Figure 5-3: Dual-channel two-photon microscopy images of sulforhodamine B in SLS-
treated skin as a function of skin depth. Key: red - sulforhodamine B, green - skin auto-
fluorescence, C - representative corneocyte. Image size: 120 ptm x 120 rtm. The
horizontal white bar represents 24 ptm.
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5.3.1.2 Qualitative Analysis of SRB Penetration in US-Treated and
Untreated Skin
A qualitative analysis of Figure 5-2 for the delivery of SRB in untreated skin and of
Figures 5-4 and 5-5 for the delivery of SRB in the non-LTRs and the LTRs of US-treated
skin, respectively, reveals that the penetration of SRB in the LTRs of US-treated skin is
much greater than the penetration of SRB in untreated skin and in the non-LTRs of US-
treated skin. In Figures 5-2 and 5-4, SRB is visualized to a depth of 10 rIm. At depths of
20 p~m to 40 jm, the intensity of SRB in the LTRs of US-treated skin is higher relative to
the intensity of SRB in untreated skin and in the non-LTRs of US-treated skin. This
observation suggests that SRB penetrates deeper into the skin in the LTRs of US-treated
skin relative to untreated skin and to the non-LTRs of US-treated skin, where SRB
penetration is restricted to the stratum corneum.
In addition to suggesting that more SRB penetrates into the skin in the LTRs of
US-treated skin, there is also a change in the structure of the skin below 20 Rm in the
LTRs of US-treated skin (see Figure 5-5). The structure of the corneocytes, which have a
diameter of 30-40 gm in human skin, is observed in the images corresponding to z = 0, 5,
and 10 p~m in Figures 5-2 through 5-5. However, this structural pattern is not observed in
Figure 5-5 in the images corresponding to depths greater than 20 pm. Instead, in Figure
5-5, the images corresponding to z = 30 ýpm and z = 40 gm contain a smaller pattern of
dots (2 - 3 ptm in diameter). These dots may represent the nuclei of cells in the stratum
spinosum (SS) layer of the viable epidermis, which have similar dimensions.31 This
observation suggests that SRB is able to penetrate into the viable epidermis within the
LTRs of US-treated skin.
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Figure 5-4: Dual-channel two-photon microscopy images of sulforhodamine B in the
non-LTRs of US-treated skin as a function of skin depth. Key: red - sulforhodamine B,
green - skin auto-fluorescence, C - representative comeocyte. Image size: 120 ýpm x 120
jtm. The horizontal white bar represents 24 jtm.
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Figure 5-5: Dual-channel two-photon microscopy images of sulforhodamine B in the
LTRs of US-treated skin as a function of skin depth. Key: red - sulforhodamine B, green
- skin auto-fluorescence, C - representative corneocyte, SS - stratum spinosum. Image
size: 120 pm x 120 ýpm. The horizontal white bar represents 24 pm.
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As in the case of the delivery of SRB in SLS-treated skin and in untreated skin,
there are qualitative differences in the amount of SRB present in the corneocytes at the
surface of the LTRs of US-treated skin as compared to the amount of SRB in the
corneocytes at the surface of untreated skin and at the surface of the non-LTRs of US-
treated skin. In Figures 5-2 and 5-4, at z = 0 jtm, the shapes of the corneocytes can be
clearly observed in both the red channel and in the green channel images. However, in
Figure 5-5, at z = 0 p.m, the intensity of SRB is more uniformly distributed across the
region of the skin that was imaged, making it difficult to observe individual corneocyte
cells. This observation suggests that more SRB penetrates into the corneocytes at the
skin surface in the LTRs of US-treated skin relative to both untreated skin and to the non-
LTRs of US-treated skin. As z increases from z = 0 to 10 ptm within the stratum corneum
in Figure 5-5, the shape of the comeocytes becomes more distinct, since more SRB is
present in the intercellular domain compared to the corneocytes. This result suggests that
less SRB penetrates into the corneocytes in the deeper layers of the stratum corneum
within the LTRs of US-treated skin, which agrees with claims made in previous
preliminary studies on the penetration of SRB in US-treated skin.'5
5.3.1.3 Qualitative Analysis of SRB Penetration in US/SLS-Treated and
Untreated Skin
For SRB delivery in US/SLS-treated skin relative to SRB delivery in untreated skin,
several observations can be made which are similar to the observations made for SRB
delivery in US-treated skin relative to untreated skin. Comparing the dual-channel TPM
images in Figures 5-2 and 5-6, the penetration depth of SRB in the non-LTRs of US/SLS-
treated skin is restricted to the stratum corneum, which is similar to the penetration depth
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Figure 5-6: Dual-channel two-photon microscopy images of sulforhodamine B in the
non-LTRs of US/SLS-treated skin as a function of skin depth. Key: red -
sulforhodamine B, green - skin auto-fluorescence, C - representative comeocyte. Image
size: 120 ptm x 120 [pm. The horizontal white bar represents 24 pim.
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Figure 5-7: Dual-channel two-photon microscopy images of sulforhodamine B in the
LTRs of US/SLS-treated skin as a function of skin depth. Key: red - sulforhodamine B,
green - skin auto-fluorescence, C - representative comeocyte, SS - stratum spinosum.
Image size: 120 ptm x 120 ttm. The horizontal white bar represents 24 ptm.
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of SRB in untreated skin. Comparing the dual-channel TPM images in Figure 5-8 with
Figures 5-2 and 5-7, SRB penetrates into the viable epidermis in the LTRs of US/SLS-
treated skin (see z = 40 tm in Figure 5-7). This result is consistent with previous
macroscopic digital imaging measurements of the penetration depth of SRB in skin
treated with ultrasound and SLS. 32  Furthermore, SRB appears to be more evenly
distributed between the corneocytes and the intercellular regions at the skin surface in the
LTRs of US/SLS-treated skin (see z = 0 [pm in Figure 5-7) relative to the distribution of
SRB at the skin surface of both untreated skin (see z = 0 pim in Figure 5-2) and the non-
LTRs of US/SLS-treated skin (see z = 0 pm in Figure 5-6). This observation suggests
that more SRB penetrates into the corneocytes at the skin surface in the LTRs of US/SLS-
treated skin relative to both untreated skin and to the non-LTRs of US/SLS-treated skin.
As z increases from z = 0 to z = 20 in Figure 5-7, the shapes of the corneocytes in the red
channel (SRB) images become more distinct, suggesting that less SRB penetrates into the
corneocytes in the deeper layers of the stratum corneum within the LTRs of US/SLS-
treated skin.
5.3.1.4 Qualitative Analysis of RBHE Penetration in SLS-Treated and
Untreated Skin
For the delivery of RBHE in untreated and in SLS-treated skin samples, a qualitative
analysis of the dual-channel TPM images in Figures 5-8 and 5-9 reveals that the shapes
of the corneocytes in the red channel (RBHE) images are very well defined in both the
SLS-treated skin and the untreated skin, contrary to the case of SRB. This result suggests
that unlike the case of SRB, RBHE penetration into the corneocytes does not increase in
SLS-treated skin relative to untreated skin. Furthermore, the dual-channel TPM images
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Figure 5-8: Dual-channel two-photon microscopy images of the hydrophobic fluorescent
probe rhodamine B hexyl ester (RBHE) in untreated skin as a function of skin depth.
Key: red - rhodamine B hexyl ester, green - skin auto-fluorescence, C - representative
corneocyte. Image size: 120 ýtm x 120 ptm. The horizontal white bar represents 24 ýtm.
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Figure 5-9: Dual-channel two-photon microscopy images of rhodamine B hexyl ester in
SLS-treated skin as a function of skin depth. Key: red - rhodamine B hexyl ester, green
- skin auto-fluorescence, C - representative corneocyte. Image size: 120 jm x 120 jm.
The horizontal white bar represents 24 jtm.
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also demonstrate that RBHE is able to penetrate deeper into the skin, in both the
untreated and the SLS-treated skin samples, relative to the case of SRB. In both Figures
5-8 and 5-9, an observable amount of RBHE is present at depths of up to 40 ptm.
However, this observed difference may be due solely to the existence of a thicker stratum
corneum layer in the skin samples used for the delivery of RBHE in untreated and in
SLS-treated skin relative to the skin samples used for the delivery of SRB. (Note that
different skin samples were used for each case examined, so some variation in the
stratum corneum thickness from sample to sample is possible.) In Figures 5-8 and 5-9,
the shapes of the corneocytes are observed in the green channel images for the skin auto-
fluorescence even at a depth of 40 rtm. This is different from the case of SRB delivery in
the LTRs of US-treated and US/SLS-treated skin, where SRB penetration is also
observed up to depths of 40 itm (see Figures 5-5 and 5-7). For the case of SRB delivery
in the LTRs of US-treated and US/SLS-treated skin, there is also an observed change in
the structure of the skin at depths greater than 10 Im in Figure 5-5 and at depths greater
than 20 pm in Figure 5-7, which indicates a transition into the viable epidermis (see
Section 5.3.1.2 for details). Since there is no observable change in the structure of the
skin in Figures 5-8 and 5-9 as the skin depth increases, it is still likely that penetration of
RBHE is restricted to the stratum corneum in both untreated skin and SLS-treated skin,
similar to the case ofSRB.
5.3.1.5 Qualitative Analysis of RBHE Penetration in US-Treated and
Untreated Skin
For the case of the delivery of RBHE in US-treated skin relative to the delivery of RBHE
in untreated skin, there are many similarities with the delivery of SRB in US-treated skin.
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First, LTRs are formed with RBHE as the model permeant in US-treated skin. This
observation suggests that LTR formation in skin treated with ultrasound does not depend
on whether the model permeant is hydrophilic or hydrophobic. Second, a comparison of
Figures 5-8 (untreated skin), 5-10 (the non-LTRs in US-treated skin), and 5-11 (the LTRs
in US-treated skin), indicates that, similar to the case of SRB delivery, there is
penetration of RBHE into the viable epidermis within the LTRs of US-treated skin, while
the penetration of RBHE in the non-LTRs of US-treated skin and in untreated skin is
confined solely to the stratum corneum. This observation suggests that the penetration of
the model permeants into the viable epidermis within the LTRs of US-treated skin also
does not depend on whether the model permeant is hydrophilic or hydrophobic.
Finally, the penetration of RBHE into the corneocytes of the stratum corneum for
untreated skin and for the non-LTRs and the LTRs of US-treated skin appears to be
similar to the penetration of SRB into the corneocytes of the stratum corneum for the
same skin samples. Specifically, a qualitative analysis of the dual-channel TPM images
in Figures 5-8 and 5-10 reveals that the shapes of the corneocytes in the red channel
(RBHE) images are very well-defined at the skin surface (z = 0 pm) in both the non-
LTRs of US-treated skin and in the untreated skin. On the other hand, in the image of the
skin surface for the LTRs of US-treated skin (see z = 0 p.m in Figure 5-11) the shapes of
the corneocytes are more difficult to identify, since RBHE is distributed more evenly
between the corneocytes and the intercellular regions. It also appears that, within the
LTRs of US-treated skin, the shape of the corneocytes is more easily identified as the
skin depth is increased (see z = 0, 5, 10, and 20 ptm in Figure 5-11), indicating that less
RBHE penetrates into the corneocytes in the deeper layers of the stratum corneum within
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Figure 5-10: Dual-channel two-photon microscopy images of rhodamine B hexyl ester in
the non-LTRs of US-treated skin as a function of skin depth. Key: red - rhodamine B
hexyl ester, green - skin auto-fluorescence, C - representative corneocyte. Image size:
120 ýtm x 120 [tm. The horizontal white bar represents 24 jtm.
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Figure 5-11: Dual-channel two-photon microscopy images of rhodamine B hexyl ester in
the LTRs of US-treated skin as a function of skin depth. Key: red - rhodamine B hexyl
ester, green - skin auto-fluorescence, C - representative corneocyte, SS - stratum
spinosum. Image size: 120 jtm x 120 jtm. The horizontal white bar represents 24 jtm.
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the LTRs of US-treated skin, similar to the case of SRB penetration in the LTRs of US-
treated skin (see Figure 5-5). This observation suggests that the level of penetration of
the model permeants into the corneocytes of US-treated skin also does not depend on
whether the model permeant is hydrophilic or hydrophobic. Taken together, these three
observations further suggest that the formation of LTRs in US-treated skin, the
penetration of the model permeants into the viable epidermis within the LTRs, and the
level of penetration of the model permeants into the corneocytes of the stratum corneum
within the LTRs depend solely on the effects of localized perturbations in the skin
structure due to the ultrasound treatment.
5.3.1.6 Qualitative Analysis of RBHE Penetration in US/SLS-Treated and
Untreated Skin
For the delivery of RBHE in US/SLS-treated skin relative to untreated skin, there are,
again, many similarities to the delivery of RBHE in US-treated skin relative to untreated
skin. Comparing the dual-channel TPM images for the delivery of RBHE in untreated
skin (see Figure 5-8) with the dual-channel images for the delivery of RBHE in the non-
LTRs and the LTRs of US/SLS-treated skin (see Figures 5-12 and 5-13, respectively),
RBHE penetrates into the viable epidermis in the LTRs of US/SLS-treated skin, while
RBHE penetration is confined solely to the stratum corneum in both untreated skin and in
the non-LTRs of US/SLS-treated skin. Furthermore, RBHE appears to be more evenly
distributed between the comeocytes and the intercellular regions at the skin surface in the
LTRs of US/SLS-treated skin (see z = 0 tm in Figure 5-13) relative to the distribution of
SRB at the skin surface of both untreated skin (see z = 0 pm in Figure 5-8) and the non-
LTRs of US/SLS-treated skin (see z = 0 gm in Figure 5-12). This observation suggests
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that more RBHE penetrates into the corneocytes at the skin surface in the LTRs of
US/SLS-treated skin relative to both untreated skin and the non-LTRs of US/SLS-treated
skin. As z is increased from z = 0 to z = 10 in Figure 5-13, the shapes of the corneocytes
in the red channel (RBHE) images become more distinct, suggesting that less RBHE
penetrates into the corneocytes in the deeper layers of the stratum corneum within the
LTRs of US/SLS-treated skin. These observations are also similar to the observations
made for the case of SRB delivery in US/SLS-treated skin relative to untreated skin,
suggesting that the observed enhancements in US/SLS-treated skin are independent of the
hydrophobicity/hydrophilicity of the model permeants.
5.3.1.7 Summary of the Qualitative Investigations of the Dual-Channel
TPM Images for SRB and RBHE
From the analyses conducted in Sections 5.3.1.1 - 5.3.1.6, the following key observations
can be made from Figures 5-2 through 5-13: 1) formation of the LTRs does not depend
on the presence of the chemical enhancer, SLS, or on whether the model permeant is
hydrophilic or hydrophobic, 2) penetration of both SRB and RBHE is restricted to the
stratum corneum in untreated skin, SLS-treated skin, and the non-LTRs of both US-
treated and US/SLS-treated skin, 3) penetration of both SRB and RBHE into the viable
epidermis is observed in the LTRs of both US-treated and US/SLS-treated skin, 4)
increased penetration of SRB into the corneocytes at the skin surface is observed in SLS-
treated skin and in the LTRs of US-treated and US/SLS-treated skin, while increased
penetration of RBHE into the comeocytes at the skin surface is observed in the LTRs of
US-treated and US/SLS-treated skin, and 5) the increased penetration of both SRB and
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RBHE into the corneocytes of the stratum corneum appears to decrease as a function of
skin depth in the LTRs of both US-treated and US/SLS-treated skin.
5.3.2 Quantitative Analysis of SRB and RBHE Delivery in Untreated, SLS-
Treated, US-Treated, and US/SLS-Treated Skin
5.3.2.1 Statistical Analysis of the Fluorescence Intensity Profiles for SRB
Figure 5-14 shows the average fluorescence intensity profiles of the hydrophilic model
permeant, SRB, obtained using the methods discussed in Section 5.2.7.1. In each figure
(5-14a - 5-14c), the fluorescence intensity of SRB is plotted on the y-axis and the depth
from the skin surface (at z = 0 jtm), in jtm, is plotted on the x-axis. The error bars
represent one standard deviation in the average value of the SRB fluorescence intensity
(for clarity, only the upper error bars are shown in Figures 5-14a - 5-14c). In addition,
the results of the statistical analysis of the fluorescence permeant intensity profiles are
also shown in Figure 5-14. Specifically, a bar (solid or dashed) with a single asterisk (*)
indicates the range over which the average fluorescence intensity values from the
enhanced skin sample are statistically different (p<0.05) from the average fluorescence
intensity values from the untreated skin samples. A solid bar with a double asterisk (**)
indicates the range over which the average fluorescence intensity values of the LTRs is
statistically different (p<0.05) from the average fluorescence intensity values of the non-
LTRs.
In Figure 5-14a, the SRB intensity profile in SLS-enhanced skin (open diamonds)
is compared to the SRB intensity profile in untreated skin (black diamonds). As
indicated by the solid bar with a single asterisk (*) in Figure 5-14a, there is a significant
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Figure 5-14: SRB fluorescence intensity profiles as a function of skin depth from the
skin surface (at z = 0): (a) SLS-treated skin versus untreated skin, (b) the non-LTRs and
the LTRs of US-treated skin versus untreated skin, and (c) the non-LTRs and the LTRs of
US/SLS-treated skin versus untreated skin. Key: black diamonds - untreated skin
samples, open diamonds - SLS-treated skin samples, open triangles - the non-LTRs, and
open circles - the LTRs. Error bars represent one standard deviation in the average value
of 5 - 7 skin samples. For clarity, only the upper error bars are shown. Single asterisks
(*) indicate the region of significant difference (p<0.05) between SRB delivery in
enhanced skin and in untreated skin. Double asterisks (**) indicate the region of
significant difference (p<0.05) between SRB delivery in the non-LTRs and in the LTRs.
In (c), the dashed line with the single asterisk (*) corresponds to the confidence interval
for the non-LTRs.
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indicates that more SRB penetrates in the skin as a result of SLS-treatment of the skin
relative to the case of untreated skin. In addition, there is a sharp decrease in the average
increase (p<0.05) in the intensity of SRB in the first 14 layers of the SLS-treated skin as
compared to the intensity of SRB in the first 14 layers of the untreated skin. In addition,
SRB fluorescence intensity decreases to near zero values over the first 20 layers of both
SLS-treated and untreated skin, indicating that the stratum corneum provides the primary
barrier to the delivery of SRB in SLS-treated skin, similar to untreated skin.
Furthermore, there is little penetration of SRB into the skin deeper than 20 ptm in both
SLS-treated skin and untreated skin, confirming that SRB penetration is restricted to the
stratum corneum in SLS-treated and untreated skin.
In Figure 5-14b, the SRB intensity profiles of the non-LTRs (open triangles) and
of the LTRs (open circles) in US-enhanced skin are compared to the SRB intensity
profile in untreated skin (black diamonds). As shown by the solid bar with a single
asterisk (*) in Figure 5-14b, the intensity of SRB within the LTRs of US-treated skin is
significantly greater (p<0.05) than the intensity of SRB in untreated skin up to a depth of
40 jtm, indicating that more SRB penetrates in the skin within the LTRs as a result of US-
treatment of the skin relative to the case of untreated skin. On the other hand, the
intensity of SRB within the non-LTRs is not significantly greater (p>0.05) than the
intensity of SRB in untreated skin up to a depth of 40 tim, and, therefore, no asterisked
bar for the non-LTRs is reported in Figure 5-14b, indicating that SRB penetration in the
non-LTRs of US-treated skin is similar to SRB penetration in the case of untreated skin.
Furthermore, the intensity of SRB within the LTRs of US-treated skin is significantly
greater (p<0.05) than the intensity of SRB in the non-LTRs of untreated skin up to a
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depth of 40 plm, as shown by the solid bar with a double asterisk (**) in Figure 5-14b,
indicating that more SRB penetrates into the skin within the LTRs as a result of US-
treatment of the skin relative to the non-LTRs of US-treated skin. These results are in
good agreement with previous studies examining the penetration of hydrophilic
fluorescent permeants in US-treated skin, 15,33 and suggest that ultrasound only perturbs
discrete regions of the skin to enhance the transdermal penetration of model permeants.
In Figure 5-14c, the SRB intensity profiles of the non-LTRs (open triangles) and
of the LTRs (open circles) in US/SLS-enhanced skin are compared to the SRB intensity
profile in untreated skin (black diamonds). Similar to the SRB delivery in US-treated
skin, the intensity of SRB in the LTRs of US/SLS-treated skin is significantly (p<0.05)
greater than the intensity of SRB in both untreated skin (see solid bar with a single
asterisk (*) in Figure 5-14c) and the non-LTRs of US/SLS-treated skin (see solid bar with
a double asterisk (**) in Figure 5-14c) over the depth of skin imaged. This result
indicates that more SRB penetrates into the skin within the LTRs as a result of US/SLS-
treatment of the skin relative to both untreated skin and the non-LTRs of US/SLS-treated
skin. Contrary to the SRB delivery in US-treated skin, the intensity of SRB in the first 21
layers of the non-LTRs of US/SLS-treated skin is also significantly greater (p<0.05) than
the intensity of SRB in the first 21 layers of untreated skin (see dashed bar with a single
asterisk (*) in Figure 5-14c). This result indicates that more SRB penetrates into the skin
within the non-LTRs as a result of US/SLS-treatment of the skin relative to untreated skin.
Furthermore, the intensity of SRB in the non-LTRs of US/SLS-treated skin is not
significantly (p>0.05) different from the intensity of SRB in untreated skin at depths
greater than 21 ptm (i.e. deeper than the average stratum comeum depth), indicating that
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the depth of SRB penetration in the non-LTRs of US/SLS-treated skin is similar to the
depth of SRB penetration in untreated skin. This result confirms that SRB penetration in
the non-LTRs of US/SLS-treated skin is confined solely to the stratum corneum, while
SRB penetration in the LTRs of US/SLS-treated skin extends into the viable epidermis.
Combining the results from the depth and intensity of SRB delivered into the LTRs and
the non-LTRs of US/SLS-treated skin relative to untreated skin, one may conclude that
two levels of skin perturbation take place in skin treated simultaneously with ultrasound
and the chemical enhancer, SLS. This result independently confirms the presence of two
levels of enhancement in skin treated simultaneously with ultrasound and SLS made in
Chapter 4 using skin electrical resistivity measurements.
5.3.2.2 Statistical Analysis of the Fluorescence Intensity Profiles for
RBHE
Figure 5-15 shows the average fluorescence intensity profiles of the hydrophobic model
permeant, RBHE, obtained using the methods discussed in Section 5.2.7.1. In each
figure (5-15a - 5-15c), the fluorescence intensity of RBHE is plotted on the y-axis and
the depth from the skin surface (at z = 0 pm), in p.m, is plotted on the x-axis. The error
bars represent one standard deviation in the average value of the RBHE fluorescence
intensity (again, for clarity, only the upper error bars are shown in Figures 5-15a - 5-
15c). Specifically, a bar (solid or dashed) with a single asterisk (*) indicates the range
over which the average fluorescence intensity values from the enhanced skin sample are
statistically different (p<0.05) from the average fluorescence intensity values from the
untreated skin samples. A solid bar with a double asterisk (**) indicates the range over
258
which the average fluorescence intensity values of the LTRs was statistically different
(p<0.05) from the average fluorescence intensity values of the non-LTRs.
In Figure 5-15a, the RBHE intensity profile in SLS-enhanced skin (open
diamonds) is compared to the RBHE intensity profile in untreated skin (black diamonds).
There is a significant increase (p<0.05) in the intensity of RBHE in the first 40 layers of
SLS-treated skin below the skin surface compared to the intensity of RBHE in the first 40
layers of untreated skin below the skin surface (see solid bar with a single asterisk (*) in
Figure 5-15a). The RBHE intensity curves for the SLS-treated skin and for the untreated
skin decrease toward zero intensity in the region in which the stratum corneum is present
(for the location of the stratum corneum in untreated and SLS-treated skin see z = 0 pim -
40 ptm in Figures 5-8 and 5-9). Therefore, this result suggests that RBHE penetration is
restricted to the stratum corneum in SLS-treated and untreated skin, similar to the case of
SRB delivery in SLS-treated and untreated skin.
In Figure 5-15b, the RBHE intensity profiles of the non-LTRs (open triangles)
and of the LTRs (open circles) in US-enhanced skin are compared to the RBHE intensity
profile in untreated skin (black diamonds). Similar to the SRB delivery in US-treated
skin, the intensity of RBHE in the LTRs of US-treated skin was found to be significantly
(p<0.05) greater than the intensity of RBHE in both untreated skin (see solid bar with a
single asterisk (*) in Figure 5-15b) and the non-LTRs of US/SLS-treated skin (see solid
bar with a double asterisk (**) in Figure 5-15b) over the depth of skin imaged. This
result indicates that more RBHE penetrates into both the stratum corneum and the viable
epidermis within the LTRs as a result of US-treatment of the skin relative to both
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Figure 5-15: RBHE fluorescence intensity profiles as a function of skin depth from the
skin surface (at z = 0): (a) SLS-treated skin versus untreated skin, (b) the non-LTRs and
the LTRs of US-treated skin versus untreated skin, and (c) the non-LTRs and the LTRs of
US/SLS-treated skin versus untreated skin. Key: black diamonds - untreated skin
samples, open diamonds - SLS-treated skin samples, open triangles - the non-LTRs, and
open circles - the LTRs. Error bars represent one standard deviation in the average value
of 5 - 7 skin samples. For clarity, only the upper error bars are shown. Single asterisks
(*) indicate the region of significant difference (p<0.05) between RBHE delivery in
enhanced skin and in untreated skin. Double asterisks (**) indicate the region of
significant difference (p<0.05) between RBHE delivery in the non-LTRs and in the
LTRs. In (b) and (c), the dashed line with the single asterisk (*) corresponds to the
confidence interval for the non-LTRs.
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untreated skin and the non-LTRs of US-treated skin. Contrary to the SRB delivery in US-
treated skin, the intensity of RBHE of the non-LTRs of US/SLS-treated skin is also
significantly greater (p<0.05) than the intensity of RBHE of untreated skin (see dashed
bar with a single asterisk (*) in Figure 5-15b) over the entire depth of skin imaged. This
result indicates that more RBHE penetrates into the skin within the non-LTRs as a result
of US-treatment of the skin relative to untreated skin. Combining these results, one may
conclude that two levels of skin perturbation also take place for the RBHE delivery in
US-treated skin, similar to the case of SRB delivery in US/SLS-treated skin.
In Figure 5-15c, the RBHE intensity profiles of the non-LTRs (open triangles)
and of the LTRs (open circles) in US/SLS-enhanced skin are compared to the RBHE
intensity profile in untreated skin (black diamonds). Similar to the SRB delivery in
US/SLS-treated skin, the intensity of SRB in the LTRs of US/SLS-treated skin is
significantly (p<0.05) greater than the intensity of SRB in both untreated skin (see solid
bar with a single asterisk (*) in Figure 5-15c) over the depth of skin imaged and the non-
LTRs of US/SLS-treated skin (see solid bar with a double asterisk (**) in Figure 5-15c)
at depths greater than 4 tim. This result indicates that more RBHE penetrates into the
skin within the LTRs as a result of US/SLS-treatment of the skin relative to both untreated
skin and the non-LTRs of US/SLS-treated skin. In addition, the intensity of RBHE in the
first 21 layers of the non-LTRs of US/SLS-treated skin is significantly greater (p<0.05)
than the intensity of RBHE in the first 21 layers of untreated skin (see dashed bar with a
single asterisk (*) in Figure 5-15c). This result indicates that more RBHE penetrates into
the skin within the non-LTRs as a result of US/SLS-treatment of the skin relative to
untreated skin. Furthermore, the intensity of RBHE in the non-LTRs of US/SLS-treated
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skin is not significantly (p>0.05) different from the intensity of SRB in untreated skin at
depths greater than 21 jim (i.e. deeper than the average stratum corneum depth),
indicating that the depth of RBHE penetration in the non-LTRs of US/SLS-treated skin is
similar to the depth of RBHE penetration in untreated skin. This result confirms that
RBHE penetration in the non-LTRs of US/SLS-treated skin is confined solely to the
stratum corneum, while SRB penetration in the LTRs of US/SLS-treated skin extends into
the viable epidermis. Combining the results from the depth and intensity of RBHE
delivered into the LTRs and the non-LTRs of US/SLS-treated skin relative to untreated
skin, one may conclude that two levels of skin perturbation take place in skin treated
simultaneously with ultrasound and the chemical enhancer, SLS.
5.3.2.3 Impact of Changes in Skin Morphology and Barrier Properties on
the Shape of the Probe Fluorescence Intensity Curves within the
LTRs of US-Treated and US/SLS-Treated Skin
For the delivery of SRB and RBHE in untreated, SLS-treated, and the non-LTRs of US-
treated and US/SLS-treated skin, the fluorescence intensity profiles decrease linearly in
the regions of the skin corresponding to the stratum corneum (see Figures 5-14a - 5-14c
and 5-15a - 5-15c), approaching and maintaining near zero values in the deeper layers of
the skin. However, in Figures 5-14c and 5-15c, after a similar initial linear decrease of
the fluorescent permeant intensity in the LTRs in the region of the skin corresponding to
the stratum corneum (z = 0 to z = 15 - 20 jpm), there is an increase in the fluorescence
intensity with increased skin depth. This unique shape of the fluorescence intensity
profile for SRB and RBHE in the LTRs of US/SLS-treated skin can be attributed to two
effects: (i) changes in the skin morphology as a function of depth, and (ii) differences in
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the penetration of SRB and RBHE into the corneocytes of the SC and into the
keratinocytes of the viable epidermis. First, the diameter of the skin cells increases from
the viable epidermis (diameter = 10-12 ýpm)27 up to the stratum corneum (diameter -
40 ýtm). 34 Also, the intercellular porosity of the viable epidermis (15%)27 is much larger
than the intercellular porosity of the stratum corneum (8-9%).34 This decrease in the cell
diameter, and the corresponding increase in the intercellular porosity, takes place in the
stratum granulosum, which is the layer of the viable epidermis between the stratum
corneum and the stratum spinosum layer of the viable epidermis. The location of this
layer of the skin is in good agreement with the location of the observed increase in the
fluorescence intensity curve for the LTRs in Figures 5-14c and 5-15c. Second, SRB and
RBHE should be able to more easily penetrate across the cell membranes of the
keratinocytes in the viable epidermis than across the cell membranes of the corneocytes
in the stratum corneum. Indeed, it is well known that the corneocyte cell membranes
contain a highly cross-linked network of covalently bound proteins and lipids, which
form a cornified envelope. 2 7 This cornified envelope, which provides a large barrier to
diffusion, begins to form in the upper layers of the stratum spinosum, and continues to
form through the stratum granulosum layer of the viable epidermis. 27 Therefore, as a
result of changes in the skin morphology and in the barrier properties of the skin cell
membranes, the average intensity of SRB and RBHE in the upper layers of the epidermis
could be larger than the average intensity of SRB and RBHE in the lower layers of the
stratum corneum over the same area of the skin.
This effect is also observed in the fluorescence intensity profiles of SRB and
RBHE in the LTRs of US-treated skin (see Figures 5-14b and 5-15b, respectively). In
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these figures, the increase in the intensity of SRB and RBHE in the upper layers of the
viable epidermis is less pronounced. Recall from Section 5.2.4 that for the case of US-
treatment, the skin is exposed to SRB and RBHE for 24 hours prior to imaging, while for
the case of US/SLS-treatment, the skin is exposed to SRB and RBHE for only 5 - 10
minutes prior to imaging. Therefore, for the US-treated experiments, SRB and RBHE
have more time to fully penetrate into the upper layers of the viable epidermis, allowing
for a more uniform distribution of SRB and RBHE in the viable epidermis as a function
of depth. These results also indicate that the shape of the fluorescence intensity profile
curve in the LTRs does not depend on the presence of SLS during US treatment of the
skin, or on the physicochemical properties ofSRB and RBHE.
5.3.2.4 Enhancements in the Vehicle-to-Skin Partition Coefficient, the
Intensity Gradient, and the Effective Diffusion Path Length for
SRB and for RBHE
Tables 5-2 and 5-3 report the values of the enhancement of the vehicle-to-skin partition
coefficient, EK, the enhancement of the intensity gradient, EG, and the enhancement of the
effective diffusion path length, EL for the delivery of SRB and RBHE, respectively, in
each of the three types of enhanced skin samples examined in this study - SLS-treated
skin, US-treated skin, and US/SLS-treated skin. The values reported in Tables 5-2 and 5-
3 were obtained from the experimental data presented in Figures 5-14 and 5-15 using the
methods discussed in Sections 5.2.7.2 - 5.2.7.4. The errors reported for EK, EG, and EL
are presented as +1 standard deviation.
Using Eq. (5.5), the observed increase in the intensity of SRB at the surface in
SLS-treated skin relative to the intensity of SRB at the surface in untreated skin results in
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Table 5-2: Calculated values of the vehicle-to-skin partition coefficient enhancement, the
intensity gradient enhancement, and the effective diffusion path length enhancement for
the delivery of SRB in each of the skin samples examined.a"b
Skin Type
SLS-Treated
US-Treated (non-LTRs)
US-Treated (LTRs)
US/SLS-Treated (non-LTRs)
US/SLS-Treated (LTRs)
a- EK was calculated using Eq. (5.5), EG(5.10).
b - The errors in EK, EG and EL are 1 S.D.
EK
2.34 + 1.93
1.35 + 1.06
4.32 + 2.79
3.69 + 1.47
6.36 + 2.12
was calculated using
EG
2.78 + 0.14
0.86 + 0.05
2.79 + 0.14
4.02 + 0.16
5.26 + 0.26
Eq. (5.6), and EL was
EL
0.84 + 0.70
1.58 + 1.25
1.55 + 1.00
0.92 + 0.37
1.21 + 0.41
calculated using Eq.
a value of EK which is greater than 1 (see Table 5-2). Additionally, there is a
corresponding enhancement in the intensity gradient (EG > 1) for SLS-treated skin, but no
difference in the effective diffusion path length of SRB (see Table 5-2). Therefore, using
Eq. (5.12), the observed increase in the intensity gradient is directly due to the increased
partitioning of SRB at the surface of SLS-treated skin, suggesting that SLS primarily
enhances the delivery of SRB into the skin by increasing the vehicle-to-skin partition
coefficient. For the case of SRB delivery in US-treated skin, the values for EK and EL
corresponding to the non-LTRs of US-treated skin are not different from unity, indicating
that the values of K and L corresponding to the delivery of SRB in the non-LTRs of US-
treated skin are not significantly different from the values of K and L corresponding to
the delivery of SRB in untreated skin. For the case of EG, there is a slight decrease in the
value of the intensity gradient in the non-LTRs of US-treated skin, as compared to
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untreated skin. These results further indicate that the non-LTRs of US-treated skin are
similar to untreated skin. For the delivery of SRB in the LTRs of US-treated skin, both
the values of EK and EG are greater than unity, while EL is not different from unity. In
addition, the values of EK, EG, and EL corresponding to the delivery of SRB in the LTRs
of US-treated skin behave similarly to the values of EK, EG, and EL corresponding to the
delivery of SRB in SLS-treated skin. This similarity suggests that US also enhances
transdermal delivery, in part, by increasing the vehicle-to-skin partition coefficient. For
the case of SRB delivery in US/SLS-treated skin, Table 5-2 indicates that the values of
EK and EG for the non-LTRs and the LTRs are both greater than unity. However, the
values for EK and EG for the non-LTRs are both lower than the values of EK and EG for
the LTRs, further confirming the existence of two levels of skin perturbation in skin
treated simultaneously with ultrasound and the chemical enhancer, SLS.
For the case of RBHE delivery in SLS-treated skin, the values of EK, EG, and EL
are not different from unity, suggesting that SLS has little effect on the amount of RBHE
delivered into the skin relative to untreated skin. For the case of RBHE delivery in US-
treated skin, a significant enhancement of the values of EK and EG corresponding to both
the non-LTRs and the LTRs is observed in Table 5-3. There is also a reduction in the
effective diffusion path length, L, in the non-LTRs of US-treated skin relative to
untreated skin. However, this result is due to the difference in the thickness of the
stratum corneum in the skin used for the US-treated skin samples and in the skin used for
the untreated skin samples. Recall that the stratum corneum is observed up to a depth of
40 ýtm in the skin auto-fluorescence images of untreated skin presented in Figures 5-8. In
addition, the values of EK and EG are greater for the LTRs relative to the non-LTRs,
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Table 5-3: Calculated values of the vehicle-to-skin partition coefficient enhancement, the
intensity gradient enhancement, and the effective diffusion path length enhancement for
the delivery of RBHE in each of the skin samples examined.a"b
Skin Type
SLS-Treated
US-Treated (non-LTRs)
US-Treated (LTRs)
US/SLS-Treated (non-LTRs)
US/SLS-Treated (LTRs)
a - EK was calculated using Eq. (5.5), EG
(5.10).
b - The errors in EK, EG and EL are 1 S.D.
EK
1.23 + 0.63
32.5 + 8.5
82.5 + 28.0
33.0 + 13.1
34.9 + 12.8
was calculated using
EG
1.35 + 0.24
56.6 + 4.1
78.8 + 3.4
78.5 + 8.16
60.7 + 7.6
Eq. (5.6), and EL was
EL
0.91 + 0.49
0.57 + 0.16
1.05 + 0.36
0.42 + 0.17
0.57 + 0.22
calculated using Eq.
which confirms that two levels of skin perturbation are also present in skin treated with
ultrasound for the delivery of RBHE. For the case of RBHE delivery in US/SLS-treated
skin, Table 5-3 indicates that the values of EK and EG for the non-LTRs and the LTRs are
both greater than unity. In addition, the value for EG for the non-LTRs is different from
the value of EG for the LTRs, further confirming the existence of two levels of skin
perturbation in skin treated simultaneously with ultrasound and the chemical enhancer,
SLS.
5.3.2.5 Impact of Ethanol, a Chemical Enhancer, on the Delivery of RBHE
From a comparison of the results for the delivery of SRB and RBHE reported in Sections
5.3.2.1, 5.3.2.2, and 5.3.2.4, there are two cases where the results for SRB and RBHE
differ. The first case is for SLS-treated skin relative to untreated skin. In this case, SLS
has a large impact on the delivery of SRB (see Figure 5-14a and Table 5-2), but does not
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have a large impact on the delivery of RBHE (see Figure 5-15a and Table 5-3), relative to
untreated skin. The second case is for the non-LTRs of US-treated skin relative to
untreated skin. In this case, SRB delivery in the non-LTRs of US-treated skin is similar
to the delivery of untreated skin (see Figure 5-14b and Table 5-2), while RBHE delivery
in the non-LTRs of US-treated skin is increased relative to untreated skin (see Figure 5-
15b and Table 5-3).
The observed differences can be attributed to the presence of ethanol in the RBHE
donor solution. Recall from Section 5.2.3 that ethanol was used in a 50:50 mixture with
PBS to solubilize RBHE, which is a hydrophobic permeant. However, ethanol can also
serve as a chemical enhancer for the transdermal delivery of hydrophobic permeants.
35-40
Noting that ethanol was present at a concentration of 50% (v/v) while SLS was present
only at a concentration of 1% (w/v), the enhancing effect of SLS on the transdermal
delivery is expected to be small relative to the enhancing effect of ethanol. This can
explain why the RBHE fluorescence intensity profiles for the SLS-treated skin and for
the untreated skin in Figure 5-15a are similar, as well as explain why the values of EK,
EG, and EL for SLS-treated skin are not different from unity in Table 5-3. Furthermore,
the presence of ethanol in the RBHE coupling medium during US-treatment can also
explain the increased penetration of RBHE into the non-LTRs of US-treated skin relative
to untreated skin, albeit not to the same extent observed in the LTRs of US-treated skin.
This result for RBHE is similar to the observation for SRB delivery in skin treated
simultaneously with ultrasound and with a chemical enhancer, SLS. Therefore, ethanol
also acts as a chemical enhancer to create two levels of perturbation for the case of
RBHE delivery in US-treated skin.
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5.3.2.6 Summary of Results from the Qualitative Analysis of SRB and
RBHE Delivery in Untreated, SLS-Treated, US-Treated, and
US/SLS-Treated Skin
From a quantitative analysis of the SRB and RBHE fluorescence permeant intensity
profiles (see Figures 5-14 and 5-15) and the enhancements in the vehicle-to-skin partition
coefficient, the intensity gradient, and the effective diffusion path length (see Tables 5-2
and 5-3), the following key observations can be made: 1) two levels of perturbation,
measured by probe delivery into the skin, are observed in skin samples treated
simultaneously with ultrasound and a chemical enhancer (i.e. ethanol or SLS), and 2) in
the absence of a chemical enhancer, ultrasound enhances only discrete regions (the
LTRs) of the treated skin sample, while the remaining regions of the skin (the non-LTRs)
are not significantly perturbed compared to untreated skin.
5.3.3 Investigation of the Existence of Transcellular Permeation Pathways
in the Stratum Corneum
Figures 5-16 and 5-17 show plots of the normalized average fluorescence intensity across
a five pixel wide slice of the dual-channel TPM images of SRB and RBHE, respectively,
as a function of the length of the slice, given in pixel numbers (i.e. 0 - 255). The case of
SRB and RBHE delivery in untreated skin are presented in Figures 5-16a and 5-17a,
respectively. The case of SRB and RBHE delivery in SLS-treated skin are presented in
Figures 5-16b and 5-17b, respectively. The case of SRB and RBHE delivery in the non-
LTRs of US-treated skin are presented in Figures 5-16c and 5-17c, respectively. The
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ire 5-16: SRB and skin auto-fluorescence intensity (plotted on the y-axis) as
function of the pixel number along the length of the image slice (plotted on the x-axis).
Key: red - SRB, green - skin auto-fluorescence. (a) Untreated skin, (b) SLS-treated
skin, (c) the non-LTRs of US-treated skin, (d) the LTRs of US-treated skin, (e) the non-
LTRs of US/SLS-treated skin, and (f) the LTRs of US/SLS-treated skin.
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Figure 5-17: RBHE and skin auto-fluorescence intensity (plotted on the y-axis) as a
function of the pixel number along the length of the image slice (plotted on the x-axis).
Key: red - RBHE, green - skin auto-fluorescence. (a) Untreated skin, (b) SLS-treated
skin, (c) the non-LTRs of US-treated skin, (d) the LTRs of US-treated skin, (e) the non-
LTRs of US/SLS-treated skin, and (f) the LTRs of US/SLS-treated skin.
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case of SRB and RBHE delivery in the LTRs of US-treated skin are presented in Figures
5-16d and 5-17d, respectively. The case of SRB and RBHE delivery in the non-LTRs of
US/SLS-treated skin are presented in Figures 5-16e and 5-17e, respectively. The case of
SRB and RBHE delivery in the LTRs of US/SLS-treated skin are presented in Figures 5-
16f and 5-17f, respectively. In each figure, the normalized average fluorescence intensity
is plotted on the y-axis, while the pixel number along the length of the slice, ranging in
value from 0-255, is plotted on the x-axis. The red curves in Figures 5-16 and 5-17
correspond to the normalized average fluorescence intensity curves of SRB and RBHE,
respectively. The green curves in Figures 5-16 and 5-17 correspond to the normalized
average fluorescence intensity curves of the skin auto-fluorescence.
Table 5-4 reports the measured values of the average height and the average width
of the peaks in the red curves from Figure 5-16, corresponding to the delivery of SRB,
and from Figure 5-17, corresponding to the delivery of RBHE, which were obtained
using the methods discussed in Section 5.2.7.5. The values are reported as the average
measurements, +1 standard deviation, of the height and the width of 3 - 5 peaks, which
were determined by the actual number of peaks present in Figures 5-16 and 5-17. Values
of peak widths and peak heights shown in bold are significantly different (p<0.05) from
the values of peak widths and peak heights corresponding to SRB and RBHE delivery in
untreated skin.
As the results in Table 5-4 show, the heights of the SRB peaks in SLS-treated skin
are significantly lower (p<0.05) than the heights of the SRB peaks in untreated skin.
Likewise, the widths of the SRB peaks in SLS-treated skin are significantly higher
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Table 5-4: Measured values of the average peak height and of the average peak widtha
for the delivery of SRB and RBHE at the surface (z = 0 p~m) of the skin samples
examined in Figures 5-16 and 5 -17 .b c
SRB RBHE
Skin Type Heightd Widthe Heightd Widthe
Untreated Skin 0.61 + 0.07 17+3 0.65 + 0.15 14+5
SLS-Treated 0.46 + 0.07 30 + 6 0.82 + 0.09 8 + 1
US-Treated (non-LTRs) 0.79 + 0.16 16 + 5 0.68 + 0.24 25 + 15
US-Treated (LTRs) 0.25 + 0.11 38 + 4 no discernible peaks
US/SLS-Treated (non-LTRs) 0.53 + 0.12 17 + 5 0.65 + 0.28 23 + 11
US/SLS-Treated (LTRs) 0.24 + 0.05 21 + 5 0.58 + 0.14 30 + 9
a - The peak width was evaluated at half of the height of the peaks.
b - The errors are presented as I S.D. in the average.
c - Values in bold are significantly different (p<0.05) from the values for untreated skin.
d - The height is presented as a dimensionless quantity, normalized by the maximum value of the
fluorescent permeant intensity at z = 0 rlm.
e - The width is presented in units of pixels.
(p<0.05) than the widths of the SRB peaks in untreated skin. These quantitative results
indicate that more SRB is able to penetrate into the corneocytes at the surface of SLS-
treated skin samples, than at the surface of untreated skin samples. Mechanistically, this
result suggests that SLS increases the partitioning of SRB, a hydrophilic permeant, from
the intercellular region (a hydrophobic environment) and into the corneocyte domain (a
hydrophilic environment). In Table 5-5, a significant increase (p<0.05) in the penetration
of SRB into the corneocytes is also observed down to a depth of 3 pm in SLS-treated skin
relative to untreated skin. This result suggests that transcellular permeation pathways
play a larger role in the transdermal delivery of SRB in SLS-treated skin than in
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Table 5-5: Measured Values of the Depth of Transcellular Pathways in the Stratum
Corneum.a
Skin Type SRB RBHE
SLS-Treated 3 [tm N/A
US-Treated (LTRs) 5 ptm 5 gm
US/SLS-Treated (LTRs) 2 glm 3 p.m
a - Depth of the transcellular pathways was determined by comparing the heights and the widths of the
fluorescent permeant intensity peaks in the enhanced skin with the heights and the widths of the
fluorescent permeant intensity peaks in untreated skin as a function of skin depth. Transcellular
pathways are deemed present in a layer if either the height of the peaks is significantly smaller
(p<0.05), or the width of the peaks is significantly larger (p<0.05), than the height and the width of the
peaks in untreated skin.
untreated skin. For the case of RBHE delivery in SLS-treated skin relative to untreated
skin, measurements of the average peak heights and the average peak widths reported in
Table 5-4 indicate that the width of the RBHE fluorescence peaks in SLS-treated skin is
significantly smaller (p<0.05), and that the height of the RBHE fluorescence peaks is
approximately 20% larger, than the RBHE peaks in untreated skin. This result suggests
that SLS localizes RBHE within the intercellular lipid domain of the stratum corneum,
suggesting that intercellular transport dominates the delivery of RBHE in SLS-treated
skin. These results for the delivery of SRB and RBHE in SLS-treated skin are consistent
with previous studies on the role of the chemical enhancer, oleic acid, on the transdermal
delivery of SRB.'13 14
For the delivery of SRB and RBHE in the non-LTRs of US-treated skin and
US/SLS-treated skin, there is no significant difference (p>0.05) in the heights and the
widths of the fluorescence peaks in Figures 5-16c and 5-15e when compared to the
heights and the widths of the SRB fluorescence peaks in Figure 5-16a (see also Table 5-
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4). For the delivery of RBHE in the non-LTRs of US-treated skin and US/SLS-treated
skin, there is no significant difference (p>0.05) in the heights and in the widths of the
fluorescence peaks in Figures 5-17c and 5-17e when compared to the heights and the
widths of the SRB fluorescence peaks in Figure 5-17a (see also Table 5-4). This data
provides further evidence that the delivery of SRB and RBHE in the non-LTRs in US-
treated skin occurs primarily via the intercellular route, similar to untreated skin.
The existence of transdermal pathways at the surface of the LTRs in US-treated
and US/SLS-treated skin for both SRB and RBHE is confirmed quantitatively from the
measurements of the heights and the widths of the fluorescence peaks in Figures 5-16d,
5-16f, 5-17d, and 5-17f. A comparison of the data reported in Table 5-4 for the delivery
of SRB in untreated skin and in the LTRs of US-treated skin demonstrates that the peak
widths are significantly larger (p<0.05), and the peak heights are significantly smaller
(p<0.05), in the US-treated skin samples than in the untreated skin samples. For the case
of RBHE delivery in the LTRs of US-treated skin, there are no discernable peaks present
in Figure 5-17d, due to the uniform distribution of RBHE in the corneocytes and in the
intercellular regions. Therefore, no peak width or peak height is reported in Table 5-4.
Comparing the values of the heights and the widths of the peaks in the SRB fluorescence
curve for the LTRs of US/SLS-treated skin (see Figure 5-16f) and untreated skin (see
Figure 5-16a) presented in Table 5-4, the heights of the peaks in the LTRs of US/SLS-
treated skin are significantly lower (p<0.05) than the heights of the peaks in untreated
skin, and the widths of the peaks are 25% larger in the LTRs of US/SLS-treated skin than
in untreated skin. These results suggest that more SRB is present in the corneocytes at
the surface of the LTRs of US/SLS-treated skin relative to untreated skin than in the
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corneocytes at the surface of the non-LTRs of US/SLS-treated skin relative to untreated
skin. Comparing the measurements of the heights and the widths of the peaks in the
RBHE fluorescence curves in the non-LTRs and in the LTRs of US/SLS-treated skin (see
Figures 5-17e and 5-17f, respectively) with the measurements of the heights and the
widths of the peaks in the RBHE fluorescence curves in untreated skin (see Figure 5-17a)
reported in Table 5-4, no significant difference (p>0.05) is observed between the values
of the peak heights and the peak widths for untreated skin and for the non-LTRs of
US/SLS-treated skin, while a significant increase (p<0.05) in the peak widths and an
insignificant decrease (p>0.05) in the peak height are observed in the LTRs of US/SLS-
treated skin relative to untreated skin. These trends are indicative of increased
penetration of SRB and RBHE in the corneocytes at the surface of the LTRs of US-
treated and US/SLS-treated skin relative to the penetration of SRB and RBHE in the
corneocytes at the surface of untreated skin. A significant increase (p<0.05) in the
penetration of SRB into the corneocytes down to a depth of 5 jtm and 2 [tm is also
observed in the LTRs of US-treated and of US/SLS-treated skin relative to untreated skin,
respectively. Likewise, a significant increase (p<0.05) in the penetration of RBHE into
the corneocytes down to a depth of 5 [tm and 3 jim is also observed in the LTRs of US-
treated and of US/SLS-treated skin relative to untreated skin, respectively. Using the
penetration of SRB and RBHE in the corneocytes as a marker for transcellular
permeation pathways in the stratum corneum, these results further suggest that
transcellular permeation pathways are utilized in the delivery of SRB and RBHE in the
L TRs in US-treated skin. This observation, resulting from an analysis of the dual-channel
TPM images, independently confirms that transcellular pathways are traversed by
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hydrophilic permeants in the LTRs of US/SLS-treated skin, as previously suggested from
an analysis of the skin electrical resistivity data in the context of the aqueous-pore
pathway hypothesis (see Chapter 4 for details).
5.3.4 Proposed Mechanisms of Enhancement in SLS-Treated, US-Treated,
and US/SLS-Treated Skin
A possible mechanism for the observed difference in the location of SRB and RBHE in
SLS-treated skin is that SLS facilitates the diffusion of water into the corneocytes of
SLS-treated skin by disrupting the cornified envelope which surrounds the corneocytes.
Indeed, there is ample evidence that SLS increases the hydration of the stratum
corneum.4 1-46 If these observed hydration effects are localized to the corneocytes, the
corneocytes in SLS-treated skin will become more hydrophilic, due to the increased
amount of water present inside the corneocytes. As a result of the increased
hydrophilicity of the SLS-treated corneocytes, SRB, a hydrophilic molecule, should
partition more favorably into the corneocytes of the SLS-treated skin than into the
corneocytes of the untreated skin. Likewise, RBHE, a hydrophobic molecule, should
partition less favorably into the more hydrophilic corneocytes of the SLS-treated skin
than into the corneocytes of the untreated skin. The proposed mechanism of SLS
disrupting the cornified envelope of the corneocytes to increase water partitioning into
the corneocytes provides a simple, single mechanism that can be invoked to effectively
explain the observation and results obtained from an analysis of the dual-channel TPM
images for the delivery of SRB and of RBHE in SLS-treated skin and in untreated skin.
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From previous studies of ultrasound-enhanced transdermal drug delivery, it has
been demonstrated that transient acoustic cavitation events near the skin surface are the
primary mechanism for the enhancement of transdermal transport.28-30 An analysis of
dual-channel TPM imaging of the delivery of SRB in US-treated skin suggests that
transient acoustic cavitation events near the skin surface are localized to discrete regions
of the ultrasound-treated skin. In these regions of the skin, the LTRs, which are regions
of high transdermal permeability, 24 are formed as a result of the ultrasound exposure. For
the delivery of SRB, the remaining regions of US-treated skin, the non-LTRs, are
comparable to untreated skin, both in the intensity of SRB and in the depth of the SRB
penetration, suggesting that little to no transient acoustic cavitation events take place near
the surface of this region of US-treated skin.
Similar to the delivery of SRB in US-treated skin, LTRs are observed in skin
treated simultaneously with ultrasound and a chemical enhancer (i.e. SLS or ethanol).
These results suggest that ultrasound-induced localized transient acoustic cavitation
events near the skin surface are required for the formation of LTRs. Contrary to the
delivery of SRB in US-treated skin, the intensity of SRB and RBHE in the non-LTRs in
skin treated simultaneously with ultrasound and a chemical enhancer was found to be
higher than the intensity of SRB and RBHE in untreated skin. This result suggests the
presence of a chemical enhancer in the coupling medium during ultrasound treatment of
the skin is required to achieve two levels of enhancement in skin treated with ultrasound.
Acoustic streaming in the coupling medium, another effect of ultrasound treatment of the
skin, may be responsible for enhancing the delivery of the chemical enhancer into the
skin during ultrasound treatment. Specifically, the existence of acoustic streaming in the
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coupling medium during ultrasound treatment provides an additional convective driving
force to assist in the penetration of the chemical enhancer into the skin. Once the
chemical enhancer has penetrated the skin, it is then able to enhance the transdermal
delivery of SRB and RBHE by disordering the intercellular lipid bilayers, disrupting the
corneocyte cornified envelope, or extracting lipids from the stratum corneum. Therefore,
the enhancement of the non-LTRs in skin treated simultaneously with ultrasound and
with a chemical enhancer may be due to increased transdermal penetration of the
chemical enhancer, which results from convective driving forces that are supplied by
acoustic streaming in the coupling medium during ultrasound exposure.
For the delivery of SRB and RBHE in skin treated with ultrasound and a chemical
enhancer (i.e. SLS or ethanol), SRB and RBHE penetration in the non-LTRs was found
to be restricted to the stratum corneum similar to untreated skin, while SRB and RBHE
penetration in the LTRs extended into the viable epidermis. The penetration of SRB and
RBHE into the viable epidermis of the LTRs in both US-treated and US/SLS-treated skin
may be the result of high-velocity microjets, which form during transient cavitation
bubble collapse, impinging repeatedly on the surface of the skin where transient acoustic
cavitation events take place. Additionally, the high-velocity microjets may be
responsible for the formation of transcellular permeation pathways near the skin surface
in the LTRs of US-treated and US/SLS-treated skin. Since the corneocytes represent
over 99% of the skin surface, it is highly probable that the high-velocity microjets contact
the skin primarily in the corneocyte region, rather than in the intercellular lipid region,
pushing the fluorophore-containing coupling medium into the corneocytes near the skin
surface.
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5.4 Conclusions
Dual-channel two-photon microscopy images were generated and analyzed to compare
the transdermal delivery of SRB, a fluorescent hydrophilic permeant, and RBHE, a
fluorescent hydrophobic permeant, in skin treated with SLS (a chemical enhancer),
ultrasound, and the simultaneous application of ultrasound and SLS, with the transdermal
delivery of SRB and RBHE in untreated skin. From an analysis of the dual-channel TPM
images as a function of skin depth for SRB and for RBHE, it was observed that both SRB
and RBHE penetrate into the viable epidermis in the LTRs of US-treated and of US/SLS-
treated skin, while the penetration of SRB and RBHE was confined solely to the stratum
corneum in untreated skin, in SLS-treated skin, and in the non-LTRs of US-treated and
US/SLS-treated skin.
From an analysis of the average fluorescence intensity profiles and the values of
EK, EG, and EL, which were obtained from the average fluorescence intensity profiles, it
was observed that two significant levels of skin perturbation exist when the skin is treated
simultaneously with ultrasound and with a chemical enhancer (i.e. SLS or ethanol).
Greater perturbation of the skin was observed in the LTRs of skin treated with ultrasound
and a chemical enhancer relative to the extent of skin perturbation observed in the non-
LTRs of skin treated with ultrasound and a chemical enhancer. These results are
consistent with our previous conclusions reached using the skin electrical resistivity
measurements of the non-LTRs and the LTRs presented in Chapter 4. In the absence of a
chemical enhancer during ultrasound treatment of the skin, the non-LTRs were found not
to be significantly enhanced by ultrasound, as compared to untreated skin. This result
suggests that ultrasound, in the absence of a chemical enhancer, discretely enhances the
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skin through the mechanism of transient acoustic cavitation near the skin surface. This
result also suggests that the presence of a chemical enhancer in the coupling medium
during ultrasound treatment of the skin is required to obtain two levels of significant
enhancements in the perturbation of the skin structure.
Finally, by comparing the heights and the widths of the fluorescence intensity
peaks obtained from the dual-channel TPM images, transcellular pathways were observed
in the LTRs of US-treated and of US/SLS-treated skin for both SRB and RBHE, as well
as in SLS-treated skin for SRB. These observations provided confirmation of the results
presented in Chapter 4 based on an analysis of the skin electrical resistivity data in the
context of the aqueous-pore pathway hypothesis, which suggested that transcellular
pathways may be present in the LTRs of skin treated simultaneously with ultrasound and
a chemical enhancer.
In the next chapter, the differences of the non-LTRs and the LTRs formed in skin
treated simultaneously with ultrasound and SLS will be investigated further to build on
the knowledge gained in this chapter and in Chapter 4. Specifically, the aqueous-pore
pathway hypothesis will be utilized to analyze the differences in the porosity, the
tortuosity, and the pore distribution for the aqueous pore pathways in the non-LTRs and
in the LTRs to gain additional mechanistic information on how the US/SLS enhancement
system can produce two different levels of perturbation in the skin.
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Chapter 6
Evaluation of the Porosity, the Tortuosity, and the
Hindrance Factor for the Transdermal Delivery of
Hydrophilic Permeants in the LTRs and in the Non-
LTRs of Skin Treated Simultaneously with a
Chemical Enhancer and Low-Frequency Ultrasound
6.1 Introduction
In Chapter 4, I demonstrated that the red spots that are formed in skin treated
simultaneously with a chemical enhancer and low-frequency ultrasound in the presence
of the hydrophilic fluorescent probe, sulforhodamine B (SRB), are indeed localized
regions of high permeability. Using calcein, another hydrophilic fluorescent probe, I also
demonstrated that the localized transport regions (LTRs) are approximately 80-fold more
permeable than the surrounding regions of the skin (the non-LTRs).' The difference in
the enhancements of the LTRs and the non-LTRs due to treatment of the skin with a
chemical enhancer and low-frequency sonophoresis was confirmed using skin electrical
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resistivity measurements.' For these measurements, the skin electrical resistivity in the
LTRs was found to be approximately 30-fold lower than in the non-LTRs.' This result is
consistent with the skin permeability measurements utilizing calcein, since the skin
electrical resistivity is inversely proportional to the skin permeability. In addition, the
skin electrical resistivity measurements indicated that both the LTRs and the non-LTRs
were significantly enhanced relative to untreated skin. Specifically, the skin electrical
resistivity of the non-LTRs was found to be approximately 170-fold lower than that of
untreated skin, while the skin electrical resistivity of the LTRs was found to be
approximately 5000-fold lower than that of untreated skin.' This important result
indicated that there are two levels of enhancement in skin treated simultaneously with a
chemical enhancer and low-frequency ultrasound, which was subsequently confirmed in
Chapter 5 using two-photon microscopy. Using the results of the skin electrical
resistivity measurements, values of the porosity-to-tortuosity ratio, (c/t), were determined
in the non-LTRs and in the LTRs,' and compared to the threshold value of (s/t) for the
intercellular regions of the stratum corneum, 2 which was obtained in Chapter 3. This
analysis suggested that transcellular pathways may be present in the LTRs formed in skin
treated simultaneously with a chemical enhancer and low-frequency ultrasound. The
presence of transcellular pathways in the LTRs was subsequently confirmed in Chapter 5
using two-photon microscopy.3
In light of the work discussed above, it would be instructive to deepen our
understanding of the differences between the LTRs and the non-LTRs by further
examining the differences in the porosity, the tortuosity, and the aqueous pore radii in
these two regions of ultrasound/chemical enhancer treated skin. In Chapter 4, because a
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single fluorescent permeant was delivered across the skin, only the ratio, (s/r), could be
determined from the available experimental permeation data. By utilizing the theoretical
and experimental methods introduced in Chapter 2 to carry out and analyze permeability
experiments using two radiolabeled permeants, in conjunction with the methods
introduced in Chapter 4 to analyze the sizes of the LTRs and the non-LTRs, as well as to
carry out diffusion masking experiments, it will be possible to separately evaluate the
porosity, E, the tortuosity, t, and the aqueous pore radii, rpore, in the non-LTRs and in the
LTRs (see Materials and Methods, Section 6.2). Specifically, the permeability data
obtained from the LTRs and the non-LTRs (see Section 6.3.1) will be analyzed using the
three approaches presented in Chapter 2. In the first approach (see Section 6.3.2), the
steady-state permeability data are analyzed using the methods of Peck et al.4 and Tang et
al.,5 who assumed that the porosity and the tortuosity of the aqueous pore channels are
independent of the radii of the permeants which are delivered across the skin, to evaluate
a single average pore radius for the aqueous pore channels present in the skin. In the
second approach (see Section 6.3.3), the methods presented in Section 2.4.6 are used to
evaluate the porosity, the tortuosity, and the hindrance factor, H(Q), for the case of a
distribution of pore radii, as proposed by Tezel et al.6 In the final approach (see Section
6.3.4), the methods of Section 2.4.6 are used to evaluate the porosity and the tortuosity as
a function of the extent of skin perturbation and of the radius of the permeant for the
limiting case of infinitely-large aqueous pores, where rpore -0 oo and H(X) = 1. The results
of these investigations will highlight the differences in the structure of the aqueous pore
channels present in the LTRs and in the non-LTRs, which should further increase our
mechanistic understanding of how these two distinct regions of the skin are formed as a
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result of a single treatment of low-frequency ultrasound in the presence of a chemical
enhancer (see Section 6.3.5).
6.2 Materials and Methods
6.2.1 Chemicals
Four hydrophilic permeants, 14C-Urea (MW = 60.1 Da), 3H-Mannitol (MW = 182.2 Da),
3H-Raffinose (MW = 504.4 Da), and 3H-Inulin (MW = 5,000 Da), were obtained from
American Radiolabeled Chemicals, Inc. (St. Louis, MO). Phosphate Buffer Saline and
Sodium Lauryl Sulfate (SLS) were obtained from Sigma-Aldrich (St. Louis, MO).
Sulforhodamine B (SRB) was obtained from Molecular Probes (Eugene, OR). All these
chemicals were used as received.
6.2.2 Skin Preparation
Full-thickness human cadaver skin was obtained from the National Disease Research
Institute (Philadelphia, PA) and stored at -800 C until use. Prior to use in the diffusion
experiments, the skin was thawed and the subcutaneous fat was removed from the skin
using a razor blade. The skin was then sectioned and mounted in vertical Franz diffusion
cells (15-mm inner diameter) obtained from Permegear (Bethlehem, PA).
6.2.3 Skin Electrical Resistivity Measurements
Prior to ultrasound pre-treatment, the electrical resistance of the skin mounted on the
diffusion cells was measured according to previously published methods,7 which are
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summarized next. A 100 mV AC voltage source at 10 Hz was generated using a signal
generator (Hewlett-Packard, model HP 33120A) and applied across the skin membrane
using two Ag/AgCl electrodes (In Vivo Metrics, Healdsburg, CA) for 5-10 seconds. The
skin electrical current was measured using a Fluke Multimeter (Model 139, Fluke
Corporation). The skin electrical resistance was obtained from the skin electrical current
using Ohm's Law. Since this measurement also includes the resistance of the donor and
the receiver cell solutions, a background electrical resistance measurement of just the
PBS solution was made separately, and was then subtracted from the electrical resistance
of the skin in the diffusion cell to determine the actual skin electrical resistance. The
electrical resistance, R, of all the skin samples was measured and multiplied by the skin
area available to ultrasound exposure in the diffusion cell (A = 1.77 cm 2) to obtain the
skin electrical resistivity. Any skin sample with an initial RA value of <50 kOhm*cm2,
corresponding to an initial current of 3.3 jtAmps, was considered damaged and was
discarded, and was subsequently replaced with an intact skin sample.7
6.2.4 Ultrasound Pre-Treatment Protocol
Ultrasound, in the presence of a coupling medium containing 1% (w/v) SLS and 0.5%
(w/v) SRB in PBS, was applied to the intact human full-thickness skin samples following
previously published methods. 8' 9 Ultrasound (VCX 400, Sonics and Materials, Inc.,
Newtown, CT) was applied to the skin samples at the following conditions: frequency -
20 kHz, intensity - 7.2 W/cm 2, pulse length - 5 sec on, 5 sec off, and tip displacement - 3
mm,8'9 until the skin electrical current reached approximately - 225 ýtAmps. This value
of the skin electrical current was selected because it was the lowest value of the skin
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electrical current investigated in Chapter 4 for the formation of LTRs in ultrasound-
treated skin.' After each minute of ultrasound exposure, the coupling medium was
changed to minimize the impact of thermal effects on the permeation enhancement of the
skin,8'9 and measurements of the skin electrical current were conducted to determine if
the target skin electrical current had been reached. Once the desired skin electrical
current was attained, the skin sample was removed from the diffusion cell and was rinsed
for 15 minutes in PBS to remove all excess coupling medium from the skin surface in
preparation for digital imaging of the skin surface to quantify the areas of the LTRs and
the non-LTRs (see Section 4.2.5 for details).
6.2.5 Dual Radiolabeled Masking Experiments
Following digital imaging of the skin surface, the ultrasound-treated skin samples were
divided into two groups: A) non-LTRs and B) LTRs. The surface of the skin was masked
with vacuum grease (High Vacuum Grease, Dow Coming, Midland, MI) according to the
methods presented in Section 4.2.6.' In the non-LTR group, the LTRs were masked with
vacuum grease to permit permeation only through the non-LTRs, while for the LTR
group, the non-LTRs were masked with vacuum grease to permit permeation only
through the LTRs.
After masking of the skin, dual radiolabeled diffusion experiments were carried
out using vertical Franz diffusion cells. In each experiment, urea, which is carbon-14
labeled, was paired with a tritium-labeled permeant - mannitol, raffinose, or inulin. 2 ml
of a solution containing 1 jtCi/ml of urea and 1 p~Ci/ml of one of the three tritium-labeled
permeants was placed in the donor chamber. Aliquots (-400 gtL) of the receiver chamber
294
were taken at predetermined time points over a period of 48 hours to ensure transition
into the steady-state regime for each of the permeants and skin sample types considered.
The radioactivity of these aliquot samples was then measured using the dual radiolabeled
counting mode in a scintillation counter (Packard, Tri-Carb®, 2200 CA) to measure the
cumulative mass of permeant delivered into the receiver cell as a function of time, M(t).
To evaluate the cumulative mass of permeant per unit area, Q(t), delivered through the
LTRs and the non-LTRs, the following expressions are used:
M(t)Q(t),M, - (6.1)AL,7 r.
M(t)Q( t) ,oL 7, - (6.2)Anon-l.'Rs
where ALTRs and Anon-LTRs are the areas of the skin surface available for transport in the
LTRs and in the non-LTRs, respectively. Plots of Q(t)LTRs and Q(t)non-LTRs versus time
were then generated from the results of the scintillation counting of the aliquots taken
from the receiver cells.
6.2.6 Regression Analysis of the Experimental Diffusion Data to Evaluate
the Steady-State Permeability, the Porosity, the Tortuosity, and the
Aqueous Pore Radii in the LTRs and in the Non-LTRs
As in Chapter 2, the Q(t) versus time data generated from the dual radiolabeled masking
experiments were analyzed using DataFit 8.1 (Oakdale Engineering). Equations (2.35a)
and (2.35b) were used as the model equations for the nonlinear regression analysis, and
the quantities, (sCdrL) and [DH(X)/(rL) 2], were selected as the regression parameters for
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analysis of the experimental data sets. DataFit 8.1 uses the Levenberg-Marquardt
method as the algorithm to adjust the values of the initial estimates of the regression
parameters to improve the fit of the nonlinear regression model. Once (SCdTL) and
[D'H(X)/(tL) 2] were determined for both urea and the selected tritium-labeled permeant,
the porosity, the tortuosity, and the aqueous pore radii in the non-LTRs and in the LTRs
could be determined using the theoretical methods presented in Eqs. (2.36) - (2.40) (see
Section 2.4.6).
6.3 Results and Discussion
6.3.1 Dual Radiolabeled Diffusion Experimental Data
Figures 6-la and 6-lb show the cumulative amounts of radiolabeled permeant delivered
across the skin, Q(t), as a function of time, t, for the LTRs and for the non-LTRs,
respectively. In each plot, the black diamonds correspond to the delivery of urea, the
open circles correspond to the delivery of mannitol, the open squares correspond to the
delivery of raffinose, and the open triangles correspond to the delivery of inulin. Each
data point represents an average of 5 - 6 skin samples. Representative error bars,
corresponding to + 1 S.D., have been included to provide an estimate of the error in the
average value of Q(t).
From the data presented in Figures 6-la and 6-1b, two trends may be observed.
First, in both Figures 6-la and 6-1 b, Q(t) decreases as the size of the permeant increases.
This observation follows the expected trend that permeability decreases as the radius of
the permeant increases, since larger permeants generally have smaller diffusion
coefficients, according to the Stokes-Einstein equation.' 0 Second, the value of Q(t)
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Figure 6-1: Plots of the cumulative amount of hydrophilic permeant, Q(t), delivered
across the skin as a function of time, t, normalized by the initial donor concentration, Cd.
(a) LTRs and (b) non-LTRs. Key: Urea - black diamonds, mannitol - open circles,
raffinose - open squares, inulin - open triangles. Sample error bars correspond to + 1
S.D.
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Ir
corresponding to the LTRs for each of the four permeants is larger than the value of Q(t)
corresponding to the non-LTRs for each of the four permeants. For the four permeants
considered, the permeabilities in the LTRs were 3-fold to 10-fold higher than the
permeabilities in the non-LTRs formed in full-thickness human skin. This result is in
qualitative agreement with the results presented in Chapter 4, in which the permeability
of calcein in the LTRs was shown to be 80-fold higher than that in the non-LTRs formed
in full-thickness pig skin.'
6.3.2 Evaluation of the Average Aqueous Pore Radii in the LTRs and in
the Non-LTRs from an Analysis of Log P3H vs. Log Purea Plots using
Steady-State Analysis Methods
Figure 6-2 shows plots of the permeability data from the three dual radiolabeled systems
examined in this experimental study. The 3H-mannitol - 14C-urea permeability data is
presented in Figure 6-2a, the 3H-raffinose - 14C-urea permeability data is presented in
Figure 6-2b, and the 3H-inulin - 14C-urea permeability data is presented in Figure 6-2c.
The values of the permeability for both the tritium-labeled permeant and urea were
calculated from the regression parameters, (6Cd-rL) and [D" H(,)/(TL) 2], by using Eq.
(2.41) in the time interval from 0 - 20 hours. The open circles and the open triangles
correspond to the permeability data from the non-LTRs and the LTRs, respectively, while
the black diamonds, the black circles, the black squares, and the black triangles
correspond to the permeability data obtained in Chapter 2 for the delivery in untreated,
low dose US-treated, high dose US-treated, and dermis skin samples, respectively. Note
that each data point in Figures 6-2a through 6-2c represents a single diffusion experiment.
298
.1
-I .U
-2.0
c
C.
0
S-4.0
-'J.IJ
-4.5 -3.5 -2.5 -1.5 -0.5
Log Purea (cm/hr)
Figure 6-2: Log P of the tritium-labeled permeants plotted against log P of urea, the
carbon-14 labeled permeant. (a) Mannitol-Urea, (b) Raffinose-Urea, and (c) Inulin-Urea.
Key: LTRs - open triangles, non-LTRs - open circles, untreated skin - black diamonds,
low dose US-treated - black circles, high dose US-treated skin - black squares, dermis -
black triangles, ideal slope of 1 - solid line, and the limiting case of infinitely large
aqueous pore channels - dashed line.
299
-4.0 -3.0 -2.0 -1.0
Log Purea (cm/hr)
-3.0 -2.0
Log Purea (cm/hr)
300
E
o
-j
...
-0.5
-1.5
-2.5
-3.5
-4.5
-5.5
-5.0 0.0
-2.0
-3.0
-4.0
-5.0
-4.0 -1.0
In addition, a solid line through the data from Chapter 2, representing the ideal slope of 1
predicted by Eq. (2.4b), and a dashed line, representing the limiting case of infinitely
large aqueous pores (see Eq. (2.42), where rpore -- oo and H(X) = 1, have been added for
reference.
From an examination of Figures 6-2a through 6-2c, one may again conclude that
the LTRs (see the open triangles) are more permeable than the non-LTRs (see the open
circles) for each of the three delivery systems considered. If it is assumed that the
porosity and the tortuosity ratios are unity (as was done by Peck et al. and by Tang et
al.),4,5 it is then possible to determine the value of the hindrance factor ratio using Eq.
(2.4b), from which the average available pore radii, rpore, may be determined. The values
of the hindrance factor ratios and of the average available pore radii are reported in Table
6-1. An examination of the values of the hindrance factor ratios reveals that the
hindrance factor ratio in the LTRs is significantly larger (p<0.05, using the t-statistic for
the difference in the two means") than in the non-LTRs. This observed difference in the
hindrance factor ratios in the LTRs and in the non-LTRs also leads to a difference in the
average available pore radii in the LTRs and in the non-LTRs. From Table 6-1, the
average available pore radius in the LTRs is also significantly larger (p<0.05) than the
average available pore radius in the non-LTRs. These results, obtained using the analysis
methods of Peck et al. and of Tang et al.,4' 5 suggest that the aqueous pores formed in the
LTRs have a larger average radius than the aqueous pores formed in the non-LTRs. This
observation further supports the hypothesis presented in Chapters 4 and 5,1,2 that there are
two distinct mechanisms of enhancement operating in skin treated simultaneously with a
chemical enhancer (SLS) and low-frequency ultrasound. This observation also
301
Table 6-1: Values of the Hindrance Factor Ratio, H(W)3H/H(,)Urea, and of the Average
Available Pore Radii of the LTRs and the non-LTRs Calculated from the Steady-State
Permeability Data Obtained from the Mannitol-Urea, the Raffinose-Urea, and the Inulin-
Urea Delivery Systems.
Delivery System
Mannitol-Urea
Raffinose-Urea
Skin Type
Non-LTRs
LTRs
Non-LTRs
LTRs
Inulin-Urea Non-LTRs
LTRs
a - Errors correspond to + I S.D.
b - The high and the low values reported
aqueous pore radii.
H(AH,
H(Aurea
0.87 + 0.1 la
2.10 + 0.85
0.23 + 0.10
0.49 + 0.19
0.37 + 0.15
0.66 + 0.13
correspond to
Average
Low
38
0o
15
21
36
74
Available Pore Radiib (A)
Average High
70 450
00 0o
18 22
32 54
51
108
72
182
I standard deviation from the average value of the
contradicts the claim made by Tang et al.5 and by Tezel et al.6 that ultrasound only forms
additional aqueous pore channels that have similar structural properties to those present
in untreated skin. However, in the previous studies, the hindrance factor ratio and the
average available pore radius were evaluated over the entire region of ultrasound-treated
skin, since it was assumed that low-frequency ultrasound perturbed the skin uniformly
over the entire area of exposed skin. As my studies in Chapters 4 and 5 have
demonstrated, this assumption on the uniformity of ultrasound enhancement of the skin
can no longer be considered valid.
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6.3.3 Evaluation of the Distribution of Pore Radii, the Porosity, and the
Tortuosity as a Function of both the Radius of the Hydrophilic
Permeant and the Extent of Skin Perturbation Induced in the LTRs
and in the Non-LTRs
In the previous section, the hindrance factor ratio and the average available pore radius
were evaluated in the context of the aqueous pore pathway hypothesis using two
simplifying assumptions: (1) the porosity and the tortuosity of the aqueous pore channels
do not depend on the radius of the permeant delivered across the skin, and (2) the two
permeants being delivered across the skin are able to access the same aqueous pore
channels. In this section, the permeability data obtained from the three delivery systems
considered are again analyzed in the context of the aqueous pore pathway hypothesis to
evaluate the hindrance factor, the porosity, and the tortuosity as a function of both the
extent of skin perturbation and the radius of the permeant considered. The results are
reported in Table 6-2. In this analysis, the possible existence of a distribution of aqueous
pore radii in the skin is considered, as proposed by Tezel et al. (see Eq. (2.40)),6 which,
in turn, also allows for the possibility that the porosity and the tortuosity of the aqueous
pore channels may depend on the radius of the permeant which is delivered across the
skin.
An initial examination of the data reported in Table 6-2 indicates that some of the
values obtained for the porosity and the tortuosity are physically unrealizable. For the
porosity, the upper bound of physically realizable values is unity, which corresponds to
the entire surface area of the skin being available for transport. From Table 6-2, the
average values of the porosities of urea, of mannitol, and of raffinose in the LTRs are all
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Table 6-2: Values of the Hindrance Factor, H(X), the Porosity, c, and the Tortuosity, t, of
the LTRs and the non-LTRs Calculated from the Permeability Data Obtained from the
Mannitol-Urea, the Raffinose-Urea, and the Inulin-Urea Delivery Systems Using the
Methods Presented in Section 2.4.6 for the Case of a Distribution of Pore Radii.a
Non-LTRs LTRs
Permeant
Urea 0.49 + 0.37 0.28 + 0.15 1.44 + 0.61 0.69 + 0.39 1.01 + 1.10 2.04 + 0.77
Mannitol 0.94 + 0.15 0.20 + 0.03 3.35 + 0.41 0.84 + 0.39 1.40 + 0.80 2.87 + 1.14
Raffinose 0.02 + 0.02 0.27 + 0.05 0.20 + 0.24 0.40 + 0.48 1.54 + 2.01 1.01 + 0.95
Inulin 0.03 + 0.03 0.18 + 0.06 0.20 + 0.13 0.53 + 0.51 0.56 + 0.37 0.95 + 0.71
a - The errors correspond to + 1 S.D.
greater than the upper bound of unity. Since the error bars associated with these values
of the porosity do include unity, one may claim that the porosity of urea, of mannitol, and
of raffinose in the LTRs is not statistically greater than the upper bound of unity. For the
tortuosity, the lower bound of physically realizable values is also unity, which
corresponds to the permeant traversing the skin along a straight path perpendicular to the
skin surface. From Table 6-2, the average values of the tortuosities of raffinose and of
inulin in the non-LTRs, and of inulin in the LTRs, are all less than the lower bound of
unity. Since the error bars associated with the value of the tortuosity of inulin in the
LTRs includes unity, one may claim that the tortuosity of inulin is not statistically less
than the lower bound of unity. However, for the values of the tortuosities of raffinose
and of inulin in the non-LTRs, the error bars do not include unity, and, therefore, one
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must conclude that the values of the tortuosities of raffinose and of inulin in the non-
LTRs are statistically less than the lower bound of unity.
Comparing the values of the hindrance factor, of the porosity, and of the
tortuosity reported for the four permeants for delivery in the non-LTRs, there is
considerable statistically significant variation in the values of the hindrance factors and of
the tortuosities, while there appears to be little statistically significant variation in the
values of the porosities. Specifically, five of the six permeant pairs (urea-mannitol, urea-
raffinose, urea-inulin, mannitol-raffinose, and mannitol-inulin) have significant
differences (p<0.05) in the values of the hindrance factors and of the tortuosities, while
raffinose-inulin is the only permeant pair that has a significant difference (p<0.05) in the
porosity. This result for the porosity would suggest that the porosity in the LTRs can be
considered to be independent of the permeant radius, and, therefore, to be an intrinsic
property of the skin, which is consistent with the observations made in Chapter 2. Even
though there is evidence that the values of these parameters depends on the radii of the
permeants, due to the large values of the hindrance factor and of the tortuosity
corresponding to mannitol, there is no clear decreasing trend in these values as the radius
of the permeant increases, as was observed in Chapter 2.
In the LTRs, there is less statistically significant variation in the hindrance factor,
in the porosity, and in the tortuosity for the four permeants considered. There is no
statistically significant difference (p>0.05) in the values of the hindrance factors for any
of the six permeant pairs considered. This result suggests that there is no dependence of
the hindrance factor on the radius of the permeant, which is contrary to the result
expected based on Eqs. (2.2) and (2.3). In addition, only one permeant pair, mannitol-
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inulin, has a significant difference (p<0.05) in the corresponding values of the porosities.
Similar to the results obtained for the non-LTRs, this result would again suggest that the
porosity in the LTRs can be considered to be independent of the permeant radius, and,
therefore, to be an intrinsic property of the skin, which is consistent with the observations
made in Chapter 2. These statistical results for the hindrance factor and for the porosity,
however, are primarily due to the large variations in the calculated values of the
hindrance factor, of the porosity, and of the tortuosity, especially for the data
corresponding to the LTRs, as indicated by the large values of the standard deviations
reported in Table 6-2. Finally, for the tortuosity, only three permeant pairs, urea-inulin,
mannitol-raffinose, and mannitol-inulin, have statistically significant differences (p<0.05)
in their tortuosity values. Based on this statistical analysis, there is no significantly
observable increasing, or decreasing, trend in the value of the tortuosity in the LTRs as a
function of the radius of the permeant.
Comparing the values of the hindrance factor, the of porosity, and of the
tortuosity reported in Table 6-2 in the non-LTRs and in the LTRs for each of the four
permeants, in all cases except one, the calculated p value from the t-test is greater than
0.05, corresponding to less than 95% confidence. This result would suggest that there is
little statistical difference between the values of these structural parameters reported for
the non-LTRs (lower extent of skin perturbation due to ultrasound) and for the LTRs
(higher extent of skin perturbation due to ultrasound). This statistical result is again due
to the large variations in the calculated values of the hindrance factor, the porosity, and
the tortuosity, especially for the data corresponding to the LTRs, as indicated by the large
values of the standard deviations reported in Table 6-2. These large standard deviation
306
values are the result of large variations in the shape of the distribution of pore radii,
characterized by the value of a in Eq. (2.40), which were found to range in value from 3
A to infinity.
As in Chapter 2, given that the values reported for the porosity and the tortuosity
corresponding to some permeants are physically unrealizable, and that there is a large
variation in the value of a for the distribution of pore radii, it is questionable whether
hindered transport, as modeled by the distribution of pore radii proposed by Tezel et al.,6
is useful to the overall modeling of hydrophilic transdermal transport. Therefore, it is
instructive to evaluate the porosity and the tortuosity of the aqueous pore channels in the
LTRs and in the non-LTRs as a function of the extent of skin perturbation and of the
permeant radius for the limiting case of infinitely large pores, for which rpore---oo and
H(X) = 1 (see Eqs. (2.2) and (2.3)).
6.3.4 Evaluation of the Porosity and the Tortuosity as a Function of Both
the Radius of the Hydrophilic Permeant and the Extent of Skin
Perturbation in the LTRs and in the non-LTRs for the Limiting Case
of Infinitely Large Aqueous Pores
In this section, the analysis carried out in Section 6.3.3 is repeated for the limiting case of
infinitely large aqueous pore channels, where rpore -* 0o and H(k) = 1. The values of the
porosity and the tortuosity of the aqueous pore channels present in the LTRs and in the
non-LTRs for each of the four permeants considered are reported in Table 6-3. By
assuming that the aqueous pores are infinitely large, and, therefore, that hindered
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Table 6-3: Values of the Porosity, c, and the Tortuosity, ', of the LTRs and the non-
LTRs Calculated from the Permeability Data Obtained from the Mannitol-Urea, the
Raffinose-Urea, and the Inulin-Urea Delivery Systems Using the Methods Presented in
Section 2.4.6 for the Case of Infinitely Large Aqueous Pores.a
Non-LTRs LTRs
Permeant
Urea 0.15 + 0.04 2.25 + 0.26 0.50 + 0.30 2.63 + 0.53
Mannitol 0.21 + 0.03 3.47 + 0.21 1.00 + 0.29 3.34 + 0.43
Raffinose 0.03 + 0.02 1.70 + 0.55 0.20 + 0.11 2.43 + 0.38
Inulin 0.03 + 0.01 1.20 + 0.23 0.23 + 0.11 1.51 + 0.12
a - The errors correspond to + 1 S.D.
transport does not contribute to the transdermal transport of the hydrophilic permeants,
more physically realizable results for both the porosity and the tortuosity can be obtained.
Specifically, the average values of the tortuosities, t, in both the LTRs and in the non-
LTRs, are all greater than the lower bound of 1. Likewise, the average values of the
porosities, E, in both the LTRs and in the non-LTRs, are all lower than, or equal to, the
upper bound of 1. These results, physically, are an improvement over the results reported
in Table 6-2, which include porosity values that are greater than 1 (see the delivery of
urea, mannitol, and raffinose in the LTRs in Table 6-2) and tortuosity values that are
lower than 1 (see the delivery of raffinose and inulin in the non-LTRs, and the delivery of
inulin in the LTRs in Table 6-3).
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In addition, the values of the porosities and the tortuosities reported in Table 6-3
also indicate that these quantities do depend on the nature of the permeant delivered
transdermally. In the non-LTRs, there is a significant difference (p<0.05) in the porosity
values of all the permeant pairs except for raffinose and inulin, which have statistically
similar porosity values. Likewise, there is a significant difference in the tortuosity values
of urea and mannitol, urea and inulin, mannitol and raffinose, and mannitol and inulin.
However, as with the data reported in Table 6-2, there is no clear decreasing trend in the
porosity values and in the tortuosity values as a function of the permeant radius in the
LTRs and in the non-LTRs, since the values of the porosity and the tortuosity of mannitol
are higher than those of urea.
Finally, a comparison of the porosity and the tortuosity values corresponding to
the LTRs with those corresponding to the non-LTRs reported in Table 6-3 suggests that
there is a greater difference in the porosity of the LTRs and of the non-LTRs than in the
tortuosity values of the LTRs and of the non-LTRs for the four permeants considered.
Specifically, the porosity values reported for the LTRs are 3-fold to 8-fold larger than
those reported for the non-LTRs for the four permeants considered, while there is only a
significant difference (p<0.05) in the reported tortuosity values of the non-LTRs and the
LTRs for raffinose and inulin. These results suggest that the primary difference between
the non-LTRs and the LTRs, under the assumption that the aqueous pore channels are
infinitely large, is that a greater fraction of the skin surface is made available for transport
in the LTRs than in the non-LTRs. In fact, the observed difference in the porosity values
of the LTRs and the non-LTRs is in excellent agreement with the observed difference in
the permeability values of the LTRs and the non-LTRs reported in Section 6.3.1 (3-fold
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to 10-fold). These differences further confirm that there are two distinct levels of skin
perturbation induced by the simultaneous treatment of the skin with a chemical enhancer
(SLS) and low-frequency ultrasound leading to the formation of the LTRs and the non-
LTRs.
6.3.5 Proposed Mechanism of Enhancement in Skin Treated
Simultaneously with a Chemical Enhancer and Low-Frequency
Ultrasound
Prior to the studies carried out as part of this thesis, transient cavitation events near the
skin surface were thought to be the primary mechanism responsible for the observed
enhancement of the transdermal transport of hydrophilic permeants in skin treated
simultaneously with SLS, a chemical enhancer, and low-frequency ultrasound, 12 as well
as in skin treated solely with low-frequency ultrasound. 13 Furthermore, from an analysis
of the skin permeability and the skin electrical resistivity measurements in the context of
the aqueous pore pathway hypothesis, it was demonstrated that new aqueous pore
channels, similar in radius to those present in untreated skin, were formed in skin treated
simultaneously with a chemical enhancer and low-frequency ultrasound,6 as well as in
skin treated solely with low-frequency ultrasound.: Finally, it was assumed that the
observed enhancement due to ultrasound treatment of the skin was uniform over the
entire surface of the treated skin sample.
In Chapter 2, it was shown that ultrasound treatment of the skin: (i) increases the
porosity values by orders of magnitude, while the tortuosity decreases at most by a factor
of 3-fold, and (ii) results in no significant increase, or decrease, in the hindrance factor,
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over the range of ultrasound conditions studied. These results suggest that the observed
enhancement in the transdermal transport of hydrophilic permeants result primarily from
an interaction of the skin surface with the low-frequency ultrasound waves and the
surfactant, SLS. These results, then, provide further support for the idea that ultrasound
enhancement is the result of transient cavitation events, which are triggered by the
ultrasound acoustic field, acting near the skin surface.
In Chapter 4, the skin permeability and the skin electrical resistivity of both the
LTRs and the non-LTRs were evaluated for this first time. The results of this
investigation clearly demonstrated that two distinct levels of enhancement can be
observed in skin treated simultaneously with SLS and low-frequency ultrasound. In
addition, the porosity-to-tortuosity ratio corresponding to the LTRs was compared to a
threshold value of the porosity-to-tortuosity ratio corresponding to the intercellular
domains of the stratum corneum, calculated in Chapter 3, to demonstrate that
transcellular permeation pathways may be present in the LTRs formed in skin treated
simultaneously with SLS and low-frequency ultrasound. Both of these observations -
the presence of two levels of enhancement and of transcellular permeation pathways in
the LTRs - were confirmed in Chapter 5 using Two-Photon Microscopy. These results
suggested that skin treated simultaneously with SLS and low-frequency ultrasound is not
uniformly enhanced, as was previously assumed.
In the analyses presented in this chapter, the key observations made in Chapters 4
and 5, that ultrasound-treated skin is not uniformly enhanced, are again confirmed. The
steady-state analysis methods of Peck et al.4 and of Tang et al.5 revealed that the values
of the hindrance factor and of the average available pore radius are significantly larger in
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the LTRs than in the non-LTRs for the each of the three delivery systems (mannitol-urea,
raffinose-urea, and inulin-urea) considered. This result suggests that a single application
of low-frequency ultrasound produces aqueous pore channels having different radii in
different regions of the skin. Evaluation of the porosities and the tortuosities in the LTRs
and in the non-LTRs for the case where rpore - oo and H(0) = 1 revealed that the
differences observed in the porosity values in the LTRs and in the non-LTRs for each of
the four permeants considered were much larger than the difference in the tortuosity
values in the LTRs and in the non-LTRs. This result suggests that a surface-related
phenomenon is primarily responsible for the observed difference in the transdermal
transport of hydrophilic permeants in the LTRs and in the non-LTRs. Since the value of
the porosity is much higher in the LTRs than in the non-LTRs, this surface-related
phenomenon appears to cause a greater increase in the fraction of the skin surface
occupied by the aqueous pore channels in the LTRs than in the non-LTRs. Since
previous studies have demonstrated that transient cavitation events near the skin surface
are the primary ultrasound enhancement mechanism,12,13 it is likely that a greater number
of these transient cavitation events occur over the surface of the skin where the LTRs will
eventually form relative to the number of transient cavitation events that occur over the
surface of the skin where the non-LTRs will eventually form. This hypothesis may be
confirmed by future studies (see Section 7.2.3) which would need to demonstrate: 1) the
existence of spatial variations in the density of transient cavitation events near the skin
surface (defined as the number of cavitation events per unit area), and 2) that high density
regions of transient cavitation events near the skin surface result in the formation of the
highly permeable LTRs which are observed in ultrasound-treated skin.
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6.4 Conclusions
In this chapter, I evaluated the hindrance factor, the porosity, and the tortuosity of the
LTRs and the non-LTRs formed in skin treated simultaneously with a chemical enhancer
(the surfactant, SLS) and low-frequency sonophoresis, for four hydrophilic permeants,
using three different analysis approaches.
In the first analysis approach, steady-state permeabilities were used to evaluate
the hindrance factor and the average available pore radius for the case where the porosity
and the tortuosity were assumed to be independent of the radius of the permeant being
delivered transdermally. The results obtained using this analysis approach revealed that
both the hindrance factor and the average available pore radius are significantly larger in
the LTRs than in the non-LTRs. These results suggest that ultrasound treatment results in
larger aqueous pore channels in the LTRs than in the non-LTRs, an indication that two
separate enhancing mechanisms are exploited by ultrasound to make the skin more
permeable to hydrophilic permeants.
In the second analysis approach, transient and steady-state diffusion data were
used to evaluate the hindrance factor, the porosity, and the tortuosity for the case where a
distribution of pore radii was assumed to exist in the skin. The results of this analysis
approach revealed little statistical difference in the values of the hindrance factor, of the
porosity, and of the tortuosity of the LTRs as compared to those of the non-LTRs due to
the large values of the standard deviations in the hindrance factor, in the porosity, and in
the tortuosity calculated from the experiments conducted in the LTRs. Because of the
large variation in the a parameter, which determines the shape of the function
characterizing the distribution of pore radii, from 3 A to infinity, and some physically
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unrealizable values of the porosity and the tortuosity, it is questionable whether the
distribution of pore radii given in Eq. (2.40) accurately describes the range of aqueous
pore radii present in the skin. This finding is consistent with observations made in
Chapter 2 using this analysis approach.
In the final analysis approach, transient and steady-state diffusion data were again
used to evaluate the porosity and the tortuosity for the limiting case where the aqueous
pore channels are infinitely large, such that hindered transport may be neglected (i.e.
H(X) = 1). The results of this analysis approach revealed that the primary difference
between the LTRs and the non-LTRs is in the values of the porosity. For the four
permeants considered, the porosity values of the LTRs are 3-fold to 8-fold larger than the
porosity values of the non-LTRs, which is excellent agreement with the observed
difference in the permeability values of the LTRs and the non-LTRs (3-fold to 10-fold)
There is also a small difference in the tortuosity values of the LTRs and the non-LTRs for
the four permeants considered, but the difference is much smaller, only 50% difference in
the tortuosity values, compared to the observed differences in the porosity values. These
results suggest that the difference in the permeabilities of the LTRs and of the non-LTRs
is due to the creation of more aqueous channels in the LTRs than in the non-LTRs.
The observations made using these three analysis approaches provide additional
support for the hypothesis put forward in Chapters 4 and 5 that enhancement of the skin
due to ultrasound treatment does not occur via a uniform, homogeneous process. From
the data obtained on the structural parameters of the aqueous pore channels in the LTRs
and in the non-LTRs, it appears that transient cavitation events near the skin surface,
which were previously shown to be the primary enhancing mechanism of low-frequency
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ultrasound, occur more frequently over the areas of the skin which eventually become the
LTRs. It is the main closing hypothesis of this thesis, then, that these high density
domains of transient cavitation events near the skin surface (defined as the number of
cavitation events per unit area) are responsible for the formation of the highly permeable
LTRs, as well as for the formation of transcellular pathways associated with the
transdermal transport of hydrophilic permeants within the LTRs.
315
6.5 References
1. Kushner J, Blankschtein D, and Langer R. 2004. Experimental demonstration of
highly permeable localized transport regions in low-frequency sonophoresis. J
Pharm Sci. 93:2733-2745.
2. Kushner J, Deen W, Blankschtein D, and Langer R. First-principles, structure-
based transdermal transport model to evaluate lipid partition and diffusion
coefficients of hydrophobic permeants solely from stratum corneum permeation
experiments. (Submitted to J Pharm Sci).
3. Kushner J, Kim D, So PTC, Blankschtein D, and Langer R. Dual-channel two-
photon microscopy study of transdermal transport in skin treated with low-
frequency ultrasound and a chemical enhancer. (Submitted to J Invest Dermatol).
4. Peck KD, Ghanem AH, and Higuchi WI. 1994. Hindered diffusion of polar
molecules through and effective pore radii estimates of intact and ethanol treated
human epidermal membrane. Pharm Res 11:1306-1314.
5. Tang H, Mitragotri S, Blankschtein D, Langer RS. 2001. Theoretical description
of transdermal transport of hydrophilic permeants: Application to low-frequency
sonophoresis. J Pharm Sci 90:545-568.
6. Tezel A, Sens A, and Mitragotri S. 2003. Description of transdermal transport of
hydrophilic solutes during low-frequency sonophoresis based on a modified porous
pathway model. J Pharm Sci. 92: 381-393.
7. Tang H, Blankschtein D, Langer R. 2002. Effects of low-frequency ultrasound on
the transdermal permeation of mannitol: Comparative studies with in vivo and in
vitro skin. J Pharm Sci 91:1776-1794.
316
8. Tang H, Mitragotri S, Blankschtein D, Langer RS. 2001. Theoretical description
of transdermal transport of hydrophilic permeants: Application to low-frequency
sonophoresis. J Pharm Sci 90:545-568.
9. Tezel A, Sens A, Tuchscherer J, Mitragotri S. 2002. Synergistic effect of low-
frequency ultrasound and surfactants on skin permeability. J Pharm Sci 91:91-100.
10. Deen W. 1998. Analysis of Transport Phenomena. Oxford: New York. P. 19.
11. Montgomery DC, Runger GC, Hubele NF. 1998. Engineering Statistics. John
Wiley & Sons, Inc. New York.
12. Tezel A, Sens A, Mitragotri S. 2002. Investigations of the role of cavitation in low-
frequency sonophoresis using acoustic spectroscopy. J Pharm Sci 91:444-453.
13. Tang H, Wang CCJ, Blankschtein D, Langer R. 2002. An investigation of the role
of cavitation in low-frequency ultrasound-mediated transdermal drug transport.
Pharm Res 19:1160-1169.
317
Chapter 7
Thesis Summary and Proposed Future Research
Directions
7.1 Thesis Summary
The central goal of this thesis has been to build upon, and to extend, previous research in
the areas of both passive and ultrasound-enhanced transdermal drug delivery.
Specifically, I have further examined the theoretical modeling of the transdermal
transport of both hydrophilic permeants (Chapter 2) and of hydrophobic permeants
(Chapter 3). These modeling studies were subsequently used to further our
understanding of the mechanism by which low-frequency ultrasound enhances
transdermal drug delivery. My investigations in the field of low-frequency sonophoresis
focused on furthering our understanding of the localized transport regions (LTRs), and
the surrounding regions of the skin (the non-LTRs), that form in skin treated with low-
frequency ultrasound in the presence of a chemical enhancer, the surfactant - sodium
lauryl sulfate (SLS). Specifically, these studies examined: 1) if the LTRs are, in fact,
regions of high permeability through the use of diffusion masking experiments (Chapter
4), 2) what types of permeation pathways exist in the LTRs and in the non-LTRs through
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the use of dual-channel two-photon microscopy (Chapter 5), and 3) the differences in the
values of the porosity, the tortuosity, and the hindrance factor associated with the
aqueous-pore channels located in the LTRs and in the non-LTRs that form in skin treated
simultaneously with low-frequency sonophoresis and the chemical enhancer SLS through
the use of the aqueous-pore pathway hypothesis (Chapter 6). The key results from each
of these five research topics are summarized in greater detail below.
In Chapter 2, the aqueous pore pathway hypothesis was extended to model the
transient domain of the transdermal transport of hydrophilic permeants, in addition to the
previously-investigated steady-state domain, to verify various assumptions regarding the
behavior of the hindrance factor, the tortuosity, and the porosity as a function of both
permeant radius and the extent of skin perturbation. Diffusion experiments were
conducted with 14C-urea combined with tritium-labeled mannitol, tritium-labeled
raffinose, or tritium-labeled inulin as the model permeants. An analysis of the
cumulative amount of the permeant delivered per unit area, Q(t), as a function of time, t,
showed that the lag time to reach steady-state was 10-fold to 40-fold lower in the dermis
than in untreated full-thickness skin, indicating that the tortuosity of the aqueous pore
channels does not increase with increasing skin perturbation, contrary to a suggestion
made previously by Tezel et al.'1
Analysis of the steady-state permeability data by linear regression revealed that
the slope of the best-fit line through the steady-state permeability data was statistically
similar to the predicted slope of 1 over the range of permeant radii investigated in this
study (rp = 2.6 A - 12 A). Using steady-state analysis methods, I showed that the
average available aqueous pore radius ranges in size from 41 A to infinity. Given the
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large range of values for the average available aqueous pore radius, as well as the large
value of the standard deviation in the average available pore radius (in some cases
varying from 21 A to infinity), it is questionable whether the inclusion of a hindrance
factor improves the overall modeling of transdermal transport of hydrophilic permeants.
To further investigate the need to include the hindrance factor, as well as to
investigate how the porosity and the tortuosity vary as a function of the permeant radius
and the of extent of skin perturbation, the Q(t) vs. t data were analyzed with the proposed
model equations describing the transdermal transport of hydrophilic permeants in the
transient and the steady-state domains. For the case where a distribution of pore radii
exists in the skin, as proposed by Tezel et al.,"l my results indicated that: 1) the value of
the hindrance factor depends on the radius of the permeant delivered through the skin,
while there is little change in the value of the hindrance factor as a function of the extent
of skin perturbation, 2) the value of the porosity does not depend on the radius of the
permeant delivered, while the value of the porosity increases as the extent of skin
perturbation increases, and 3) the value of the tortuosity decreases as the radius of the
permeant increases, while there is little evidence that the tortuosity depends on the extent
of skin perturbation. These trends would seem to suggest that ultrasound treatment of the
skin results in the formation of aqueous pore channels that are structurally similar to
those found in untreated skin.
Because the tortuosity values of inulin where found to be statistically significantly
lower than unity, and because of the large standard deviations in the hindrance factor
values of urea, mannitol, and raffinose, the values of the porosity and the tortuosity were
also evaluated in the limiting case of infinitely large aqueous pores (rpore --+ oo). This
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analysis showed that, similar to the previous case where a distribution of aqueous pore
channels was assumed to exist in the skin, the tortuosity exhibited some dependence on
the radius of the permeant, while the porosities of urea, of mannitol, and of raffinose were
found to be statistically similar. In addition, a significant decrease in the tortuosity of
each permeant was observed as a function of the extent of skin perturbation. While the
use of infinitely large pores resulted in tortuosity values of inulin which were greater than
unity, the value of the porosity for inulin was found to be significantly lower than those
of the other three permeants considered, suggesting that there were some aqueous pore
channels which could not be accessed by inulin due to its larger radius. These results
indicate that additional studies are needed to improve the model for the distribution of the
aqueous pore radii in the skin to better understand the transdermal transport of inulin, and
other large hydrophilic permeants, in the context of the aqueous pore pathway hypothesis.
In Chapter 3, a new theoretical model that describes Fickian diffusion of
hydrophobic molecules which diffuse through the intercellular lipid domains of the
stratum comeum was developed from first principles. This new theoretical model, the
two-tortuosity model, utilized the structural parameters of the stratum corneum to
evaluate the porosity and the tortuosity parameters. The novel feature in the model was
the introduction of two tortuosity factors in the model equations, which accounted for: 1)
the total amount of lipids in the SC, and 2) the impact of parallel diffusion pathways on
the diffusive flux through the SC. Based on a regression analysis of data obtained from
the simulated stratum corneum diffusion experiments performed with FEMLAB, the two-
tortuosity model deduced Kb, the vehicle-lipid partition coefficient, and Db, the diffusion
coefficient of the permeant in the lipid bilayers, to within a 2-3% error for native stratum
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corneum structures, out-performing all the five previous structure-based transport models
considered. The regressed values of Kb = 233 (+44) and Db = 1.6*10 -7 (+0.3*10-7 ) cm 2/S
for naphthol and of Kb = 100 (+31) and Db = 1.8*10-8 (+0.5*10-8) cm 2/S for testosterone,
obtained using the two-tortuosity model, were comparable to the values obtained using
two previously published experimental techniques: 1) permeation experiments combined
with octanol-water partition experiments, and 2) permeation experiments combined with
solute-release experiments. This result demonstrated that Kb and Db values of
hydrophobic permeants can be evaluated solely from permeation experiments using the
new theoretical model, which should greatly simplify the experimental method used to
evaluate Kb and Db of hydrophobic permeants.
In Chapter 4, the focus of the thesis shifted from examining transdermal transport
models to examining the mechanism of enhancement in skin samples treated with
ultrasound in the presence of a chemical enhancer (the surfactant, SLS). Specifically, a
series of diffusion masking experiments with ultrasound-treated full-thickness pig skin
were performed for the purpose of demonstrating quantitatively that the patterns of "red
spots" observed on the skin when the red-colored hydrophilic permeant SRB and the
chemical enhancer SLS are used in the ultrasound coupling medium are, indeed, markers
for localized regions of high transdermal permeability. The results of these experiments,
carried out over a range of skin electrical currents (225 - 325 ptAmps), revealed that the
transdermal permeability of the LTRs is 80-fold higher, on average, than the transdermal
permeability of the less permeable non-LTRs. Although most of the transdermal delivery
occurs in the more permeable LTRs, an analysis of the skin electrical resistivity data also
indicated that there is a significant enhancement in both the highly permeable LTRs and
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in the less permeable non-LTRs when compared to untreated skin (-5000-fold and -170-
fold, respectively). This suggests that the skin may be experiencing two levels of
structural perturbation in the ultrasound/SLS system. Finally, by comparing the (6/1)
values of the less permeable non-LTRs and of the highly permeable LTRs with the (e/t)
value of the intercellular regions of the SC obtained in Chapter 3 for steady-state
transport (3.6*104), it was suggested that the transdermal transport pathways that exist in
the less permeable non-LTRs may be entirely intercellular, while the transdermal
transport pathways that exist in the more permeable LTRs are likely to be both
intercellular and transcellular.
In Chapter 5, dual-channel two-photon microscopy (TPM) studies were
performed to confirm the existence of transcellular transdermal transport pathways in the
more permeable LTRs, as well as to better understand how two levels of structural
perturbation may be induced in skin samples treated simultaneously with low-frequency
ultrasound and SLS, which were both observed in Chapter 4. Dual-channel TPM images
were generated and analyzed to compare the transdermal delivery of SRB, a fluorescent
hydrophilic permeant, and of RBHE, a fluorescent hydrophobic permeant, in skin treated
with SLS (a chemical enhancer), with ultrasound, and with the simultaneous application
of ultrasound and SLS, with the transdermal delivery of SRB and of RBHE in untreated
skin. From an analysis of the dual-channel TPM images as a function of skin depth for
SRB and for RBHE, it was observed that both SRB and RBHE penetrate into the viable
epidermis in the LTRs of US-treated and of US/SLS-treated skin, while the penetration of
SRB and of RBHE was confined solely to the stratum corneum in untreated skin, in SLS-
treated skin, and in the non-LTRs of US-treated and of US/SLS-treated skin. From an
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analysis of the average fluorescence intensity profiles and the values of EK (the
enhancement in the vehicle-skin partition coefficient), EG (the enhancement in the
fluorescent permeant intensity gradient in the skin), and EL (the enhancement in the
effective diffusion path length), which were obtained from the average fluorescence
intensity profiles, it was observed that two significant levels of skin perturbation exist
when the skin is treated simultaneously with ultrasound and with a chemical enhancer
(i.e. SLS or ethanol). Greater perturbation of the skin was observed in the LTRs of skin
treated with ultrasound and a chemical enhancer relative to the extent of skin perturbation
observed in the non-LTRs of skin treated with ultrasound and a chemical enhancer.
These results are consistent with our previous conclusions reached using the skin
electrical resistivity measurements of the non-LTRs and of the LTRs presented in
Chapter 4. In the absence of a chemical enhancer during ultrasound treatment of the skin,
the non-LTRs were found not to be significantly enhanced by ultrasound, as compared to
untreated skin. This result suggests that ultrasound, in the absence of a chemical
enhancer, discretely enhances the skin through the mechanism of transient acoustic
cavitation near the skin surface. This result also suggests that the presence of a chemical
enhancer in the coupling medium during ultrasound treatment of the skin is required to
obtain two levels of significant enhancement in the perturbation of the skin structure.
Finally, by comparing the heights and the widths of the fluorescence intensity peaks
obtained from the dual-channel TPM images, transcellular pathways were observed in the
LTRs of US-treated and of US/SLS-treated skin for both SRB and RBHE, as well as in
SLS-treated skin for SRB. These observations provided confirmation of the results
presented in Chapter 4 based on an analysis of the skin electrical resistivity data in the
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context of the aqueous-pore pathway hypothesis, which suggested that transcellular
pathways may be present in the LTRs of skin treated simultaneously with ultrasound and
a chemical enhancer.
In Chapter 6, I evaluated the hindrance factor, the porosity, and the tortuosity of
the LTRs and the non-LTRs formed in skin treated simultaneously with a chemical
enhancer (the surfactant, SLS) and low-frequency sonophoresis, for four hydrophilic
permeants, using three different analysis approaches.
In the first analysis approach, steady-state permeabilities were used to evaluate
the hindrance factor and the average available pore radius for the case where the porosity
and the tortuosity were assumed to be independent of the radius of the permeant being
delivered transdermally. The results obtained using this analysis approach revealed that
both the hindrance factor and the average available pore radius are significantly larger in
the LTRs than in the non-LTRs. These results suggest that ultrasound treatment results in
larger aqueous pore channels in the LTRs than in the non-LTRs, an indication that two
separate enhancing mechanisms are exploited by ultrasound to make the skin more
permeable to hydrophilic permeants.
In the second analysis approach, transient and steady-state diffusion data were
used to evaluate the hindrance factor, the porosity, and the tortuosity for the case where a
distribution of pore radii was assumed to exist in the skin. The results of this analysis
approach revealed little statistical difference in the values of the hindrance factor, of the
porosity, and of the tortuosity of the LTRs as compared to those of the non-LTRs due to
the large values of the standard deviations in the hindrance factor, in the porosity, and in
the tortuosity calculated from the experiments conducted in the LTRs. Because of the
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large variation in the a parameter, which determines the shape of the function
characterizing the distribution of pore radii, from 3 A to infinity, and some physically
unrealizable values of the porosity and the tortuosity, it is questionable whether the
distribution of pore radii given in Eq. (2.40) accurately describes the range of aqueous
pore radii present in the skin. This finding is consistent with observations made in
Chapter 2 using this analysis approach.
In the final analysis approach, transient and steady-state diffusion data were again
used to evaluate the porosity and the tortuosity for the limiting case where the aqueous
pore channels are infinitely large, such that hindered transport may be neglected (i.e.
H(X) = 1). The results of this analysis approach revealed that the primary difference
between the LTRs and the non-LTRs is in the values of the porosity. For the four
permeants considered, the porosity values of the LTRs are 3-fold to 8-fold larger than the
porosity values of the non-LTRs, which is excellent agreement with the observed
difference in the permeability values of the LTRs and the non-LTRs (3-fold to 10-fold)
There is also a small difference in the tortuosity values of the LTRs and the non-LTRs for
the four permeants considered, but the difference is much smaller, only 50% difference in
the tortuosity values, compared to the observed differences in the porosity values. These
results suggest that the difference in the permeabilities of the LTRs and of the non-LTRs
is due to the creation of more aqueous channels in the LTRs than in the non-LTRs.
The observations made using these three analysis approaches provide additional
support for the hypothesis put forward in Chapters 4 and 5 that enhancement of the skin
due to ultrasound treatment does not occur via a uniform, homogeneous process. From
the data obtained on the structural parameters of the aqueous pore channels in the LTRs
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and in the non-LTRs, it appears that transient cavitation events near the skin surface,
which were previously shown to be the primary enhancing mechanism of low-frequency
ultrasound, occur more frequently over the areas of the skin which eventually become the
LTRs. It is the main closing hypothesis of this thesis, then, that these high density
domains of transient cavitation events near the skin surface (defined as the number of
cavitation events per unit area) are responsible for the formation of the highly permeable
LTRs, as well as for the formation of transcellular pathways associated with the
transdermal transport of hydrophilic permeants within the LTRs.
7.2 Proposed Future Research Directions
7.2.1 Generalization of the Two-Tortuosity Model to More Complex
Transdermal Transport Problems
In Chapter 3, the Two-Tortuosity model was developed to model the transdermal
transport of permeants, which are confined to the intercellular regions of the stratum
corneum. As such, the Two-Tortuosity model, in its present form, is applicable for
transdermal drug delivery in specific cases (i.e. hydrophobic permeant delivery). Several
avenues are available to generalize the Two-Tortuosity model to more accurately and
broadly describe transport through human skin for a variety of permeants, including
accounting for: 1) penetration into the corneocytes, 2) diffusion through the viable
epidermis and the dermis, 3) non-uniformity in the stratum corneum structure as a
function of depth, which can lead to a dependence of the partition and the diffusion
coefficients on skin depth, and 4) the existence of shunt pathways - sweat glands and hair
follicles - in the skin. Each of these added complexities to the Two-Tortuosity model of
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transdermal transport could be introduced via a first-principles approach, similar to the
methods used to derive the original Two-Tortuosity model from first principles (see
Section 3.3 for details). To account for penetration into the corneocytes, a partition
coefficient describing permeant partitioning between the intercellular and the corneocyte
domains would need to be added to the Two-Tortuosity model, as well as adding a
diffusion coefficient describing permeant transport in the corneocyte domain. Diffusion
through the viable epidermis and the dermis may be addressed in a similar manner to
penetration into the comeocyte domain (i.e. partition and diffusion coefficients for both
the viable epidermis and the dermis would need to be incorporated into the model), with
the additional requirement of estimating the skin structural parameters characterizing the
viable epidermis and the dermis. Transport models for the viable epidermis and the
dermis can then be added, in series, to the transport model for the stratum corneum to
obtain an overall skin transport model. Variation in the SC structure as a function of skin
depth can also be addressed in a similar manner to the addition of the viable epidermis
and the dermis to the overall skin transport model. The stratum corneum consists of two
layers: i) the stratum disjunctum, which comprises the outer layers of the stratum
corneum and where desquamation of the corneocytes occurs, and ii) the stratum
compactum, which comprises the inner layers of the stratum corneum and is more
densely packed than the stratum disjunctum.' Specifically, these two layers can be
modeled as two skin layers in series, similar to what was proposed to model the viable
epidermis and the dermis. Finally, the presence of shunt pathways can be incorporated
into the Two-Tortuosity model by modeling these pathways in parallel to transport
through the stratum corneum. Transport through hair follicles and sweat glands may be
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incorporated using modeling techniques similar to those used in the aqueous-pore
pathway hypothesis, since transport through small, cylindrical-shaped channels is
common to both hydrophilic transport through the skin and to transport through the shunt
pathways. In addition, future modeling efforts should also be directed to better
understanding how the tortuosity should be modeled in a 3-D representation of the
stratum corneum. This investigation would help determine the accuracy of the 2-D
modeling of transdermal transport relative to modeling transdermal transport with a 3-D
representation of the stratum corneum.
7.2.2 Identification of Classes of Permeants that Exhibit Enhanced Delivery
in the LTRs
In Chapters 4 and 6, I examined the transdermal delivery of several hydrophilic
permeants, ranging in molecular weight from 182 Da to 5,000 Da, to evaluate the
differences in their permeabilities in the LTRs and in the non-LTRs formed in skin
treated simultaneously with low-frequency ultrasound and a chemical enhancer (SLS).
Further studies examining the transdermal transport of several additional permeants
through the LTRs and the non-LTRs should be conducted to determine what additional
classes of permeants would benefit the most from the formation of the highly-permeable
LTRs during ultrasound treatment of the skin. These permeants may include: 1) a low
molecular weight hydrophobic permeant (for example, estradiol, MW = 272.4), 2) a high
molecular weight hydrophobic permeant (for example, erythropoietin, MW = 34,000 Da),
3) drug-containing nanoparticles (diameter: 200-400 nm), 4) oligonucleotides (20 base
pairs, -12,000 Da), and 5) drug-containing liposomes (diameter: 70-200 nm). These
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representative permeants should allow the determination of which classes of permeants
would benefit the most from LTR formation in ultrasound-treated skin.
Specifically, in vitro diffusion masking experiments (see Section 4.2.6 for details)
may be conducted with full-thickness pig skin as the model skin membrane for the five
model permeants listed above. The skin should be pretreated with ultrasound, both in the
presence and in the absence of SLS, according to the ultrasound pre-treatment protocol
outlined in Section 4.2.4. Skin electrical current measurements can be carried out using
the procedures outlined in Section 4.2.3. After ultrasound pretreatment, the skin can be
digitally imaged, following the protocol outlined in Section 4.2.5, to determine the areas
of the LTRs and of the non-LTRs on the skin. After digital imaging, the skin samples
should be masked according to the protocol outlined in Section 4.6. After masking, a
solution containing one of the five model permeants listed above, which should be
radiolabeled, can be placed in the donor compartment of the diffusion cell. Diffusion of
the radiolabeled permeant should continue under passive conditions for 48 hours, with
samples being taken from the receiver cell at predetermined time points. These samples
should be analyzed in a scintillation counter to determine the quantity of permeant
delivered across the unmasked regions of the skin membrane. The permeability through
these unmasked regions can be evaluated using Eq. (4.1). Transdermal permeability
experiments with the radiolabeled permeants through untreated full-thickness pig skin
samples should also be conducted to evaluate the permeability of each skin region
relative to the permeability of untreated skin.
7.2.3 Mechanisms of LTR Formation in Low-Frequency Sonophoresis
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In previous work, our group demonstrated that transient acoustic cavitation events near
the skin surface are primarily responsible for the structural perturbations in skin exposed
to low-frequency ultrasound, which lead to the observed enhancements in the transdermal
permeabilities and in the skin electrical current measurements.2 Because the LTRs
consist of the most perturbed regions of the skin, I have hypothesized that transient
acoustic cavitation events near the skin surface play a significant role in the formation of
the LTRs (see Section 5.3.4). In order to better understand the formation of the LTRs
formed by low-frequency ultrasound, I first propose demonstrating that transient acoustic
cavitation events near the skin surface are required for LTR formation (see Section
7.2.3.1). I then propose examining how ultrasound, the skin surface topography, and the
presence of a chemical enhancer (e.g. SLS) in the coupling medium affects LTR
formation in skin exposed to low-frequency ultrasound (see Sections 7.2.3.2 and 7.2.3.3,
respectively).
7.2.3.1 Investigation of the Role of Acoustic Cavitation in LTR Formation
In this set of experiments, full-thickness pig skin samples can be treated with low-
frequency ultrasound at previously-investigated conditions (i.e. frequency - 20 kHz,
intensity - 7.5 W/cm2, duty cycle - 5 sec ON: 5 sec OFF, and tip displacement - 3 mm)
using different coupling media to determine if acoustic cavitation events are indeed
necessary for the formation of LTRs. The coupling media that can be used in these
experiments include: i) castor oil, ii) degassed PBS, iii) regular PBS, and iv) gas-filled
microspheres (e.g. Albunex) in a PBS solution. Castor oil, since it is highly viscous, has
been shown to suppress acoustic cavitation events.2'3 Also, degassed PBS will have
reduced acoustic cavitation activity compared to regular PBS, since the dissolved gases,
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which nucleate into cavitation bubbles, have been removed from the solution prior to
ultrasound exposure. The coupling medium containing gas-filled microspheres should
exhibit increased acoustic cavitation activity compared to regular PBS due to an
increased amount of dissolved gas in the coupling medium, which should lead to an
increase in the number of cavitation bubbles formed by exposure to low-frequency
ultrasound.2 The goal of this investigation would be to demonstrate that the size of the
LTRs formed in the skin increases with the amount of dissolved gases in the coupling
medium, and, therefore, with the amount of cavitation activity in the coupling medium.
7.2.3.2 Investigation of the Role of Ultrasound and Surface Topography in
LTR Formation
In this section, I discuss how ultrasound and the surface topography affect the location of
acoustic cavitation events in the skin. Specifically, investigations are proposed to
examine how the dissolved gases in the coupling medium interact with the acoustic field
generated by the ultrasound transducer and the surface topography to control where
transient cavitation events occur, which lead to the formation of the LTRs on the skin
surface. Transient cavitation events near the skin surface may be induced by dissolved
gases in the coupling medium or on the skin surface. The skin surface may contain
crevices, folds, and/or pores which can trap gases that lead to the acoustic cavitation
events which result in LTR formation. For a material with a smooth surface, which
would be unable to trap any gases, any transient cavitation events near the skin surface
should result from the acoustic field interacting with the coupling medium. Similarly,
for a material with a smooth surface, any variation in the pattern of acoustic cavitation
activity would be the result of variations in the ultrasound acoustic field. Based on our
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preliminary studies, when full-thickness pig skin samples are treated with identical US
conditions in the presence of SLS, a variety of LTR patterns are generated.4
The following set of experiments is proposed to decouple the effect of the skin
surface topography from the effect of the acoustic field on the location of transient
cavitation events near the skin. (Recall that, as discussed in Section 7.2.3.1, it will be
demonstrated that transient cavitation events near the skin surface are necessary to
produce the LTRs.) A material with a smooth surface (for example, aluminum foil or
another highly polished metal surface) may be exposed to identical ultrasound conditions,
both in the presence and in the absence of the surfactant SLS. The size, location, and
distribution of the pits formed from transient cavitation events near the surface can be
recorded and compared for each sample. Since there is no variation in the surface
topography, or in the ultrasound exposure conditions, there should be no variation in the
pattern of pits on the material surface. (However, if a variation in the pattern of pits is
observed when the samples are exposed to identical ultrasound conditions, one may
conclude that transient cavitation events near the skin surface are chaotic and
irreproducible.) The acoustic field used to treat the smooth-surfaced material may be
varied by changing the transducer diameter and/or the ultrasound operating conditions.
Again, any variations in the pattern of pits on the material surface would be a result of
variations in the acoustic field. Finally, using identical ultrasound conditions, the surface
smoothness may be varied by roughening selected portions of the material surface, to
determine if the surface topography induces variations in the pattern of pits in the
material surface. From these experiments, it should be possible to determine whether the
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acoustic field, the surface topography, or both, are responsible for the pattern of pits on
the material surface that result from transient cavitation events near the material surface.
7.2.3.3 Investigation of the Role of Chemical Enhancers in Low-Frequency
Sonophoresis
From previous work, our group has demonstrated that SLS enhances the effect of
ultrasound on the skin, significantly reducing the amount of time required to reach a
desired level of skin perturbation.5, 6 I have also demonstrated that the presence of a
chemical enhancer in the coupling medium during ultrasound treatment is required to
achieve significant perturbation in the non-LTRs relative to untreated skin (see Chapter
5). I propose a series of experiments to determine how SLS, a model chemical enhancer,
impacts LTR formation in ultrasound-treated skin, as well as the enhancement of the non-
LTRs. SLS may be added to the coupling medium prior to ultrasound exposure at
concentrations of 0%, 0.01%, 0.03% (the critical micelle concentration, beyond which
SLS micelles form), 0.2%, and 1% (w/v). Ultrasound can then be applied to full-
thickness pig skin and the patterns of LTRs may be observed for significant trends in
formation and distribution. In addition, since acoustic cavitation events are the source of
skin perturbation, and, therefore, likely the source of the LTRs, experiments with
aluminum foil may also be conducted at the same SLS concentrations to determine if
there are any changes in the pitting of the aluminum foil (observed by measuring the pit
diameter and the pit depth) produced by the cavitation events. Skin electrical resistance
measurements of the non-LTRs as a function of the concentration of SLS in the coupling
medium may provide clues into the mechanisms by which a chemical enhancer produces
a second, less perturbing level of enhancement in the non-LTRs. To investigate how the
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non-LTRs are enhanced in the presence of a chemical enhancer during ultrasound
treatment of the skin, additional mechanistic studies should be performed focusing on the
secondary effects of ultrasound treatment of the skin - acoustic streaming, thermal
effects, and microjet formation resulting from transient cavitation bubble collapse. Each
of these three secondary mechanisms can be investigated in the following manner: 1) for
acoustic streaming, experiments can be performed where the donor chamber is
continuously mixed with a stir bar to approximate fluid velocities generated in the
coupling medium during ultrasound treatment, 2) for thermal effects, the coupling
medium can be heated to approximate temperatures reached in the coupling medium as a
result of ultrasound treatment, and 3) for microjet formation, the results of Section 7.2.3.1
should allow determination of whether microjet formation is required for enhancement of
the non-LTRs. Enhancements in the permeability and the electrical resistivity of the skin
from these three experiments, relative to untreated skin, can then be compared to the
enhancements in the skin permeability and the skin electrical resistivity for the non-LTRs
formed in skin treated simultaneously with ultrasound and a chemical enhancer to
determine which secondary mechanism, if any, is responsible for the observed
enhancement in the non-LTRs. These investigations should better elucidate how SLS
impacts the acoustic cavitation events leading to the formation of the LTRs, as well as the
enhancement in the perturbation of the non-LTRs.
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7.2.4 Additional Investigations of the Non-LTRs and the LTRs using Dual-
Channel Two-Photon Microscopy (TPM)
While significant progress was made using dual-channel TPM to elucidate the types of
transport pathways and mechanisms of enhancement in skin treated with ultrasound and
chemical enhancers in Chapter 5, there are three additional areas of study that may be
explored using TPM: 1) investigation of the non-LTRs and the LTRs using wide-field
TPM, 2) investigation of the number of samples required to achieve representative results
from TPM images in the non-LTRs and in the LTRs, and 3) investigation of the depth of
transcellular pathway penetration in the LTRs. I provide details of (1)- (3) below.
7.2.4.1 Investigation of the Non-LTRs and the LTRs Using Wide-Field TPM
Wide-field TPM has been previously used by our group in the area of chemical
enhancers.7 Compared to conventional TPM imaging, which captures a sample size of
100 ýtm x 100 gm, wide-field TPM has been used to capture regions of the skin up to 2
mm x 2 mm in size, which is equivalent to 400 adjacent conventional TPM images. The
advantage offered by wide-field TPM, compared to conventional TPM, is the ability to
image a larger region of the skin. By imaging a larger region of the non-LTRs and of the
LTRs, it would be possible to determine the uniformity of the penetration of the
fluorescent probe in the non-LTRs and in the LTRs. In addition, it would be possible to
observe the transition between the LTRs and the non-LTRs in a single TPM image. From
the results of Chapter 5, it was demonstrated that there is significant penetration of the
probe into the corneocytes and into the viable epidermis within the LTRs, while the probe
is restricted to the intercellular domain of the stratum corneum in the non-LTRs. Wide-
field TPM imaging would allow investigation into the boundary region between the LTRs
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and the non-LTRs, furthering our understanding of the differences between these two
regions of US-treated skin.
7.2.4.2 Investigation of Representative Sample Sizes Required for Imaging
of the Non-LTRs and the LTRs
Previous studies with chemical enhancers demonstrated that a larger number of TPM
images is required to obtain reproducible results for hydrophilic permeants (12-24
samples) in human skin as compared to hydrophobic permeants (4-6 samples).8 A larger
number of samples is required for hydrophilic permeants due to the heterogeneous
distribution of the hydrophilic permeants in the skin. It would be worthwhile to evaluate
the number of TPM images required to obtain reproducible results for the non-LTRs and
for the LTRs of skin treated with ultrasound, both in the presence and in the absence of a
chemical enhancer. Using the wide-field TPM images discussed in Section 7.2.4.1,
which contain the equivalent of 400 conventional TPM images, values of EK, EG, and EL
can be determined from image subsets having a size of 6, 12, 18, 24, and 30 images.
Several image subsets can be selected for each total number of images by randomly
selecting the location of the individual TPM images in the wide-field image. The
appropriate number of TPM images for the non-LTRs and for the LTRs can then be
determined by evaluating the size of the standard deviation in the values of EK, EG, and
EL as a function of the number of samples examined.
7.2.4.3 Investigation of the Depth of Transcellular Pathway Penetration in
the LTRs
In Chapter 5, a preliminary investigation of the penetration depth of the transcellular
pathways observed in the LTRs of ultrasound-treated and of US/SLS-treated skin, as well
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as in SLS-treated skin, for the hydrophilic permeant, SRB, and for the hydrophobic
permeant, RBHE, was conducted. Additional studies should be conducted to confirm the
results presented in Chapter 5. One challenge that will need to be overcome in this area
is obtaining significant penetration of the fluorescent probe deep into the stratum
corneum to obtain fluorescence signals that are much stronger than the background noise.
Since the method for evaluating the penetration of the probe into the corneocyte domain
presented in Chapter 5 depends on the normalized difference in the fluorescent signal in
the intercellular domain and in the corneocyte domain, a low signal-to-noise ratio in the
fluorescence data from the deeper layers of the stratum corneum can produce a false
positive result. This false positive result would then suggest that transcellular pathways
are present in the deeper layers of the stratum corneum, when, in effect, the penetration of
the fluorescent probe is confined solely to the intercellular domain. In order to increase
the signal-to-noise ratio, a higher concentration of SRB and RBHE in the coupling
medium would be required to increase the fluorescence signal of the exogenous
permeants. However, this increase in the fluorescent permeant concentration would need
to be balanced against the signal of the skin auto-fluorescence, since too much exogenous
fluorescent permeant may mask the skin auto-fluorescence signal.
7.2.5 Investigations of the Safety of LTR Formation
Previous studies have shown that low-frequency ultrasound is safe for the skin, inducing
no permanent damage to the skin or to the underlying tissues.9 However, these studies
were conducted without recognizing that ultrasound-treated skin samples experience
heterogeneous structural perturbation through the formation of the LTRs and of the non-
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LTRs. Therefore, it is possible that the previous safety analysis may not have specifically
examined the LTRs, which are the most structurally-perturbed regions of the ultrasound-
treated skin, since it was previously assumed that low-frequency ultrasound uniformly
perturbs the skin structure. Therefore, it is necessary to examine the safety of LTR
formation to determine if low-frequency ultrasound is truly safe for the skin and for the
underlying tissues. Specifically, the safety issues involved in LTR formation resulting
from ultrasound exposure can be classified into: i) reversibility of the changes induced in
the skin barrier properties by LTR formation, and ii) biological effects of LTR formation
on the skin membrane and on the underlying tissues. Below, I discuss each issue in
detail, as well as propose experiments to investigate each of them.
7.2.5.1 Reversibility of the Changes Induced in the Skin Barrier Properties
by LTR Formation
Although ultrasound pretreatment enhances skin permeability for several hours, the skin
permeability should eventually return to its baseline level, in both the LTRs and the non-
LTRs. A detailed investigation of the recovery of structural changes in the SC, as well as
of the skin barrier properties, after sonophoresis, should be conducted. Using Yorkshire
pig as the in vivo animal model, the skin can be pre-treated using 20 kHz ultrasound over
a range of intensities (0 - 30 W/cm2 ). The skin samples should then be masked using the
methods described in Chapter 4 and the time dependence of the transdermal flux of
radiolabeled mannitol may be tracked in the LTRs and in the non-LTRs by measuring the
amount of mannitol excreted in the pig urine. Over time, the amount of mannitol
excreted in the urine should decrease as the ultrasound-treated skin restores its barrier
properties. Skin electrical resistance measurements may also be used to quantify the
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reversibility of the skin permeability changes in the LTRs and in the non-LTRs due to
ultrasound application. Over time, the skin electrical resistance will increase as the
ultrasound-treated skin restores its barrier properties. The electrical resistance of the skin
is inversely proportional to the mobility of the ions in the skin. Because of the small size
of an ion, a small structural change in the skin causes a significant change in its electrical
resistance. Consequently, the electrical resistance of the skin is a very sensitive indicator
of its barrier properties. Furthermore, measurements of electrical resistance are much
more sensitive to structural changes in the skin than permeability measurements.
Measurements of the skin permeability and of the skin electrical resistance in the LTRs
and in the non-LTRs can be made separately using the protocols discussed in Chapter 4.
7.2.5.2 Biological Effects of Localized Transport Regions on the Skin
In vivo studies with the Yorkshire pig animal model can be conducted in which the effect
of LTR formation in the skin is compared with untreated skin samples to determine the
biological effects of LTR formation. The skin should be exposed to 20 kHz ultrasound,
with SLS (1.0% w/v) and without SLS, in the presence of SRB at several sites and at
different ultrasound intensities (0 - 30 W/cm 2). The skin should be perturbed by low-
frequency ultrasound, using the ultrasound pre-treatment protocol outlined in Section
4.2.4, until the skin reaches the desired level of skin perturbation. The skin can then be
harvested so that the LTR and the non-LTR skin samples formed under different
ultrasound intensities can be compared with untreated skin samples to assess the
existence of any damage induced to the skin. For the histology studies, the LTRs and the
non-LTRs can be harvested separately from the same ultrasound-treated skin tissues.
Damage may be assessed by erosion of the stratum corneum layer and by the necrosis of
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cells in the epidermal layer, the dermal layer, and/or the underlying tissues. This
investigation should determine the range of US intensities that are safe to induce LTR
formation in the skin.
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